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1. Summary 
Broadening the understanding of mechanisms linked to innate immunity is of primordial 
importance in a time of continuous emergence of rapidly spreading viral diseases. The 
domestic cat represents an ideal model for the study of host-virus interactions, as it is an 
outbred species naturally susceptible to many viruses sharing biological properties with 
those affecting humans. Additionally, due to their acquisition of infallible transmission 
strategies, rapid propagation of feline viruses within a group is particularly difficult to 
inhibit, reflecting the challenges linked to the prevention of pandemics. The present 
work was designed to gain insights on the innate immune responses of the domestic cat 
to viruses, and to determine whether early antiviral mechanisms can be manipulated to 
enhance resistance to viral infection in this species.  
In a first phase, real-time polymerase chain reaction (PCR) systems were developed, 
enabling to measure the expression of feline genes considered to be hallmarks of innate 
responses to viral infection, including various interferon (IFN)α and IFNω subtypes, 
IFNβ, intracellular antiviral Myxovirus resistance (Mx) factor, natural killer (NK) cell 
stimulator IL-15 and effectors perforin and granzyme B, as well as Toll-like receptors 
(TLRs) 3, 7, 8 and 9. These tools could then be employed to evaluate innate immune 
parameters in both in vitro and in vivo models of infection, conferring valuable 
information not only regarding strength, breadth and kinetics of antiviral defences in 
feline cells, but also possible biological properties of important viruses affecting the cat. 
In a further step, the newly developed PCR assays were utilized to assess the 
immunomodulatory potential of various immune response modifiers (IRMs) in feline 
cells in vitro. The IRMs mimicking natural viral components were selected, namely 
Poly IC and Resiquimod (R-848), artificial models of viral dsRNA and ssRNA, as well 
as dSLIM and ODN 2216, synthetic oligonucleotides containing several 
unmethylated CpG motifs. Although all analysed IRMs positively modulated the innate 
immune state of treated peripheral mononuclear cells (PBMCs), ODN 2216 induced by 
far the most potent response: this molecule not only altered the gene expression profile 
of feline PBMCs in an antiviral orientation, but also significantly enhanced the 
proliferation of these immune cells and increased the presence on their surface of co-
stimulatory molecules necessary for the diffusion of immunological defence signals. 
Moreover, when incubated in vitro with target cells of epithelial and fibroblastic origin, 
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the supernatants of ODN 2216-stimulated PBMCs not only induced high production of 
intracellular antiviral proteins in these cells but also inhibited the replication of five 
feline viruses, namely the feline calici- (FCV), herpes- (FHV), parvo- (FPV), corona- 
(FCoV) and leukemia (FeLV) viruses.  
Altogether, this study procures a better understanding of innate antiviral mechanisms in 
an outbred species and highlights the promising potential of CpG-containing molecules 
such as ODN 2216 to protect domestic cats against a broad range of virus infections. 
Further in vitro and in vivo investigations will determine the feasibility of stimulation of 
the innate immune system by such molecules to prevent viral propagation in humans, 
cats and other species. 
 
 
Zusammenfassung 
Infolge der immer häufigeren Ausbrüche noch unbekannter, sogenannter „emerging“ 
viralen Krankheiten, wird es heutzutage immer wichtiger, das Verständnis der 
Mechanismen des angeborenen Immunsystems zu verbessern. Für solchen Studien ist 
die Hauskatze ein ideales Modell, da sie ausgezüchtet und empfänglich für verschiedene 
Viren ist, die nahe verwandt sind mit denjenigen die auch Menschen betreffen. Aehnlich 
wie im Falle einer Pandemie ist die schnelle Ausbreitung viraler Infektionen in einer 
Gruppe von Katzen zudem schwierig zu verhindern, da feline Viren während der 
Evolution effiziente Uebertragungsstrategien entwickelt haben. Die Ziele der 
vorliegenden Arbeit umfassten das Erwerben neuer Erkenntnisse über das angeborene 
Immunsystem der Katze und die Prüfung der Möglichkeit zur Induktion einer 
allgemeinen Resistenz gegen virale Infektionen in dieser Spezies durch die 
Stimulierung antiviraler Immunmechanismen.    
In einem ersten Schritt wurden real-time Polymerase Ketten Reaktion (PCR) Systeme 
entwickelt, mit denen die Expression von felinen Genen gemessen werden können, die 
im Ablauf einer angeborenen Immunantwort gegen Virusinfektionen eine Rolle spielen. 
Dazu gehören verschiedene Interferon (IFN) α and IFNω Subtypen, IFNβ, der 
intrazelluläre antivirale Myxovirus Resistenz (Mx) Faktor,  das (Natural Killer) NK Zell 
stimulierende Zytokin IL-15 sowie NK Effektorproteine Perforin and Granzyme B, und 
die Toll-like Rezeptoren (TLR) 3, 7, 8 und 9. In einer zweiten Phase wurden diese 
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neuen Assays eingesetzt, um die angeborenen Immunparameter in Infektionsmodellen 
in vitro und in vivo zu evaluieren. Die Resultate lieferten wertvolle Angaben über die 
Stärke, Breite und Kinetik von antiviralen Abwehrmechanismen in felinen Zellen. Die 
weitere Anwendung der entwickelten PCR Systemen erlaubte das immunmodulierende 
Potential verschiedener sogenannten „immune response modifiers“ (IRMs) in vitro in 
Katzenzellen zu evaluieren. Es wurden IRMs ausgewählt, welche natürlichen viralen 
Komponenten ähnlich sind, nämlich Poly IC und Resiquimod (R-848), synthetische 
Varianten der viralen doppelsträngigen (ds) RNA and einzelsträngigen (ss) RNA, sowie 
dSLIM und ODN 2216, synthetische Oligonukleotide,  die unmethylierten Cytosine-
Phosphat-Guanosine (CpG) Motive beinhalten. Obwohl alle analysierten IRMs den 
Immunstatus von stimulierten peripheren mononukleären Zellen (PBMCs) positiv 
beeinflussten, erwies sich ODN 2216 als der stärkste IRM: dieses Molekül induzierte 
nicht nur die Expression von antiviralen Effektorgenen in felinen PBMCs, sondern 
stimulierte auch die Proliferation dieser Immunzellen und erhöhte die Präsenz auf deren 
Oberfläche von costimulatorischen Molekülen, welche für die Verbreitung von 
antiviralen Signalen äusserst wichtig sind. Zudem induzierten Ueberstände,  welche in 
vitro durch ODN 2216-stimulierte PBMCS produziert worden waren, die Produktion 
von intrazellulären antiviralen Mx Proteinen in Zielzellen aus epithelialem und 
fibroblastischem Ursprung, womit die Replikation von fünf felinen Viren markant 
gehemmt wurde. Bei den Viren handelt es sich um die felinen Calici- (FCV), Herpes- 
(FHV), Parvo- (FPV), Corona- (FCoV) und Leukaemie. (FeLV) Viren, die alle zu 
verschiedenen Familien gehören.   
Insgesamt vermittelt diese Studie ein besseres Verständnis der angeborenen antiviralen 
Mechanismen in einer ausgezüchteten Spezies und zeigt das vielversprechende 
Potenzial von CpG-enthaltenden Molekülen die Hauskatze gegen ein breites Spektrum 
von Virusinfektionen zu schützen. Mit weiteren in vitro und  in vivo Untersuchungen 
sollte die Möglichkeit geprüft werden, die Uebertragung von Virusinfektionen in 
Menschen,  Katzen, und anderen Spezies zu hemmen. 
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2. Introduction  
Close to 7 billion people and more than 600 million domestic cats (felis catus) inhabit 
our planet. These two populations have evolved alongside one another for thousands of 
years rendering today’s Tom, Sylvester and Garfield the results of a long respectful 
relationship between very independent entities. Despite the cat’s relatively little 
contribution to human survival in comparison to other species originally domesticated 
for their milk, meat, wool or labour capabilities, recent genetic and archaeological 
discoveries indicate that cats and humans have been associated for at least 9,500 years 
[1]. 
 
How did humans and cats come to share common paths? Each side probably had 
individual interests in cohabitation. In 2009, Driscoll and colleagues traced the common 
ancestry of the cat back to the wildcat of the Middle East, felis sylvestris lybica [2]. 
Most likely due to restricted food basis, this ancestor of today’s domestic cat was 
obliged to lead a solitary way of life and defend its hunting territories from other cats. 
With the emergence of early human settlements however, a new environment with 
abundance of food allowed cats to live in groups: both the house mouse (Mus musculus 
domesticus) that quickly populated the settlements and the trash dumped on the 
outskirts of towns most likely prompted the cats to live among humans. In turn, the 
inhabitants probably did not mind the company of the cats, considering not only that 
they were discrete and caused no harm, but also that they eliminated mice and snakes 
form the villages. Some experts additionally speculate that wild cats naturally possess 
features such as large eyes, small faces and high round foreheads that are known to 
elicit nurturing from humans and might facilitate the development of a relationship with 
people [1]. Today, cats occupy all continents, and have gained the status of the most 
popular pet on the planet [1].  
 
One downside linked to the domestication of cats remains the dispersion of specific 
microorganisms. In order to survive in their host population, feline viruses in particular 
have adapted to the solitary way of life of cats over hundreds of thousands of years. 
Thus, they possess both the capability to induce latent and/or asymptomatic infections 
and very efficient transmission strategies enabling them to infect susceptible individuals 
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upon the rare contact between animals [3]. In view of the opportunistic behaviour of 
feline viruses, it is not difficult to imagine that the advent of domestication gave a free 
way to these pathogens, which readily spread, as a consequence, to every individual 
living in a group. As it is currently accepted that the biology of virus-host interactions is 
a continuous co-evolutionary process involving both host immune system and viral 
escape mechanisms [4], the survival of the domestic cat in the course of evolution 
suggests the presence or selection of strong antiviral defence mechanisms in this 
species. The immunological factors responsible for this evolutionary retaliation against 
fatal viruses however, remain poorly understood to date.  
 
Viruses remain a threat to human and animal populations worldwide, killing millions of 
individuals each year. Unfortunately, the elaboration of specific medical care against 
viral infections has proven to be particularly tricky, as viruses possess highly developed 
adaptation faculties. Simple mutational alterations result in resistant strains that 
considerably limit the potential of existing antiviral drugs, rendering prophylactic 
measures especially important in the combat against viruses. In view of developing new 
approaches to prevent viral propagation, many research groups worldwide currently 
focus on characterising the early interactions of viruses with the immune system. It just 
so happens that felids are naturally affected by members of many different viral 
families, that share biological properties with pathogens held responsible for pandemics 
not only in humans, but also in other animal populations (for further detail see section 
2.3.2) [5]. Thus, a better understanding of the immunological antiviral defence 
mechanisms of the domestic cat may not only support the development of more efficient 
prophylactic measures against feline viruses, but also provide new insights on host and 
virus specific factors that play a significant role in pathogenesis of important human and 
animal diseases. The cat may indeed play a much more important role in its relationship 
with humans than running after mice and providing a cuddly face…  
  
Along these lines, the present work sheds light on fundamental questions linked to 
immune responses of the domestic cat and further defines this species as an alternative 
model in studies related to host-virus interactions. Two manuscripts included in chapter 
3 of this document summarize the main developments and findings of this project. In 
order to support their understanding by the reader and to provide a more detailed 
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perspective in the relevance of this study, current facts concerning host-virus 
relationships of human and feline populations as well as conventional and alternative 
preventive methods are delineated as background information hereafter (section 2.1). 
The objectives of the present study are then clearly formulated in section 2.2. Finally, 
although results are extensively discussed in the respective manuscripts included in this 
document, the overall outcome of this study is thoroughly examined in the final 
discussion (chapter 5), which also opens perspectives for future experiments.    
 
2.1 Background and state of research in the field 
2.1.1 You, me, viruses… 
In 1901, Walter Reed was the first to imply that viruses could induce disease in humans, 
when he discerned that the devastating yellow fever plague that hit America in the late 
19th century was caused by a viral pathogen. Since then, viruses have been held 
responsible for millions of deaths worldwide, even starting hundreds of years before 
their discovery. Although rapid advances in technology during the past century have 
enabled to identify, treat, prevent, and sometimes even eradicate viruses, the list of 
theses dangerous pathogens keeps growing posing major challenges to human health. 
According to the World Health Organization (WHO), up to one third of all deaths 
worldwide each year are linked to viral diseases.  
 
In the last century, vaccination has been developed and used with fantastic success as 
preventive measure against many viral infections. Today, children are immunized at a 
very young age with the MMR vaccine, which combines protection to viruses causing 
measles, mumps, and rubella. Since introduction of the earliest versions of MMR in the 
1970s, over 500 million doses have been used in more than 60 countries worldwide. 
Vaccination against poliovirus enabled to eradicate poliomyelitis, a devastating disease 
affecting the nervous system, from the Western hemisphere in the second half of the 
20th century.  Hepatitis A and B vaccines furthermore confer protection against severe 
virally-induced liver disease. The herpes zoster vaccine helps reduce the risk of 
shingles, the painful rash caused by the reactivation of a member of the herpes virus 
family causing chickenpox, and the more recently developed human papillomavirus 
(HPV) vaccine helps protect against cervical cancer and genital warts induced by this 
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virus. Although the development of an effective and safe antiviral vaccine is a 
notoriously long and costly process governed by stringent regulatory controls typically 
lasting 8 to 12 years and costing between $300 and $800 million, vaccination most often 
elicits strong, specific immune responses that confer long-term protection.   
 
The currently most dangerous viral pathogens tend to be the “emerging” and “re-
emerging viruses”, which are defined by the WHO as “newly recognised, newly 
evolved or occurred previously but have shown an increase in incidence or expansion of 
geographical, vector or host range” and for which consequently no vaccination is 
available. “Emerging” viruses most often enter the human population sporadically from 
animal reservoirs and include those pathogens responsible for the severe acute 
respiratory syndrome (SARS), avian influenza, and the Nipah encephalitis. These 
viruses are mostly unrecognized and of unknown origin when they appear in a 
population, or have undergone uncharacterised mutations giving an open path to their 
rapid dissemination before effective prevention strategies can be developed. “Re-
emerging” viruses such as West Nile, Chikungunya and Dengue viruses, the Japanese 
Encephalitis virus and the Human Immunodeficiency virus (HIV) are most often vector 
borne (transmitted by flies and mosquitoes) or, as in the case of HIV, sexually 
transmitted. These pathogens are known and sometimes endemic, but may emerge again 
to cause more outbreaks and in places not previously known for outbreaks to occur. 
Most emerging and re-emerging viruses cause severe human disease and possess 
dangerous pandemic potential. In those cases when other animal populations like 
poultry or pigs may also be affected, additional issues arise including economic losses 
related to the culling of animals and the unavailability of food due to real or suspected 
contamination. These risks have the potential to severely disrupt global food supply 
chains and further harm human health and welfare.  
  
The influential factors contributing to the current appearance and dissemination of new 
viruses are linked to societal-based decisions and demographic changes that are 
generally considered to be a direct consequence of today’s human economic 
development [6]. Thus, specific environmental conditions coupled with the socio-
economic influences of today have defined “emerging disease hotspots” in lower 
latitudes, including tropical Africa, Latin America, and Asia [7]. Countries in this 
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region bear a rapidly growing population density and yet inadequate hygiene conditions 
and education, which together greatly facilitate the spread of communicable and 
sexually transmitted diseases. A high birth rate moreover increases the amount of 
immunologically naïve individuals who perpetuate epidemics. The typical warm, humid 
climate in affected countries promotes vector-borne diseases and the development of 
rice agriculture creates both ecological niches for insects and breeding environments for 
water birds that are natural reservoirs of various emerging and re-emerging diseases. 
The potential for pathogens to cross species barriers is exacerbated by extensive 
livestock production, persistence of livestock trading markets and deforestation, which 
altogether promote interactions between human beings, livestock and wildlife. 
Moreover, due to increasing global transportation of goods and people, viral infections 
that would have been confined to a limited geographical area can easily spread 
worldwide. Finally, these changes in population dynamics and economic activities lead 
to a great loss in biodiversity, which has recently been linked to enhanced transmission 
of disease [8].  
  
Outbreaks of emerging and re-emerging viral diseases are generally accompanied by 
devastating public health and economic consequences. In the event of a pandemic, not 
only many human and animal lives are at stake, but industries in life science, food and 
health care sectors are highly exposed to considerable deficits. Other industries suffer 
economic losses due to reduction in workforces as well as decrease in public gatherings, 
travel, and tourism. Presently, the most feared global emerging disease scenario 
internationally is the influenza pandemic. In 1918, influenza virus was responsible for 
an estimated 50 million deaths worldwide, and a new influenza pandemic is expected 
when the virus mutates to a form that is readily transmitted among humans. Current 
epidemiological models of the WHO project that a pandemic could kill as many as 10 
million people worldwide and losses to global economies could top $1 trillion. These 
dark prospects assuredly pressure the development of new preventive methods to impair 
the dissemination of emerging viruses. An effective prophylaxy would induce broad 
protection against a wide selection of viruses, as emerging viral microorganisms cannot 
be specifically targeted due to their unpredictable nature. The development of novel 
preventive strategies to emerging viral diseases remains a great challenge in medical 
research today.  
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2.1.2 Cats and viruses 
The domestic cat is a natural host of several viruses that infect the feline population 
worldwide, along with wild felids and in some cases other wild carnivores (for 
references see individual virus sections below). Feline viruses have acquired over the 
course of evolution elaborate strategies to persist within their host population. In order 
to convey a basic idea about the relationship between the cat and its viruses, the six 
feline viruses commonly encountered in the field will be briefly portrayed in this 
section, with a focus not only on the disease they cause in the cat, but also on structural 
and epidemiological properties that render them particularly challenging to combat. 
Experiments conducted in the present project and described in the manuscripts of 
chapter 3 also include most of the feline viruses introduced here. For further 
information regarding these and other feline pathogens, fact sheets and guidelines have 
been issued by the European Advisory Board for Cat Diseases (ABCD) in 2009 and can 
be consulted online (www.abcd-vets.org).  
 
2.1.2.1 Feline herpes virus 
The feline herpes virus (FHV) is an enveloped virus with a double-stranded DNA 
(dsDNA) genome that belongs to the Varicellovirus genus and the subfamily 
Alphaherpesvirinae. Although the virulence can differ among strains, only one serotype 
is known and distributed in domestic cats and some wildcat populations worldwide [9]. 
The disease caused by feline herpes virus affects the upper respiratory tract and is often 
referred to as feline viral rhinotrachetitits or cat flu, which is characterized by 
conjunctivitis, profuse ocular and nasal discharges, and in some cases, severe keratitis 
and corneal ulceration. Co-infections with feline calicivirus and bacteria are not 
uncommon, causing a multi-agent respiratory syndrome with exacerbated symptoms 
[10]. Transmission occurs via oral, nasal or conjunctival routes and, as the virus is 
rapidly inactivated in the environment, requires direct contact with a shedding cat. 
Acute disease is accompanied by viral excretion for 1-3 weeks after which the clinical 
symptoms usually disappear. However, a latent/chronic course of disease is the typical 
outcome of an acute FHV infection due to neuronal latency of the virus, and affected 
cats become lifelong carriers. Intermittent reactivation of viral secretion can occur in 
carrier cats upon glucocorticoid treatment or during stressful events such as lactation or 
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moving into a new environment. Vaccines are available for domestic cats, however 
vaccination may not always prevent infection [11]. Furthermore, under some 
circumstances, vaccinated cats can still develop latent FHV-1 infections with 
consequent periodic reactivations which allow the virus to transmit [12]. Prevalence of 
disease in feline population varies in several studies from 1% in small healthy 
populations to 20% in shelters and multicat households with respiratory problems [13]. 
 
2.1.2.2 Feline calicivirus 
The feline calicivirus (FCV) belongs to the Vesivirus Genus and the Caliciviridae 
family. This highly contagious pathogen is a non-enveloped virus consisting of a small 
single-stranded RNA (ssRNA) genome [14]. Although mainly restricted to cat 
populations, FCV presents a high genome plasticity, which allows the virus to respond 
rapidly to environmental selection pressures. Most isolates consequently present 
antigenic differences [15]. Acute infection typically leads to oral ulcers and upper 
respiratory disease with sneezing and nasal discharge. A virulent systemic form of FCV 
disease has also been reported [16]. As mentioned under 2.1.2.1, FCV is often 
associated with FHV and various bacterial strains in a common respiratory syndrome. 
Similarly to FHV, transmission occurs during direct contact with a shedding animal via 
the oral, nasal and conjunctival routes. FCV can persist for up to one month in the 
environment under dry conditions at room temperature, so that indirect transmission 
through contaminated objects can also occur [17]. The virus is shed not only during 
acute disease, but also for more than 30 days thereafter, and in some individuals for 
several years [18]. Vaccines against FCV are available, however several studies indicate 
the appearance of field strains that are resistant to vaccine-induced immune responses 
[19]. The prevalence of disease seems proportional to the number of cats in a household, 
ranging from around 10% in small groups up to 25-40% in colonies and shelters, with a 
high variability between individual colonies [20]. 
 
2.1.2.3 Feline panleukopenia virus 
The feline panleukopenia virus (FPV) is a non-enveloped virus with a ssDNA genome, 
which belongs to the parvovirus genus and the Parvoviridae family. This virus is known 
as the prototype parvovirus of carnivores, and has been shown to infect other members 
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of the felidae, as well as racoons, minks and foxes [21]. Cats are additionally 
susceptible to canine parvovirus (CPV)-2 [22] so that superinfection and co-infection 
with multiple parvovirus strains may occur, potentially facilitating recombination and 
high genetic heterogeneity [23]. FPV is transmitted by the faecal-oral route, and 
distributed to rapidly dividing cells of the body including those of bone marrow, 
lymphoid tissues and intestinal crypts, as the virus requires cells in the S-phase of 
division for its replication. Consequently, immunosuppression, severe diarrhoea and 
dehydration are hallmark symptoms of infection. Mortality is extremely high, and can 
occur in up to 90% of infected kittens. Diseased carnivores shed virus at high titres and 
the virus displays resistance to both physical factors and chemical agents, leaving 
contaminated environments infectious for months and rendering indirect transmission 
the main mode of infection [24]. Vaccines against FPV are available on the market; 
however, this virus has re-emerged as a major cause of mortality in cats in shelters and 
rescue homes, most probably due to insufficient vaccination linked to budget reasons 
[25]. 
 
2.1.2.4 Feline coronavirus 
The feline coronavirus (FCoV) is a large, spherical, enveloped ssRNA virus that 
belongs to the Coronaviridae family of the order Nidovirales. FCoV infection is 
ubiquitous in dometic cats (seroprevalence 20-100%) and wild felids may also be 
seropositive. Most cats are infected following contact with FCoV in faeces of 
asymptomatic cats, begin to shed virus within one week and continue to shed for weeks, 
months or even sometimes for life [26, 27]. FCoV can survive for 7 weeks in a dry 
environment and may be transmitted indirectly. While most FCoV positive cats are 
asymptomatic or display only mild enteritis, about 12% will eventually develop feline 
infectious peritonitis (FIP), a highly fatal pyogranulomatous vasculitis [28]. 
Pathologically, FIP has been classified into two forms: an effusive (wet) form 
characterised by polyserositis (eg, thoracic and abdominal effusion) and vasculitis, and 
a non-effusive (dry) form characterised by granulomatous lesions in various organs. 
Clinical symptoms linked to FIP are highly variable and often unspecific. Generally, the 
affected cat presents fever, anorexia and lethargy often accompanied by ascites in the 
wet form of FIP.  Although the precise pathogenesis leading to the development of FIP 
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remains to be fully understood, it is believed that the continuous emergence of new 
phenotypes by mutation and recombination during replication of this large RNA virus 
enables it to spread efficiently in the host by circumventing natural specific immune 
responses [29]. Infectious viral load, viral genetics and the cat’s individual immunity all 
play a role in determining whether FIP will develop [30]. A vaccine against FIP has 
been introduced, however with limited efficacy in the field, as most cats become 
infected many weeks before they can be vaccinated. Infection is particularly common in 
multi-cat environments and where conditions are crowded, whereas the prevalence is 
lower in single pets [31]. 
 
2.1.2.5 Feline leukemia virus 
The feline leukemia virus (FeLV) belongs to the gammaretrovirus genus and the 
Retroviridae family. Infections with this virus occur worldwide, and in addition to 
domestic cats, FeLV has been detected in other small felids such as the wildcats (felis 
silvestris) and Iberian lynxes [32, 33]. Like other retroviruses, FeLV is an enveloped 
virus with a ssRNA genome that must be reverse transcribed and integrated as a 
“provirus” DNA form into the host’s genome. Although they may or may not produce 
infectious virus, infected cells are consequently permanently infected and pass the virus 
on to daughter cells. Individual immunological factors that have yet to be identified 
determine whether the host cells of a particular cat will eliminate (20-30%), persistently 
produce (30-40%) or transiently replicate (30-40%) virus [34]. Clinical signs are mainly 
linked to persistent FeLV replication and include anaemia, immunosuppression and 
lymphoma; most affected cats die within 2-3 years. As FeLV does not survive for long 
periods outside the host, direct contact is usually required for effective infection of 
another cat. The virus is mainly transmitted through saliva, milk, faeces and nasal 
secretions during friendly contacts, but also through bites [35]. Vaccines against FeLV 
are available; however they do not prevent infection and thus cannot confer 100% 
efficacy of protection against disease. Indeed, minimal viral replication occurs in 
infected vaccinated cats, and provirus can be readily detected in these animals [36]. The 
prevalence of FeLV infections is highly influenced by the density of cat populations, 
and studies indicate a high geographical variability. In most developed countries the 
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prevalence in individually kept cats is usually less than 1%, while in multi-cat 
households lacking specific preventive measures it may exceed 20% [34]. 
 
2.1.2.6 Feline immunodeficiency virus 
The feline immunodeficiency virus (FIV) belongs to the lentivirus genus and the 
Retroviridae family. FIV infection is endemic in domestic cat populations worldwide, 
and a variety of species-specific strains have been isolated from wild feline populations 
including the puma, lion, leopard and Pallas cat [37-40]. Like FeLV, FIV is an 
enveloped ssRNA virus that integrates in the host genome during its replication cycle. 
The viral reverse transcriptase that mediates transcription of the RNA genome into a 
DNA copy for its integration is error-prone and lacks a proofreading function, 
facilitating rapid mutation of the virus that displays great genetic diversity. Five 
genetically distinct FIV subtypes or clades have been defined that cluster in a 
geographic manner, indicating local adaptation of the virus [41-43]. Although FIV is 
closely related to the human immunodeficiency virus (HIV) and shares a similar 
structure, life cycle and pathogenesis, humans cannot be infected. Virus is shed in saliva 
and transmitted almost exclusively through bites. Older, free-roaming male cats are thus 
more prone to infection due to exhibition of territorial behaviour. Transmission from 
mother to kittens may occur, especially if the queen is undergoing early or late phases of 
infection. Once in contact with the blood of a host cat, FIV persistently infects CD4+ T 
lymphocytes, which play a central role in the development of both cellular and humoral 
immune responses to pathogens. Infected cats generally remain asymptomatic for 
several years, and most clinical signs are finally the consequence of immunodeficiency 
and secondary infection linked to the chronic loss of CD4+ T cells. A vaccine against 
FIV is commercially available in the USA, Australia and New Zealand. This whole 
inactivated virus preparation however does not protect against all different clades of 
FIV, and failed to induce protection against European FIV subtypes [44]. Several 
seroepidemiological surveys have revealed an overall seroprevalence worldwide of 
approximately 10% among both healthy and sick cats screened in North America, Asia, 
Europe and Oceania [45]. Cats living in environments with high population density 
belong to higher risk groups. 
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2.1.2.7 Feline viral strategies for persistence 
As can be noted in the descriptive sections 2.1.2.1-2.1.2.6, various traits of feline 
viruses enable them to persist within the cat population and render their prevention very 
tricky. Most feline viruses apply the “hit and stay” strategy, in that they remain for a 
long time within the host after infection [46]. This is most likely the signature of viral 
adaptation to the individual way of life of the wild ancestor of today’s domestic cat: 
feline viruses had to develop ways to both wait for contact between individuals and 
efficiently spread with high efficiency from one cat to another on this rare occasion (see 
introduction). 
The astuteness of feline viruses relies on several mechanisms varying from induction of 
latency in the host and affection of a broad host range to persistence in the environment 
and rapid adaptation to external pressures. Latency of infection is common in FHV, 
FeLV and FIV, and infected cats are likely to renew viral shedding in stressful 
situations most often implying contact with other cats, such as mating, lactation and 
moving to new locations in which territories must be re-established. Additionally, 
animals infected with FCV, FCoV, and FeLV may remain chronic shedders for a 
lifetime, even in the absence of clinical signs of disease. This asymptomatic carrier state 
is of primordial importance in the epidemiology of feline viruses. FPV infection may be 
the exception to this rule, as dissemination of this virus relies more on a strategy known 
as “hit and run”. Infected kittens are quickly killed during FPV infections, depleting the 
pool of susceptible individuals and presenting a higher risk of extinction for the virus. 
Thus, this pathogen has evolved compensatory methods to “stay around anyway” and 
wait for the next cat to come: infected animals shed extremely high amounts of virus, 
which is so resistant that it can persist in the environment for many months. Similarly, 
FCV and FCoV also exhibit significant resistance outside the host and persist in the 
environment as a threat for uninfected cats. Most feline viruses moreover exhibit a 
broad host range, infecting not only domestic cat populations, but also wild felids and, 
in the case of FPV, other carnivores. The possibility to affect wider populations 
increases chances both to encounter another susceptible individual and to disseminate 
over larger geographical areas. Another advantage of certain feline viruses resides in 
their genomic structure and replication characteristics. Indeed, RNA viruses generally 
possess high antigenic variability [47] and those affecting cats (FCV, FCoV, FeLV and 
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FIV) typically utilize this capability to escape immune responses and propagate more 
efficiently. Thus, the genetic diversity among viral strains across their geographic range, 
typically observed in FCV, FeLV and FIV, suggests local viral adaptations [48]. 
Finally, feline viruses support each other through narrow collaboration: FeLV and FIV 
both disarm the host from its systemic immune defences opening windows of 
opportunities for other members of the feline virus family, while FHV and FCV weaken 
local barriers of the upper respiratory tract and thus promote each other’s proliferation.  
Altogether, the infectious strategies of feline viruses have enabled their survival in the 
feline population over evolution and additionally seem to drive them to adapt to current 
pressures induced by vaccines. No vaccination available to date fully protects domestic 
cats against these pathogens, and resistant strains of individual viruses are already 
emerging. 
 
2.1.2.8 Where cats and viruses meet 
Many studies have highlighted the role of the host population structure as a selection 
pressure for infectious pathogens [49, 50]. In concordance with this, field observations 
reveal a high variability in viral prevalence according to the cat social organisation and 
mating system: viruses thrive in large groups with narrow contacts [48]. Indeed, over 
the course of time, feline viruses seem to have conserved their opportunistic behaviour: 
efficient transmission strategies enable them to infect virtually every cat living in a 
group.  
 
It is consequently not surprising that multi-cat households, breeding facilities, shelters 
and rescue homes are the preferred places for feline viruses to “hang out” [10, 51, 52]. 
Close proximity and high social contact rates among individuals from different 
backgrounds, continuous resident turnover and stressful environments are characteristic 
for most multi-cat households, shelters and rescue homes. In large colonies, communal 
rearing of kittens by females also enhances viral spread. As the viruses remain “hidden” 
within asymptomatic or healthy carriers for long periods of time, there is unfortunately 
often no apparent urgent need for prophylactic measures. Furthermore, since clinical 
symptoms of many feline viral diseases appear only long after the time point of 
infection, the relation to a stay at a breeding facility or a shelter is often overseen. 
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Unfortunately, it is also in shelters and rescue homes, where antiviral prevention is of 
primordial importance, that vaccines may not systematically be employed due to budget 
constraints.   
 
2.1.3 “Teflonization”: boosting innate antiviral defences 
All living beings are constantly exposed to microorganisms that are present in the 
environment, and have consequently developed over time a means to cope with invasion 
of microbial pathogens in the body. The vertebrate immune system utilizes two general 
strategies to combat infectious diseases: innate and acquired immunity. Innate immunity 
represents the organism’s first line of defence against invading pathogens. According to 
a concept elaborated by Janeway [53], the efficacy of the mammalian innate immune 
system relies on its ability to recognize pathogen-associated molecular patterns 
(PAMPs), or evolutionarily conserved microbial structures that are essential for the 
survival of the pathogens and thus cannot be changed in the course of evolution. The 
elicited response is not specific to a certain pathogen but directed against a group of 
microorganisms sharing the same microbial signature. Innate recognition of viruses, 
whose components are mainly all synthesized within host cells, is based on the 
recognition of viral nucleic acids. Discrimination between self (host) and viral nucleic 
acids occurs on the basis of specific chemical modifications and structural features that 
are unique to viral RNA and DNA, as well as on the cellular compartments where viral 
(but not host-derived) nucleic acids are normally found. Thus, 3 classes of PAMPs have 
been defined to date: dsRNA, ssRNA, and DNA containing unmethylated cytosine-
phosphate-guanosine (CpG) motifs [54]. In contrast to innate immunity, acquired or 
adaptive immune responses are the result of a precise but rather slow process that 
requires, prior to the execution of effector anti-pathogen responses, the proliferation of 
clonally distributed immune cells expressing highly specific receptors. While the 
adaptive immune system can provide specific recognition of foreign antigens and 
immunological memory of infection, the innate immune system induces immediate 
immunological defence mechanisms against a large variety of pathogens. Moreover, 
although the duration of innate immune mechanisms is generally only of several days, 
its considerable contribution to the activation of more specific subsequent immune 
responses must not be underestimated [55]. 
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Current knowledge concerning the molecular and cellular mechanisms linked to innate 
immune responses upon viral invasion in humans and in cats are reviewed in the 
introduction of the manuscript “The innate antiviral immune system of the cat: 
molecular tools for the measurement of its state of activation” presented in section 3.1 
of this document, and will thus not be explained in further detail here. Particularly 
relevant to this project however, is the development in recent years of synthetic 
molecules called immune response modifiers (IRMs) that can mimic the effects of 
natural PAMPs and thus have been shown to induce antiviral mechanisms in vitro and 
in vivo in various host models. Popular IRM imitators of viral PAMPs include among 
others Poly IC, a synthetic double-stranded polyriboinosinic–polyribocytidylic acid, 
imidazoquinolines, and synthetic CpG molecules [56]. The primary consequence of 
stimulation of innate immune mechanisms by natural or synthetic viral PAMPs is the 
production of type I interferon (IFN), the family of the most biologically potent antiviral 
molecules known to date. Type I IFN not only represent the fundamental link between 
those immune cells which are first to recognize the invading viral agent, and those 
which confer both innate and adaptive immunity to infections [57], but also effectively 
induce the synthesis of various intracellular antiviral proteins which interfere with 
several steps of the virus replication cycle [58]. Due to the ubiquitous repartition of type 
I IFN receptors, expression of these effector antiviral proteins can be induced in a 
majority of yet uninfected cells [59]. Key components of intracellular antiviral 
resistance conferred by type I IFN and largely referred to in this study are the 
cytoplasmic Mx GTPases [60]. Initially discovered 25 years ago as indispensable for the 
recovery of mice from influenza virus [61], Mx proteins in various species have since 
been linked to defence mechanisms against many viruses. Although the mechanism of 
action of Mx is still incompletely understood, these intracellular proteins were found to 
bind to essential viral components and block their intracellular transport. In recent years, 
the detection of Mx is readily used as a marker for upregulation and biological activity 
of type I IFN [60]. 
 
The potent defence mechanisms induced by type I IFN after preventive IRM treatment 
could help mount a global “antiviral state”, considerably restricting viral invasion and 
tilting the immunological balance in favour of the host. This leads to the novel concept 
of “teflonization” in biology. Teflon is the brand name of a synthetic polymer used to 
Dissertation 
Celine Robert-Tissot • July 2011 21 
coat cookware such as frying pans. This plastic polymer is characterized by a 
particularly low coefficient of friction, meaning that it is highly slippery. Consequently, 
most solid materials will virtually slide off any object coated with Teflon or 
“teflonized”. With allusion to these facts, Teflon is a nickname used in media jargon 
given to persons, particularly politicians, to whom criticism does not seem to stick. 
Thus, Ronald Reagan, the 40th President of the United States, was nicknamed the Teflon 
President after scandals surrounding members of his staff seemed to have no effect on 
Reagan's popularity with the public. Along these lines, “teflonization” by an effective 
IRM or combination of IRMs could create a temporary shield from which viral particles 
would virtually “slip off” the host, thus enhancing resistance of a susceptible individual 
to infections by viruses. In an era of constant emergence of new viral diseases, 
elaboration of this idea could open to exciting new perspectives in medical science.  
 
2.2 Objectives of the study 
Four main aims were pursued in the course of this project:  
 
1) Establishment of the necessary tools enabling to measure the expression of relevant 
genes during both innate and early adaptive immune responses in the domestic cat. 
 
2) Utilization of the newly designed tools for the characterization of early immune 
mechanisms in the context of acute feline infections in vitro and in vivo. 
 
3) Analysis of the immunomodulatory properties of various IRMs in vitro on feline cell 
lines and PBMCs.  
 
4) Assessment of the antiviral or “teflonizing” (see section 2.1.3) potential of various 
IRMs against in vitro inoculation of feline cell lines with common viruses affecting the 
domestic cat.   
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2.3 Relevance of the study 
A better understanding of early immune responses of the domestic cat to viral invasion, 
together with a methodical analysis on the possibility of manipulating antiviral defence 
mechanisms in order to enhance resistance to a broad spectrum of viral pathogens 
represents a significant step in both veterinary and human medicine. Reasons to work 
for the cat and reasons to work with the cat when it comes to immunological research 
are described in sections 2.3.1 and 2.3.2 respectively.  
 
2.3.1 Working for the cat 
Cats are affected by many dangerous viral pathogens that tend to induce latent, chronic 
or persistent infections with usually fatal outcomes. Due to these biological properties 
of feline viruses, disease management is most often long and tedious. Most protocols 
are based on “tender loving care” from the owner, where supportive treatment, good 
nursing, and patience are the key to success. Specific therapies are unavailable for most 
feline viral diseases, and when existent, they tend to be very costly. Moreover, in face of 
the ever-changing identity of feline viruses adapting to their environment, vaccines, 
when available, are slowly becoming insufficient for protection of domestic cats against 
most of these pathogens (see sections 2.1.2.1-2.1.2.6. for details on specific viruses). 
Thus, as feline viruses remain a danger for the domestic cat population today, the 
analysis of early immune responses to these pathogens could provide a better 
understanding of host-pathogen interactions and support the development of more 
effective ways to combat feline viruses. Also, prevention of viral propagation is of 
primordial importance in environments such as shelters, catteries and rescue homes, 
where many cats from different backgrounds have narrow contacts. The availability of 
an antiviral agent capable of transiently conferring resistance to a broad range of viruses 
would thus be highly desirable to temporarily protect cats when in such situations with 
increased risks of infection. In the development of methods and tools enabling to 
measure hallmarks of innate immunity, in the measurement of early immune responses 
to viruses in feline cells in vitro and in vivo, as well as in the screening of various IRMs 
for their potential to increase resistance to feline viruses in vitro, this study represents 
several steps forward in feline immunology research. Promising results could support 
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the development of new antiviral prophylactic drugs that would greatly contribute to the 
well being of cats and their owners.  
 
2.3.2 Working with the cat 
Infectious diseases have been a dominant cause of human morbidity and mortality 
throughout history, and emergence of new viral diseases, such as SARS, avian 
influenza, and Hendra encephalitis constitute a growing threat to public health (see 
section 2.1.1). The prospect of bioterrorist attacks represents another serious new danger 
that could have devastating effects. In this context, the stimulation of innate immune 
defences with “teflonizing” (see section 2.1.3) antiviral agents could have high 
relevance from both public health and economic perspectives: business travels and 
tourism in countries with nascent, still unidentified viruses would be of lesser worry; 
personnel working in hospitals, where patients affected by new viral diseases are being 
treated, could be more effectively protected against infection; resistance to various 
nosocomial infections could be conferred to patients needing elective surgery; entire 
populations could be temporarily protected against the spread of an “emerging” virus 
while awaiting the development of more specific preventive methods.  
 
When compared to laboratory mice, the feline model holds several advantages in studies 
related to innate immunity and viral diseases. First, appropriate models of viral infection 
in mice often necessitate the modification of infectious agents or the creation of 
transgenic animals considerably limiting the possibilities to extrapolate data from mice 
to humans [62]. Second, cats belong to an outbred species, enabling more realistic 
consideration of individual variability in immunologic responses. Studies with felids 
also enable to circumvent issues related to the notable differences between the innate 
immune systems of mice and humans, including altered expression and repartition of 
TLRs [62], different NK cell activating ligands [62], and absence of important antiviral 
mechanisms in inbred strains [63]. Finally, while feline viruses have acquired 
challenging propagation strategies throughout evolution, cats have retaliated with the 
development of a stark innate antiviral immune system. Altogether, almost 30 subtypes 
of feline type I IFN have been identified [64-66] and their biological properties 
characterized [67, 68].  
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The interaction of deadly infectious agents with the cat host's genome is seen as an 
unprecedentedly powerful biomedical model [5]. Indeed, the domestic cat is affected by 
a wide range of viruses that have over time gained properties rendering their infections 
particularly challenging to prevent. Many natural feline viruses share biological and 
clinical properties with others affecting humans or other species. Along these lines, cats 
are commonly affected by a virus from the herpes virus family, FIV infection is 
considered a close model of HIV [69], and the strong antigenic and clinical diversity of 
feline calicivirus is similar to that of human noroviruses [70]. Even the recently 
discovered devastating SARS human coronavirus has a feline counterpart, FCoV. 
Recent events have furthermore shown that domestic cats may act as interface between 
humans and wild animals in the propagation of some viruses such as cowpox virus [71], 
rabies [72] or H5N1 avian influenza virus [73] as a result of contact with infected 
rodents or birds. Finally, domestic cats and their wild relative have closely witnessed 
emerging virus outbreaks. In the mid 1970s, a feline panleukopenia virus cultivated in a 
cat vaccine factory appears to have abruptly jumped from cats to dogs, producing an 
extremely virulent strain that caused widespread puppy mortality across the world 
within a few months [21]. Dogs got their chance for payback when a strain of canine 
distemper, endemic in the pet dogs of Masai tribesman in Tanzania, breached the 
species barrier and affected first hyenas and then African lions, killing a third of the 
huge lion population of Serengeti National Park in a six month interval in 1994 [74]. All 
in all, feline viral infections could prove valuable to biomedical research, providing we 
have a better working knowledge of the immune system of cats. Also, intervening in the 
host virus interactions of felids appears particularly challenging, and elaboration of 
efficient preventive measures by stimulation of the innate immune system in this model 
would reveal solid optimism for their application in humans and other animal species. 
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3. Publications 
Two manuscripts presenting data obtained in the course of the present study were 
written and submitted to scientific journals. In the next sections, a brief explanation 
concerning the structure of text, the selection of data presented, the scientific journal in 
which the publication should appear, and the state of submission precedes each 
manuscript. 
 
3.1 Manuscript 1 
This first manuscript “The innate antiviral immune system of the cat: molecular tools 
for the measurement of its state of activation “combines many features of a review 
article with the presentation of original research, providing a “one-stop shop” to readers 
wishing to understand current state of knowledge on the innate immune system of the 
cat. In order to illustrate the shortcomings in the field of feline innate immunity, the 
Introduction gives a brief overview on innate antiviral mechanisms in humans and mice 
and highlights that which has been investigated in the domestic cat. This tour de force 
on current research in innate immunology is followed by the presentation of newly 
developed polymerase chain reaction (PCR) assays enabling to measure the expression 
of various genes selected as markers for innate immunity, as well as the utilization of 
these novel tools for the characterisation of early immunomodulation in feline cells 
following stimulation with various IRMs or inoculation with a selection of viruses in 
vitro. The validity of the assays in vivo is also confirmed by the measurement of an 
altered gene expression profile in FIV-infected kittens. All in all, this article reveals new 
tools for further research in feline immunity, provides new insights on host-pathogen 
interactions in the context of feline viral diseases, and further supports the development 
of the feline model for immunology research. The text has been accepted for publication 
in Veterinary Immunology and Immunopathology, and will appear in a special edition 
created following the 10th International Feline Research Retrovirus Symposium 
(IFRRS), which took place in May 2010. 
1 
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 16 
Abstract 17 
The innate immune system plays a central role in host defence against viruses. While 18 
many studies portray mechanisms in early antiviral immune responses of humans and 19 
mice, much remains to be discovered about these mechanisms in the cat. With the 20 
objective of shedding light on early host-virus interactions in felids, we have developed 21 
12 real-time TaqMan qPCR systems for feline genes relevant to innate responses to 22 
viral infection, including those encoding for various IFNα and IFNω subtypes, IFNβ, 23 
intracellular antiviral factor Mx, NK cell stimulator IL-15 and effectors perforin and 24 
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granzyme B, as well as Toll-like receptors (TLRs) 3 and 8. Using these newly 25 
developed assays and others previously described, we measured the relative expression 26 
of selected markers at early time points after viral infection in vitro and in vivo. Feline 27 
embryonic fibroblasts (FEA) inoculated with feline leukemia virus (FeLV) indicated 28 
peak levels of IFNα, IFNβ and Mx expression already 6 hours after infection. In 29 
contrast, Crandell feline kidney (CrFK) cells inoculated with feline herpes virus (FHV) 30 
responded to infection with high levels of IFNα and IFNβ only after 24 hours, and no 31 
induction of Mx could be detected. In feline PBMCs challenged in vitro with feline 32 
immunodeficiency virus (FIV), maximal expression levels of IFNα, β and ω subtype 33 
genes as well as IL-15 and TLRs 3, 7 and 8 were measured between 12 hours and 24 34 
hours after infection, whereas expression levels of proinflammatory cytokine gene IL-6 35 
were consistently downregulated until 48 hours post inoculation. A marginal 36 
upregulation of granzyme B was also observed within 3 hours after infection. In an in 37 
vivo experiment, cats challenged with FIV exhibited a 2.4-fold increase in IFNα 38 
expression in blood 1 week post infection. We furthermore demonstrate the possibility 39 
of stimulating feline immune cells in vitro with various immune response modifiers 40 
(IRMs) already known for their immunostimulatory properties in mice and humans, 41 
namely Poly IC, Resiquimod (R-848) and dSLIM, a synthetic oligonucleotide 42 
containing several unmethylated CpG motifs. Stimulation of feline PBMCs with 43 
dSLIM and R-848 effectively enhanced expression of IFNα within 12 hours by 44 
factors of 6 and 12 respectively, and Poly IC induced an increase in Mx mRNA 45 
expression of 28-fold. Altogether, we describe new molecular tools and their successful 46 
use for the characterization of innate immune responses against viruses in the cat and 47 
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provide evidence that feline cells can be stimulated by synthetic molecules to enhance 48 
their antiviral defence mechanisms.  49 
 50 
Keywords: cat, innate immune system, virus, immune response modifier, real-time 51 
TaqMan qPCR 52 
 53 
1. Introduction  54 
In the course of evolution, feline viruses have gained properties rendering their 55 
infections particularly challenging to prevent and treat. Presumably, the way of life of 56 
felids has driven over time the development of viruses with highly efficient viral 57 
transmission strategies and the potential to induce chronic or latent infections, thus 58 
increasing carrier populations and viral dissemination (Pontier et al., 2009). It is today 59 
widely accepted that the initial antiviral immune response of the mammalian host plays 60 
an essential role in determining the outcome of viral infection. Although extensive 61 
studies have been carried out in mouse models, the antiviral innate immune system of 62 
the cat remains poorly understood, leaving open questions regarding initial responses to 63 
viral infection as well as the possibility of manipulating innate immune mechanisms in 64 
favour of the host. In order to illustrate the current status of research concerning innate 65 
antiviral defence mechanisms in cats, we will first give a short overview of general 66 
knowledge in this field.  67 
 68 
Studies in mice and humans have demonstrated that early pathogen recognition by the 69 
innate immune system relies on its ability to sense microbial components known as 70 
pathogen-associated molecular patterns (PAMPs) (Akira et al., 2006). With respect to 71 
Manuscript 1 
Celine Robert-Tissot • July 2011 29 
viruses, the host’s intrinsic defence structures recognize mostly genomic nucleic acids 72 
and replication intermediates. Three main classes of PAMPs have emerged to date: 73 
double-stranded RNA (dsRNA), single-stranded RNA (ssRNA), and unmethylated CpG 74 
DNA. In turn, the detection of these PAMPs relies on a limited set of germline-encoded 75 
pattern recognition receptors (PRRs). Three classes of PRR molecules seem to survey 76 
various cell compartments for presence of PAMPs and promote intrinsic antiviral 77 
immunity: the Toll-like receptors (TLRs), the retinoic acid inducible gene-I (RIG-I)-like 78 
receptors (RLRs) and the cytoplasmic viral DNA sensors (Yoneyama and Fujita, 2010). 79 
TLRs are type I integral membrane glycoproteins either expressed on the cell surface or 80 
retained in intracellular compartments. Among the 12 TLRs in mice and 10 TLRs in 81 
humans that have been identified to date (Tabeta et al., 2004), three share the ability to 82 
bind nucleic acids, namely those expressed in endosomal compartments of various 83 
subsets of dendritic cells (DCs). Thus, upon phagocytic or endocytic events, TLR3, 84 
TLR7 and TLR9 can sense viral dsRNA, ssRNA or unmethylated CpG-DNA 85 
respectively (Vaidya and Cheng, 2003). TLR8, a structurally homologous variant of 86 
TLR7, seems to be non-functional in mice, but has been described in humans as 87 
recognising similar molecular patterns to TLR7 (Jurk et al., 2002). To date, various 88 
synthetic ligands have been identified for these TLRs, among which the most popular 89 
include Poly IC, a synthetic double-stranded polyriboinosinic–polyribocytidylic acid, a 90 
well-known synthetic analogue to dsRNA and stimulator of TLR3 (Jiang et al., 2003); 91 
imidazoquinolines such as resiquimod (R-848), synthetic compounds that bind to 92 
TLR7/8 (Wagner et al., 1999); and synthetic CpG molecules, which trigger TLR9 93 
(Vollmer et al., 2004). Such Toll-like receptor agonists have not only been used 94 
extensively for research purposes linked to the understanding of innate immune 95 
mechanisms, but have also gained much popularity in the clinical field, as treatments for 96 
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various types of disease and as vaccine adjuvants (Meyer and Stockfleth, 2008; Seya 97 
and Matsumoto, 2009).  98 
In contrast to TLRs, RLRs and DNA sensors are ubiquitously expressed in the 99 
cytoplasm and allow infected cells to detect actively replicating virus. Two main 100 
members of the RLR family, RIG-I and melanoma differentiation associated gene 5 101 
(MDA5), have been shown to play essential roles in the recognition of cytoplasmic viral 102 
RNA (Yoneyama et al., 2004; Loo et al., 2008). Recently, additional cytoplasmic DNA 103 
sensors have been proposed to detect viral dsDNA during infection (Yoneyama and 104 
Fujita, 2010). These molecules are currently under investigation. 105 
 106 
PAMP-triggered PRRs activate distinct signaling pathways that converge on the 107 
activation of specific transcription factors NFκB, AP-1, IFN regulatory factor (IRF) 3 108 
and IRF7, enhancing the expression of both proinflammatory cytokines such as IL-6 109 
and TNFα, and type I IFNs, the main players in eradication of replicating viruses in 110 
antiviral innate immunity (Schindler et al., 2007). In humans, the large family of type I 111 
IFNs primarily include IFNα, IFNβ and IFNω (Bekisz et al., 2004). IFNα consists of a 112 
group of 13 structurally related proteins, each encoded by a separate intronless gene, 113 
while only one protein each for IFNβ and IFNω have been characterised. Type I IFNs 114 
are produced by almost all cell types, with IFNβ being the main IFN secreted by 115 
fibroblasts in response to viral challenge. Essentially, the ubiquitous presence of IFN 116 
receptor complex composed of two subunits IFNαR1 and IFNαR2 (Uze et al., 2007) 117 
and the pleiotropy of these cytokines enable IFNs to initiate potent antiviral responses. 118 
First, type I IFNs activate, in uninfected target cells, the production of intracellular 119 
effectors that can interfere with several steps of virus replication cycles. Well-studied 120 
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examples of these antiviral proteins include myxovirus-resistance protein (Mx) GTPase, 121 
the RNA-dependent protein kinase (PKR), the 2’,5’-oligoadenylate synthetase (OAS) 122 
and the interferon stimulated gene (ISG) 15 (mechanisms reviewed in Sadler and 123 
Williams, 2008). Mx protein, for instance, binds to essential viral components thus 124 
blocking their intracellular transport (Haller et al., 2007). Moreover, production of this 125 
protein is widely recognized as a marker for upregulation of type I IFNs (Haller et al., 126 
2007). Through positive feedback processes, type I IFNs were additionally shown to 127 
enhance the expression of TLRs, further sensitizing cells to microbial recognition (Siren 128 
et al., 2005). Finally, type I IFNs effectively bridge innate and adaptive immunity by 129 
promoting the differentiation and function of various immune cell populations such as 130 
DCs, NK cells, B cells, as well as CD4+ and CD8+ T cell populations (Colonna et al., 131 
2004).  132 
 133 
NK cells represent another important antiviral cell population (Hamerman et al., 2005). 134 
Constitutively primed to kill, these cells rapidly release IFNγ, a type II IFN affecting 135 
mainly adaptive immune cells, as well as granzyme and perforin, cytotoxic substances 136 
stored in cytosolic granules. Primary NK targets are host cells lacking MHC I molecules 137 
on their surface. As most viruses have evolved mechanisms to downregulate host cell 138 
MHC expression in order to avoid immune responses resulting from antigen 139 
presentation, virally infected cells are readily attacked by NK cells. In addition to type I 140 
IFNs, IL-15 was shown to support development and survival of NK cells as well as to 141 
stimulate their cytokine production. Liberated mainly by PAMP-activated DC, IL-15 142 
thus also plays a crucial role in antiviral defence (Vujanovic et al., 2010). 143 
 144 
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Various essential players in the innate immune system of the cat have to date been 145 
characterised. Thus, TLRs 1-9 were shown to be differentially expressed in various 146 
feline lymphoid tissues and cell lines (Ignacio et al., 2005). Concerning TLRs 3, 7, 8 147 
and 9, high expression levels were measured in the mesenteric lymph nodes and in the 148 
spleen. Interestingly, both B and T lymphocyte subsets purified from lymph nodes 149 
expressed TLRs and expression in feline CD4+ and CD8+ T cells was mainly restricted 150 
to these anti-viral associated TLRs. Feline viral infection in vitro also induced altered 151 
TLR expression levels in feline cells, with observed differences depending highly on 152 
cell type and TLR studied (Ignacio et al., 2005). The stimulation of feline TLRs with 153 
specific agonists has not yet been reported.  154 
Studies carried out in the past 20 years have mainly focused on the characterisation of 155 
feline type I IFN subtypes and their potential therapeutic effects in the context of 156 
various viral diseases. Nakamura et al. cloned the first cDNA sequence for feline IFN in 157 
1992 (Nakamura et al., 1992). The purified protein was classified as omega-type (Ueda 158 
et al., 1993b) and rapidly shown to exhibit antiviral activity both in vitro and in vivo 159 
(Tables 1 and 2).  As a result, Nakamura’s IFNω became the first feline antiviral drug 160 
available on the market, currently sold both in Japan (Intercat, Toray Industries, 161 
Tokyo, Japan) and Europe (Virbagenomega, Laboratoire Virbac, Carros Cedex, 162 
France) to treat feline calicivirus and canine parvovirus infections. Subsequently, 163 
therapeutic effects of this product as stand-alone or combinatorial agent were described 164 
in the context of a series of feline and canine diseases (Table 2). In recent years, many 165 
feline type I IFN subtype nucleic acid and amino acid sequences have been 166 
characterized. In all, 13 subtypes each of the feIFNα and feIFNω genes have been 167 
cloned and the biological antiviral properties of the purified proteins were demonstrated 168 
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in vitro (Table 1). Studies concerning the structure of these IFNα and IFNω subtypes 169 
have indicated that both protein families have high homology and that feline IFNω is 170 
more similar to the IFNα than to the IFNω of other animal species. Although the 171 
individual functions of all these IFN subtypes are unknown in the cat, the impressive 172 
number of type I IFN genes identified to date underlines the necessity of broad antiviral 173 
responses in felids.  174 
Regarding effector functions of feline type I IFNs, mainly the induction of intracellular 175 
antiviral proteins has been discussed. In this way, the biological activity of Nakamura’s 176 
recombinant feline IFN was initially supported by its potential to modulate OAS activity 177 
in vitro (Ueda et al., 1993a). The physiological effects of oral or ocular treatment with 178 
this recombinant IFNω were later assessed by local and systemic measurement of the 179 
feline Mx protein (Bracklein et al., 2006), which had already been previously described 180 
(Horisberger et al., 1990). More recently, recombinant IFNω stimulation of feline cells 181 
was shown to induce expression of feline ISG15. Molecular cloning of this gene 182 
enabled detection of the immunomodulatory properties of both cell-conjugated and free 183 
forms of this antiviral effector protein (Tanabe et al., 2008). Altogether, these studies 184 
illustrate the breadth of IFN-induced antiviral mechanisms in the cat. The recent cloning 185 
and molecular characterisation of the feline IFNαR2 (Xue et al., 2010) may support the 186 
study of further effector functions of type I IFNs in the cat.   187 
Finally, only few studies have targeted aspects of the feline innate immune response 188 
following viral encounter. Dean et al. reported that immunodeficiency in FIV infection 189 
also concerned early anti-pathogen defence mechanisms in vivo (Dean et al., 1998). 190 
Thus, chronically FIV-infected cats mounted weaker initial immune responses against 191 
Listeria monocytogenes, leading to a more severe form of infection. In a further study, 192 
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inoculation of FIV-infected cats with modified L.monocytogenes carrying an expression 193 
vector for various feline cytokines indicated that IL-15 played a central role in restoring 194 
FIV-related innate immune disturbances and increasing the natural killer cell population 195 
(Dean et al., 2006).  196 
 197 
Despite extensive studies on molecular structure and antiviral effects of feline IFN, 198 
much remains to be understood regarding qualitative, quantitative and timely aspects of 199 
innate immune mechanisms following viral infection in the cat. Moreover, the 200 
possibility of synthetically stimulating the intrinsic immune system has not yet been 201 
investigated in this species.  202 
Herein, we describe the development of twelve real-time qPCR assays enabling us to 203 
quantify the expression of key factors involved in feline innate immunity. Relative 204 
expression levels of various innate immune parameters were determined in viral 205 
infection both in vitro and in vivo. Furthermore, we report the quantification of innate 206 
immune responses obtained in vitro after stimulation of feline immune cells with 207 
various synthetic molecules.   208 
 209 
2. Materials and Methods 210 
2.1 Cats, FIV infection and blood collection 211 
Ten male specified pathogen-free (SPF) cats of 10 weeks of age and 4 male spf cats of 4 212 
years of age from Liberty Research Inc. (Waverly, NY, USA) were used in this study. 213 
Young and adult cats were housed separately in an animal-friendly environment and 214 
under optimal ethological conditions. All experimental procedures were reviewed and 215 
approved by the Swiss Federal Veterinary Office. 216 
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After an adaptation phase of 4 weeks, the kittens were infected intraperitoneally with 50 217 
cat infectious doses 50 (50 CID50) of the FIV Glasgow 8 (GL8) strain, previously 218 
titrated in vivo and kindly provided by Dr. M. Hosie and Prof. O. Jarret from the 219 
University of Glasgow, Great Britain. Whole blood was collected in EDTA-220 
supplemented evacuated tubes both on day 0 before infection and on day 7 post 221 
infection. 100µl of blood was mixed with 300µl mRNA lysis buffer (Roche Diagnostics, 222 
Rotkreuz, Switzerland) immediately after blood collection and samples were stored at 223 
-80°C until further analysis. 224 
EDTA-supplemented venous blood from the 4 adult spf cats was used for the 225 
purification of PBMCs required for other experiments, namely real-time qPCR assay 226 
optimisation, IRM stimulation or inoculation with FIV.   227 
 228 
2.2 Feline PBMC isolation, cell lines and cell culture 229 
Feline PBMCs were isolated from EDTA-supplemented whole blood by Ficoll-230 
Hypaque density gradient centrifugation (Histopaque-1077, Sigma-Aldrich, Buchs, 231 
Switzerland). The mononuclear cell fraction was washed once and resuspended in 232 
RPMI with Glutamax I (Gibco, Invitrogen, San Diego, CA, USA) supplemented with 233 
10% heat-inactivated fetal calf serum (Bioconcept, Allschwil, Switzerland), 100 U/ml 234 
penicillin and 100µg/ml streptomycin (Gibco, Invitrogen, San Diego, CA, USA). For 235 
the production of cDNA for real-time qPCR assay optimization, isolated PBMCs were 236 
either stimulated directly after isolation with 4µg/ml LPS (Sigma-Aldrich, Buchs, 237 
Switzerland) or with a combination of 10µg/ml Concavalin A (Sigma-Aldrich, Buchs, 238 
Switzerland) directly after isolation and 50U/ml IL-2 (Sandoz Pharmaceuticals AG, 239 
Cham, Switzerland) 24h and 96h post isolation. For experiments including IRM 240 
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stimulation or FIV inoculation of feline PBMCs, the isolated cells were counted using 241 
the Sysmex XT 2000 iV (Sysmex, Norderstedt, Germany) as previously described 242 
(Weissenbacher et al., 2010) and dispersed in 96-well plates at a density of 3x105 cells 243 
per well in 100µl complete RPMI.   244 
Crandell-Reese feline kidney (CrFK) cells and Feline Embryonic Fibroblasts (FEA) 245 
were maintained in RPMI supplemented as described above. 246 
 247 
2.3 Viruses and in vitro inoculation experiments 248 
FIV GL8 and FeLV-A/Glasgow-1 strains, generous gifts from Dr. M. Hosie and Prof. 249 
O. Jarret (University of Glasgow, Great Britain), had been previously propagated and 250 
titrated on purified feline PBMCs and FEA cells respectively. The FHV ZH5-04 strain 251 
was kindly provided by Veterinaria AG (Zurich, Switzerland), had undergone several 252 
passages in CrFK cells and was titrated in these cells before use in the present study. All 253 
viruses had been kept at -80°C for long-term storage. 254 
For in vitro inoculation experiments of adherent cells, 2x104 FEA or CrFK cells were 255 
seeded in the wells of a 96-well plate and incubated at 37°C, 5% CO2 for 24 hours. FEA 256 
cells were then inoculated with 20 tissue culture infectious dose 50 (TCID50) FeLV and 257 
CrFK cells with 50 TCID50 of FHV. For in vitro inoculation of feline PBMCs, 3x105 258 
cells isolated from one individual adult cat were distributed in wells of a 96-well plate 259 
and directly infected with 50 TCID50 of FIV stock virus. The cultures were incubated at 260 
37°C, 5% CO2 and cells from duplicate wells were harvested at the time intervals 261 
depicted in the results of the respective experiments. For each time point, duplicate 262 
wells containing uninfected cells were included as unstimulated controls for comparison 263 
in gene expression profiles. For harvesting of adherent cells, the supernatant was 264 
removed from each well and the cells were directly lysed with 300µl mRNA lysis buffer 265 
Manuscript 1 
Celine Robert-Tissot • July 2011 37 
(mRNA isolation kit I, Roche Diagnostics). PBMCs from separate wells were first 266 
pelleted and subsequently lysed in the same manner. Lysed samples were stored at -267 
80°C until further analysis. In experiments with FHV and FeLV, the presence of virus-268 
specific nucleic acids in supernatants of infected cells was confirmed by real-time qPCR 269 
24 and 48 hours post inoculation respectively using systems previously published 270 
(Vogtlin et al., 2002; Tandon et al., 2005). Measurement of FIV provirus integration in 271 
PBMCs was carried out by real time PCR as has already been described (Leutenegger et 272 
al., 1999). 273 
 274 
2.4 IRM stimulation of feline PBMCs 275 
Purified PBMCs from one adult cat were counted and 3x105 cells per well were seeded 276 
directly after isolation in a 96-well format. Cells were treated with either 144µg/ml 277 
dSLIM (Mologen AG, Berlin), 20µg/ml R-848 or 20µg/ml Poly IC (Alexis 278 
biochemicals, Enzo Life Sciences AG, Lausen, Switzerland) and maintained at 37°C, 279 
5% CO2. dSLIM and Poly IC were solubilized in PBS, R-848 in DMSO, as 280 
recommended by the manufacturers. All solutions were diluted in PBS so that cell 281 
treatments were equi-volume. Two controls for comparison in gene expression profiles 282 
were added in which cells were treated with either an equal volume of PBS, or, for 283 
comparison with R-848 stimulation, PBS containing the corresponding concentration of 284 
DMSO. After 6, 12, 24 and 48 hours, cells were harvested as described above for 285 
PBMCs. 286 
 287 
288 
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2.5 RNA isolation and synthesis of cDNA 288 
For real-time qPCR assay optimization experiments, total RNA was extracted manually 289 
from pellets of 2.5x106 PBMCs using the RNeasyPlus Mini Kit (Qiagen AG, Hilden, 290 
Germany). Cell lysis and homogenization was thereby carried out using the 291 
QIAshredderTM and genomic DNA (gDNA) was removed with the gDNA Eliminator 292 
spin column (Qiagen AG) according to the manufacturer’s recommendations. For 293 
experiments concerning the measurements of cytokine gene expression, mRNA 294 
extractions were performed with the mRNA Isolation Kit I and MagNA Pure LC 295 
Instrument (Roche Diagnostics) according to the manufacturer’s instructions. In both 296 
cases, purified RNA was stored at -80°C until further use. 297 
First strand cDNA was synthesized using the High Capacity cDNA Reverse 298 
Transcription Kit (Applied Biosystems) following the manufacturer's instructions, and 299 
samples were stored at -20°C until use for qPCR measurements.  300 
 301 
2.6 Real-time qPCR 302 
2.6.1 General conditions 303 
Real-time qPCR was carried out using a Rotor-Gene 6000 real-time rotary analyser 304 
(Corbett, Mortlake, Australia). PCR assays comprised 5µl of cDNA in a total volume of 305 
25 µl per reaction using the TaqMan® Fast Universal PCR Master Mix (Applied 306 
Biosystems, Carlsbad, CA, USA). Thermocycling conditions consisted of an initial 307 
denaturation of 20s at 95°C, followed by 45 cycles of amplification by melting at 95°C 308 
for 3s and annealing at 60°C for 45s. Systems for TLR 7 and TLR9 were used as 309 
previously described (Ignacio et al., 2005). 310 
 311 
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2.6.2 Development and validation of novel assays  312 
Primers and probes for each gene listed in Table 1 were designed using Primer 313 
ExpressTM software (versions 2 and 3, Applied Biosystems). The sequences were 314 
retrieved from Ensembl (http://www.ensemble.org) and GeneBank 315 
(http://www.ncbi.nlm.nih.gov) and oligonucleotides were commercially synthesized 316 
(Microsynth, Balgach, Switzerland). All probes were labelled with the reporter dye 317 
FAM (6-carboxyfluorescein) at the 5’ end and the quencher dye TAMRA (6-318 
carboxytetramethylrhodamine) at the 3’end. For genes containing introns, the designed 319 
systems covered putative exon-exon junctions, in order to preclude genomic DNA 320 
amplification. Primers for each system were first tested for the generation of amplicons 321 
of expected length in PCR assays comprising cDNA synthesized from ConA-stimulated 322 
PBMCs. The PCR products were subjected to gel electrophoresis on 3% agarose gels, 323 
stained with ethidium bromide and visualized using the Chemigenius 2 BioImaging 324 
System (Syngene, Cambridge, UK). Only primers indicating appropriate specificity and 325 
amplification products of correct length were utilized for further optimisation. Primer 326 
and probe concentrations for each system were optimized on five-fold serial dilutions of 327 
cDNA derived from ConA-stimulated PBMCs. cDNA was diluted in 30µg/ml salmon 328 
sperm DNA (Invitrogen, Basel, Switzerland) and quadruplicates of each dilution were 329 
tested simultaneously. Matched forward and reverse primer concentrations of 300, 600 330 
and 900nM were evaluated first with a probe end concentration of 250nM. The 331 
performance of the assays was further optimized using the best primer concentrations 332 
combined with 3 different probe end concentrations, namely 50, 150, and 250nM. 333 
Amplification efficiencies of the newly designed assays were calculated as previously 334 
described (Klein et al., 1999) using the following equation:  335 
E = [10(-1/slope)]-1.  336 
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The system for IL-6 had already been described (Taglinger et al., 2008). Optimization 337 
experiments for this assay in our laboratory indicated best results with concentrations of 338 
800nM for forward and reverse primers and 250nM for the probe, rendering an 339 
efficiency of 0.99. We also designed new systems for TLR 3 and TLR8, as we were 340 
unable to obtain an adequate efficiency with those previously described (Ignacio et al., 341 
2005). 342 
 343 
2.6.3 Relative expression analysis of feline genes 344 
Expression levels of selected genes were calculated using GeNorm version 3.5 345 
(Vandesompele et al., 2002), using β-glucuronidase (GUSB) and tryptophan 5-346 
monooxygenase activation protein, zeta polypeptide (YWHAZ) as reference genes, under 347 
conditions previously validated for the feline species (Kessler et al., 2009). For 348 
illustration of relative expressions of the various genes in the figures of the present 349 
report, a cut-off of 2-fold up- respectively downregulation measured at least at one time 350 
point in each experiment was selected.  351 
  352 
2.7 Statistical analysis 353 
For the measurement of the effect of FIV on cytokine expression in vivo, statistical 354 
analysis was performed with GraphPad Prism for Windows, Version 3.0 (GraphPad 355 
software, San Diego, CA, USA). Normalized cytokine expression factors were tested 356 
for statistical differences between samples of week 0 and week 1 post infection using a 357 
non-parametric Wilcoxon signed rank test for paired samples. 358 
 359 
 360 
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3. Results 361 
3.1 Development of novel real-time qPCR systems  362 
Primer and probe sequences for real-time qPCR systems of 12 feline genes relevant to 363 
innate immune responses against viruses were designed and validated (Table 1). The 364 
assay developed for IFNω encompasses the expression of all IFNω subtype genes 365 
simultaneously. Due to the sequence dissimilarities in IFNα subtype genes, several 366 
systems had to be created for this type I IFN family: a separate assay was designed for 367 
IFNα14 while common probes and reverse primers are shared by the IFNα3, IFNα7 and 368 
IFNα systems that recognize IFNα subtypes 3, 7 and the remaining subtypes (IFNα1, 2, 369 
5, 6, 8-13) respectively.  370 
Amplicon sizes of the developed real-time qPCR assays ranged from 69 to 135 bp. A 371 
single band could be visualized after initial amplification analysis of primers only, when 372 
tested with cDNA derived from purified feline PBMCs. Both primer and probe 373 
concentrations were optimized and reaction efficiencies were evaluated.  374 
 375 
3.2 Stimulation of feline cells with various IRMs 376 
Both immortalized and primary cells of feline origin were stimulated with 3 IRMs of 377 
different classes, namely dSLIM, a covalently-closed oligonucleotide containing 378 
several unmethylated CpG motifs (Schmidt et al., 2006), R-848 and Poly IC. The 379 
concentrations indicating optimal IFNα induction after 12 hours in preliminary titration 380 
experiments were selected for use in this study (data not shown). As determined by both 381 
trypan blue exclusion and cell count measurements at regular intervals after stimulation, 382 
no evidence of cellular toxicity could be observed in CrFK cells, FEAs or purified feline 383 
PBMCs treated with dSLIM or R848 (data not shown). Poly IC, however, at 384 
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concentrations capable of inducing innate immune responses, induced cell death in all 385 
three cell types, and housekeeping gene expression analysis in cell samples treated with 386 
this molecule repeatedly indicated an increase of 6-8 Ct values compared to untreated 387 
controls.   388 
IRM-treated cells were systematically screened for increased expression of IFNα, Mx 389 
and IL-6 as indicators of successful stimulation. Despite measurable basal expression 390 
levels of TLRs 3, 7, 8 and 9 in CrFK and FEA cells, all 3 IRMs failed to influence the 391 
transcription of genes relevant to innate immunity (data not shown). However, 392 
differential gene profiles were observed after treatment of purified feline PBMCs with 393 
the immune-stimulating molecules (Figure 1A-C). dSLIM and R-848 induced a 6- 394 
and 12-fold upregulation of IFNα expression within 12 hours of stimulation. However, 395 
no increase in transcription of Mx could be measured in PBMCs treated with these two 396 
molecules. In cells pulsed with Poly IC, levels of IFNα expression could not be 397 
accurately measured due to both low basal expression levels of this cytokine and cell 398 
death induced by this IRM. Nevertheless, Poly IC induced a 28-fold increase in Mx 399 
expression that could be measured already 6 hours post stimulation. Upregulation of 400 
IFNα expression was concordant with that of IL-6 after stimulation of PBMCs with Poly 401 
IC and R-848. In contrast, treatment of these cells with dSLIM induced significant 402 
downregulation of IL-6 expression. Finally, among all 3 IRMs, only dSLIM was 403 
found to modulate TLR expression, indicating a 6-fold increase of TLR9 within 12 hours 404 
of stimulation.   405 
 406 
407 
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3.3 Early immune responses of feline cell lines after inoculation with feline viruses 407 
The induction of host cell immune responses by FHV and FeLV were assessed in vitro 408 
on CrFK cells and FEAs respectively at regular time intervals early post infection. 409 
Productive infection of the cells was confirmed by real-time PCR of cell culture 410 
supernatants 24 and 48 hours post inoculation for FHV and FeLV respectively (data not 411 
shown). Modulations in relative expressions of IFNα, IFNβ, Mx and IL-6 were utilized 412 
as parameters for immune responses by the cells.  Progressively increasing levels of 413 
IFNα, IFNβ and IL-6 were measured after inoculation of CrFK cells with FHV, with 414 
highest levels corresponding to respectively 37-, 45- and 23-fold upregulation in gene 415 
expression measured after 24 hours. No changes in Mx expression were observed 416 
(Figure 2A). In contrast, FEA cells indicated the most potent antiviral immune response 417 
just 6 hours after inoculation with FeLV, and transcription levels of all analysed genes 418 
decreased progressively thereafter. Within 6 hours post inoculation, increases of 15-fold 419 
in IFNα expression, 29-fold in IFNβ expression and 4-fold in IL-6 expression were 420 
measured. Presence of Mx mRNA was proportional to levels of IFNα and IFNβ 421 
expression, with highest levels also noted 6h post inoculation (Figure 2B). 422 
 423 
3.4 Evaluation of innate immune response parameters in feline PBMCs after in vitro 424 
infection with FIV   425 
The influence on the expression of 14 genes including receptors and cytokines relevant 426 
to innate immunity was tested in feline PBMCs at regular time points after inoculation 427 
with FIV. Effective integration of FIV provirus was confirmed by real-time PCR 48 428 
hours after infection of the cells (data not shown). Modulations in the expression of the 429 
tested factors are depicted in Figure 3. All genes tested were influenced within the first 430 
48 hours of stimulation, with the exception of TLR9 (not shown). The strongest 431 
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response was measured 12 hours after infection, with substantial modulation at this time 432 
point in mRNA levels of 9 out of 10 cytokines tested. Type I IFN genes were 433 
upregulated as of 6h post inoculation. Peak levels of 374-fold and 121-fold inductions in 434 
gene expression of IFNα and IFNω were achieved at 12 hours post infection, while 435 
strongest induction of IFNβ, namely by a factor of 114, was measured 24 hours after 436 
FIV inoculation. Although maximal gene expression levels were slightly lower for the 437 
individual IFNα subtypes tested (65-fold, 67-fold and 24-fold for IFNs 3, 7 and 14 438 
respectively), a similar pattern of stimulation was observed, with highest expression 12 439 
hours after infection. Mx and IL-15 genes were induced in a manner proportional to the 440 
type I IFN genes at all time points measured with highest increases at 12 hours post 441 
inoculation of 38-fold and 7-fold respectively. During the first 48 hours, FIV infection 442 
downregulated IL-6 expression attaining lowest levels within 6 hours after inoculation, 443 
when a 60-fold decrease in expression was observed. Genes encoding for contents of 444 
NK cell cytotoxic granules appeared only marginally affected when their expression 445 
was measured in PBMCs. Both perforin and granzyme B mRNA levels were maximally 446 
increased 3h post infection by 1.8-fold and 2-fold respectively. Similarly, the expression 447 
of TLR genes in PBMCs was only slightly influenced by FIV infection. Transcription of 448 
TLRs 3, 7 and 8 was however induced in a delayed manner when compared to the 449 
cytokines, attaining maximal levels 24 hours after infection with induction factors 450 
ranging from 2 to 2.6.   451 
 452 
3.5 Measurement of type I IFN in cats after FIV challenge in vivo 453 
10 spf cats were subjected to FIV infection with the highly virulent GL8 strain. 454 
Expression levels of feline IFNα were compared in whole blood samples collected from 455 
the cats immediately before and 1 week after FIV challenge infection. 9 out of 10 cats 456 
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displayed higher IFNα expression after infection. An average of 2.4-fold induction in 457 
expression of this cytokine could be measured in the cats after infection (p=0.0059) 458 
(Figure 4).  459 
 460 
4. Discussion 461 
Innate immune responses to invading pathogens play a key role in the outcome of 462 
infection. Over the course of time, mammalian hosts have developed the capacity to 463 
counterbalance virus attacks through sensing of viral signatures by specialized immune 464 
cells and immediate activation of the type I IFN system. Within minutes to hours, this 465 
family of antiviral cytokines initiates an explosion of potent defence mechanisms, 466 
leading to the suppression of viral replication and protection of the host. These intrinsic 467 
immune responses remain poorly understood in felids, a species that seems particularly 468 
sensitive to viral infections, with sporadic viral outbreaks compromising endangered 469 
populations (Evermann et al., 1988; Roelke-Parker et al., 1996; Cunningham et al., 470 
2008; Meli et al., 2010). Until now, the appropriate tools for characterizing innate 471 
immune mechanisms in this species were unavailable. In order to better understand the 472 
early host-pathogen interactions occurring in feline viral infections, we describe herein 473 
the development of 12 real-time qPCR systems to measure the expression of feline 474 
genes related to innate antiviral defence mechanisms. Through a series of experiments, 475 
we demonstrate the possibility of monitoring key events in innate immune responses 476 
both in vitro and in vivo. We further demonstrate the initiation of antiviral responses in 477 
feline immune cells upon stimulation with various IRMs.  478 
 479 
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The strength, extent and kinetics of immune responses elaborated by feline cells upon 480 
viral inoculation in vitro were evaluated. In these experiments, expression levels of 481 
IFNα and IL-6 were systematically analyzed as indicators for the initiation of innate 482 
immune mechanisms. As Mx expression is strictly regulated by type I IFN (Holzinger et 483 
al., 2007), biological functionality of the induced immune responses was assessed by 484 
simultaneous analysis of this factor. In all models of infection used in this study, we 485 
observed the characteristic transient expression of type I IFN genes, with a duration 486 
ranging from 6 to 12 hours in CrFK cells and FEAs inoculated with FHV and FeLV 487 
respectively to 36 hours in PBMCs infected with FIV. The presence of specialized cells 488 
for the production of type I IFNs in the blood is most likely linked to the longer 489 
expression of these innate cytokines in PBMCs (Colonna et al., 2004). Moreover, IFNs 490 
α, β and ω were expressed at differential levels in feline cells upon infection; while 491 
PBMCs heavily upregulated expression of IFNα and IFNω genes, cell lines retaining 492 
epithelial and fibroblast properties preferentially increased production of IFNβ mRNA 493 
levels. Time points at which highest expression of antiviral genes was measured also 494 
greatly varied with cell type and virus. Although FEA cells responded to presence of 495 
FeLV within 6 hours, induction of innate immune gene expression could only be 496 
observed after 24 hours following FHV infection in CrFK cells. Peak antiviral response 497 
in PBMCs was measured 12 hours after infection, with evidence for progressive 498 
development and rapid decrease of the response. Further experiments are necessary to 499 
determine the significance of individual properties of cells and tissues as well as virus-500 
related factors such as source and infectious dose in these observations.     501 
Interestingly, although high levels of type I IFN expression were observed 24 hours 502 
after FHV infection of CrFK cells, no induction of Mx was measured, indicating that 503 
this virus may have evolved mechanisms to interrupt IFN-induced host defence 504 
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mechanisms in infected cells. Indeed, many viruses have evolutionarily acquired 505 
sophisticated strategies to counteract the IFN system (Katze et al., 2002). Various 506 
members of the herpes virus family have been reported to directly inhibit the proteins 507 
that mediate the antiviral state (Elia et al., 1996), interfere with the expression of 508 
signaling molecules downstream of the IFNαR (Miller et al., 1998), or hypothetically 509 
support the disassembly of nuclear structures to get rid of antiviral components (Van 510 
Sant et al., 2001). These mechanisms have been linked to persistence of infections 511 
induced by some viruses of this family. Although there is no evidence for a specific 512 
viral inhibitor of Mx proteins so far, viruses can subvert the Mx system through 513 
exceptionally fast growth in host cells (Haller et al., 2007) or by affecting signal 514 
transduction upstream of IFN-regulated gene transcription. The presence of other 515 
antiviral factors in FHV-infected feline cells could shed light on possible mechanisms 516 
linked to these findings.  517 
 518 
FIV can readily infect feline immune cells in vitro, offering a system that enables the 519 
study of innate antiviral immune reactions in a heterogeneous population of cells that 520 
actively take part in complex networks of immune interactions both in vitro and in vivo. 521 
Consequently, we studied the effect of viral inoculation in PBMCs on the expression of 522 
all cytokines and receptors for which we had developed real-time qPCR systems. High 523 
levels of type I IFN expression were measured in response to infection, again most 524 
probably linked to the activation of professional dendritic cells producing extraordinary 525 
amounts of these cytokines (Colonna et al., 2004). Similar expression patterns were 526 
noted for all IFNα gene subtypes analysed. Lower induction rates of IFNα3, 7 and 14 527 
subtypes are most likely due to the measurement of individual genes versus the 528 
simultaneous quantification of many subtypes with the real-time assay developed for the 529 
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remaining IFNα subtypes. Although the induction of type I IFN genes largely overlap, 530 
the array of IFNα and IFNω subtypes produced upon stimulation seems to be 531 
determined by cell-specific levels of transcription factors IRF3 and IRF7 (Sato et al., 532 
2000). Furthermore, the extent of biological activity conferred by each individual 533 
protein depends on a variety of factors. Thus, the differential affinity of each subtype to 534 
the subunits of the IFNαR, the surface expression level of IFNαR1 and IFNαR2 in target 535 
cells, as well as the lifetime and stability of the ligand–receptor complex all play a role 536 
in the extent of the host response to infection (Genin et al., 2009). Different pathogens 537 
may influence, in this way, the phenotype of the developing immune response by 538 
shaping the profile of IFN subtypes induced (Foster et al., 2004). As previously shown 539 
for the human IFN system (Loseke et al., 2003), the expression analysis of individual 540 
subtypes by real-time qPCR can provide valuable information on host innate immune 541 
responses to pathogens. We have initiated the development of appropriate tools to study 542 
these mechanisms in more detail in feline species.  543 
Infection of feline PBMCs with FIV led to a substantial downregulation of the 544 
expression of the proinflammatory cytokine gene IL-6. These findings are reminiscent 545 
of previous experiments in which a 100 to100,000-fold reduction of IL-6 transcription 546 
was observed in monocytes from FIV-infected cats (Kipar et al., 2004). Downregulation 547 
of this cytokine was reported to be more intense when infection of the monocyte 548 
fraction itself could not be demonstrated (Kipar et al., 2004). Hypothetically, factors 549 
liberated by primarily infected lymphocytes could affect function and immune 550 
responses of monocytic cells, the main producers of IL-6 in blood. Thus, further 551 
investigations on PBMC subpopulations are required to determine the role of 552 
preferential cell tropism of certain viral strains on measured cytokine responses.  553 
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Our results further indicate a type I IFN-regulated pattern of NK cell stimulator IL-15 554 
gene expression, supporting the previously described role of IFNs in stimulation of NK 555 
cell activity (Vujanovic et al., 2010). In contrast, effectors of NK cytotoxicity were only 556 
marginally induced as measured in PBMCs acutely infected with FIV in this study. 557 
Although low levels of increase in perforin and granzyme B mRNA production have 558 
been described upon stark stimulation, preformed transcripts for these proteins have 559 
been detected in resting NK cells (Fehniger et al., 2007). Gene expression analysis in 560 
separate immune cell populations as well as specific cytotoxicity assays would confer 561 
additional information on the biological value of our observations for these NK cell 562 
related cytokines.   563 
Analysis of the expression of TLR genes demonstrated slight enhancement in mRNA 564 
levels of TLRs 3, 7 and 8 during the peak time point of innate immune response against 565 
FIV. The ssRNA phenotype of this virus coupled with the presence of dsRNA after 566 
reverse transcription during intracellular replication support the requirement for 567 
selectively higher levels of these TLRs upon infection. The relatively low levels of 568 
induction observed could be explained by the presence of a pool of receptors in the 569 
endoplasmatic reticulum that is actively transported to the endosomes following 570 
stimulation of the cell (Latz et al., 2004). Although upregulation of TLR9 after FIV 571 
inoculation of CrFK cells has been reported (Ignacio et al., 2005), our observations 572 
regarding mRNA expression of this TLR gene in acutely FIV-infected PBMCs do not 573 
corroborate with the results previously published.   574 
 575 
To our knowledge, this is the first report showing successful stimulation of innate 576 
mechanisms in feline immune cells by various IRMs. Both kinetics and potency of 577 
responses could be measured. Since mRNA expression of proinflammatory cytokine 578 
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gene IL-6 had been previously used as readout for stimulation through TLRs in 579 
pancreatic islet cells (Franchini et al., 2010), we included this cytokine as comparative 580 
indicator for biological activity of TLR agonist. Our results indicate that IFNα is a more 581 
reliable marker for TLR stimulation in immune cells due to higher stability in 582 
expression over time and apparent higher expression of these cytokines.   583 
Both R-848 and dSLIM could efficiently enhance IFNα expression within 12 hours. 584 
This level of stimulation was likely insufficient to induce measurable increase in Mx 585 
expression, as induction of the gene encoding for this antiviral factor was repeatedly 5 586 
to 10 times lower than that of IFNα in our experiments.  587 
dSLIM is a non-coding DNA molecule that contains several unmethylated CpG 588 
motifs and possesses the broad spectrum immunomodulatory properties of Class C CpG 589 
ODNs (Schmidt et al., 2006). In vitro and in vivo studies have demonstrated 590 
immunomodulatory effects and safety of dSLIM both in humans and mice (Wittig et 591 
al., 2001; Kochling et al., 2003). Moreover, this molecule has exhibited protective 592 
immune stimulation in human colon cancer and is currently undergoing second phase 593 
clinical trials (Weihrauch et al., 2005). In addition to positively influencing IFNα 594 
expression in feline immune cells, dSLIM was the only tested IRM that affected TLR 595 
mRNA levels, leading to a 6-fold upregulation of TLR9. Further experiments will 596 
determine whether such properties could support combinatorial use of this molecule to 597 
enhance effects of other IRMs.  598 
Poly IC was toxic to feline cells already at the lowest concentrations capable of 599 
inducing innate immune responses. Toxicity of this product has long been 600 
acknowledged and studied both in vitro and in vivo (Homan et al., 1972; Lv and Bao, 601 
2009). Mechanisms by which cell death is induced remain unclear, however it has been 602 
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suggested that pathways leading to the induction of type I IFN genes are uncoupled 603 
from apoptotic pathways (Han et al., 2004). We measured high induction of Mx in Poly 604 
IC-treated PBMCs after just 6 hours post inoculation. While the possibility that Mx 605 
proteins fulfil a cellular function involved in cellular trafficking and/or in stress 606 
responses has been postulated (Horisberger, 1992) it remains more likely that presence 607 
of this antiviral factor is indicative of IFNα function. 608 
 609 
Finally, the experiments here described were carried out with PBMCs from only one cat 610 
in order to ensure comparability of both the effects of infection and IRMs at different 611 
time points and the relation between expression levels of the cytokines tested. 612 
Admittedly, innate immune responses may vary considerably between individuals of an 613 
outbred species; however, when purified PBMCs from 8 adult SPF cats were previously 614 
utilized in similar smaller experiments, only slight variation was observed in their 615 
response to IRM stimulation and FIV infection (data not shown). Studies with cells 616 
from cats in the field would most likely give relevant information about individuality in 617 
responses after IRM stimulation or infection.  618 
 619 
Altogether, we describe the development of tools to measure antiviral innate immune 620 
responses in the cat and show their successful utilization in the context of various virus 621 
infections in vitro and in vivo. Moreover, we provide initial evidence of the possibility 622 
of inducing innate immune responses in feline immune cells by stimulation with various 623 
IRMs. Future plans include screening of a vast array of IRMs for optimal manipulation 624 
of the feline innate immune system and enhancing the resistance of felids to viral 625 
infection.    626 
 627 
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Table 1: Cloned feline type I IFN subtypes and the antiviral activity of their purified proteins in vitro  
 
 
Feline type I IFN genes 
 
In vitro antiviral activity of purified proteins 
Subtype Cell type / tissue for cloning Reference Virus Cell line Reference 
IFNω 1,2 T-cell line (LSA-1) Nakamura et al., 1992 
FCV 
 
VSV, FCV, FHV, FCoV, 
FPV, rotavirus 
 
FIV 
CrFK 
 
CrFK, fcwf-4, MDCK 
 
 
FetJ-Bang 
Sakurai et al., 1992 
 
Mochizuki et al., 1994 
 
 
Tanabe and Yamamoto, 2001 
IFNα1-3, 5, 6 Mesenteric lymph node cells Wonderling et al., 2002 VSV, FCV CrFK, AH927 Baldwin et al., 2004 
IFNα7-14 Epithelial cell line (CrFK) Nagai et al., 2004 
 
VSV 
 
 
 
CrFK, fcwf-4, RK-13, 
MDBK, MDCK, L-929, FL 
 
Taira et al., 2005 
IFNω1-13 Spleen of FCoV-infected cat Yang et al., 2007 VSV CrFK, MDCK, MBDK Yang et al., 2007 
 
1 initially classified as IFNω, re-termed “ω-like” by Yang et. al, 2007  
2 purified protein commercialized and utilized in various in vivo studies (see text and Table2) 
VSV: vesicular stomatitis virus, FCV: feline calicivirus, FHV: feline herpes virus, FCoV: feline coronavirus, FPV: feline parvovirus, FIV: feline immunodeficiency virus, AH927: feline embryo fibroblast cell line, CrFK: 
Crandell feline kidney cells, fcwf-4: felis catus whole fetus cells, FetJ-Bang: persistently FIV-infected feline T-cell line, FL: transformed human amnion cells, L-929: mouse fibroblast cell line, LSA-1: cells derived from 
thymic lymphosarkoma of feline leukemia virus positive cat, MDBK: Madin-Darby bovine kidney cells, MDCK: Madin-Darby canine cells, RK-13: rabbit kidney-derived cells  
856 
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856 Table 2: In vivo studies on antiviral effects of feline IFNω (Intercat and Virbagenomega) 
 
Disease Reference 
CPV infection Minagawa et al., 1999 Martin et al., 2002 
FeLV infection FeLV/FIV co-infection de Mari et al., 2004  
FeLV infection Collado et al., 2007 
FPV infection Paltrinieri et al., 2007 
FHV infection Haid et al., 2007 
Herpes dermatitis Gutzwiller et al., 2007 
Chronic gingivostomatitis Southernden and Gorrel, 2007 
FCV Ohe et al., 2008 
 
CPV: canine parvovirus, FCV: feline calicivirus, FeLV: feline leukemia virus, FHV: feline herpes virus,  
FIV: feline immunodeficiency virus, FPV: feline parvovirus  
 
  
856 
Table 3: Real-time qPCR systems for 12 feline genes related to innate immunity 
Gene Accession Number Oligo Sequence Final conc. (nM) Amplicon size (bp) Efficiency 
IFNα AY1173951 Forward 
Probe  
Reverse 
CACGTGACGAACCAGAAGATCTT 
ACTTCTTCTGCACAGAGGCGTCCTCG 
GAGGGTGGTGTTCCAAGCA 
300 
300 
250 
74 1.04 
IFNα3 AY1173931 Forward 
Probe  
Reverse 
CGTGACGAACCAGGAGATCTTC  
ACTTCTTCTGCACAGAGGCGTCCTCG 
GAGGGTGGTGTTCCAAGCA 
900 
900 
250 
72 1.07 
IFNα7 AB0949961 Forward 
Probe  
Reverse 
CACGTGACCAACCAGAAGATCTT 
ACTTCTTCTGCACAGAGGCGTCCTCG 
GAGGGTGGTGTTCCAAGCA 
600 
600 
150 
74 1.13 
IFNα14 AB0950031 Forward 
Probe  
Reverse 
CGTCTGCTCTCTGGGTTGTG 
CCTGCCTCAGACCCACGGCC 
ATTTGTCCCAGGAGCGTCAA 
600 
600 
150 
77 1.00 
IFNβ AB0217071 Forward 
Probe  
Reverse 
TGGAATGAGACCACTGTTGAGAA 
CTCCTTGCGACACTCCACTGGCAG 
GGATCGTTTCCAGGTGTTCCT 
900 
900 
50 
69 0.97 
IFNω DQ4202201 Forward 
Probe  
Reverse 
CGCAGGTTAGCAGGGACAAC 
CGGAGACTGTCCCCTTTCTTGTGCC 
GGGAAGCGGAAGTCTTTTCTG 
600 
600 
50 
93 1.07 
Mx NM0024621 Forward 
Probe  
Reverse 
ACCAGAGCTCGGGCAAGAG 
CCTTCCCAGAGGCAGCGGTATTGTC 
TTCAGCACCAGAGGACACCTT 
900 
900 
250 
96 1.00 
IL-15 ENSFCAG000000118612 Forward 
Probe  
Reverse 
AGTGATGTTCATCCCAATTGCA 
TTCGCTTGAGTCCAAAAATGCGACCA 
ACCGCTGTTTGCTAGGATAATAATG 
400 
400 
50 
135 1.00 
TLR3 ENSFCAT000000061972 Forward 
Probe  
Reverse 
CAACAACTTAGCACGGCTATGG 
AACGTGCAAACCCTAGTGGTCCTGTTGATT 
AATGTGGAGGTGAGAAAGACCC 
400 
400 
80 
72 1.07 
TLR8 ENSFCAG000000072432 Forward 
Probe  
Reverse 
GCTCCAGCTGTTTCCTCATC 
CCAGTTGCTCGACTTAAGTGG 
GAGGCTGTTGGTCAAAGAGG 
400 
400 
80 
82 1.01 
Perforin  EU0325391 Forward 
Probe  
Reverse 
TTCGCGGCCCAGAAGAC 
TTCCACGACCAGTACAGCTTCAGCACTG 
GTGAGAGCTGTAGAAGCGACATTC 
900 
900 
250 
79 0.98 
Granzyme B EU1533671 Forward 
Probe  
Reverse 
CCACCCAGACTATAATCCAAAGAA 
CCAACGACATCATGTTACTGCAGCTGG 
CAGTCAGCTTGGCCTTTTTCA 
600 
600 
250 
77 0.97 
1 GenBank, 2 Ensembl (http://www.ensembl.org/index.html) 
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Figure Legends 856 
 857 
Figure 1. Kinetics of innate cytokine expression in feline PBMCs after IRM stimulation. 858 
Feline PBMCs of one cat were incubated for 6, 12, 24 and 48 hours with A) 144µg/ml 859 
dSLIM, B) 20µg/ml R-848 and C) 20µg/ml Poly IC. mRNA expression of the 860 
indicated genes was measured by real-time qPCR and normalized to expression of two 861 
feline housekeeping genes (GUSB and YWHAZ). Depicted expression factors at each 862 
time point represent the ratio of measured mRNA levels in the IRM-stimulated samples 863 
compared to samples treated with a negative control. Only genes indicating at least a 2-864 
fold modulation in their expression at any time point are shown. Data represent means of 865 
duplicate reactions for each time point.  Standard deviations are shown as an indication 866 
for reproducibility.   867 
 868 
Figure 2. Innate immune responses to FHV and FeLV in vitro. A) CrFK cells were 869 
inoculated with 50 TCID50 of FHV and B) FEA cells were inoculated with 20 TCID50 of 870 
FeLV. mRNA expression of the indicated genes was measured by real-time qPCR and 871 
normalized to expression of two feline housekeeping genes (GUSB and YWHAZ) at time 872 
points indicated for each experiment. Depicted expression factors at each time point 873 
represent the ratio of measured mRNA levels in the infected samples compared to 874 
samples of non-infected cells. Only genes indicating at least a 2-fold modulation in their 875 
expression at any time point are shown. Data represent means of duplicate reactions for 876 
each time point.  Standard deviations are shown as an indication for reproducibility.   877 
 878 
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Figure 3. Innate immune responses to FIV infection of feline PBMCs in vitro. PBMCs of 879 
one cat were inoculated with 50 TCID50 of FIV. mRNA expression of the indicated genes 880 
was measured 3, 6, 12, 24 and 48 hours after inoculation and normalized to expression of 881 
two feline housekeeping genes (GUSB and YWHAZ) at each time point. Depicted 882 
expression factors at each time point represent the ratio of measured mRNA levels in the 883 
IRM-stimulated samples compared to samples treated with a negative control. Only 884 
genes indicating at least a 2-fold modulation in their expression at any time point are 885 
shown. Data represent means of duplicate reactions for each time point.  Standard 886 
deviations are shown as an indication for reproducibility.   887 
 888 
Figure 4. Measurement of IFNα expression levels in blood 1 week after FIV challenge 889 
infection in vivo. mRNA expression of IFNα and two housekeeping genes (GUSB and 890 
YWHAZ) from whole blood samples of 10 cats collected before and 1 week after 891 
challenge infection with FIV was measured by real-time qPCR. DeltaCt values depicted 892 
were calculated by substracting the average of 45-Ct values for two housekeeping genes 893 
(GUSB and YWHAZ) from 45-Ct values for IFNα of the corresponding sample. * 894 
p=0.0059 895 
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3.2 Manuscript 2 
This second manuscript “Stimulation with a Class A CpG Oligonucleotide Enhances 
Resistance of Feline Cells to Infection with Viruses from Five Different Families” 
presents the results of an extensive analysis on the potential of a CpG-containing 
molecule to favourably manipulate the innate immune response of feline immune cells. 
The newly designed PCR assays introduced in the previous manuscript (section 3.1) are 
first utilized to depict the immunomodulatory effects of this IRM on the gene profiles of 
immune cells isolated from the blood of 14 individual cats from different age groups. The 
observations are supported by the measurement of other innate immune parameters on a 
protein level with methods such as flow cytometry and western blot. In a second phase, a 
series of cell culture experiments demonstrate the induction by this IRM of an “antiviral 
state” in target cell lines that subsequently display significantly enhanced resistance to 5 
different feline viruses.  Although the relevance of the findings of this study for the 
human population and the advantages of the feline model for further immunological 
studies are underlined in this article, the data is obviously also of primordial importance 
in veterinary medicine. The text was submitted recently to PLoS One and is currently 
under review.    
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Stimulation with a Class A CpG Oligonucleotide Enhances 1 
Resistance of Feline Cells to Infection with Viruses  2 
from Five Different Families 3 
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 18 
Abstract 19 
Emerging viral diseases represent a considerable threat to humans and animals 20 
worldwide and pressure the development of novel strategies to prevent pandemics. 21 
Oligonucleotides (ODN) containing cytosine-phosphate-guanosine motifs of class A 22 
(CpG-A) are highly potent synthetic inducers of innate antiviral mechanisms. The aim of 23 
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this study was to test their ability to prevent viral replication as stand-alone agents in an 24 
outbred species. We used the domestic cat as a model, as felids are naturally susceptible 25 
to infection by viruses resembling in their biological properties those affecting humans. 26 
CpG-A stimulation of feline peripheral blood mononuclear cells (PBMCs) enhanced their 27 
proliferation, increased the presence of co-stimulatory molecules major 28 
histocompatibility complex (MHC) II and B7.1 on their surface and influenced their gene 29 
expression profiles in an antiviral orientation. Notably, transcription levels of interferon 30 
(IFN)α, interleukin (IL)-6, IL-12, and IFNγ were increased by up to 12’000, 40, 25, and 31 
12-fold respectively in PBMCs pulsed for 24 hours. Incubation of the supernatants of 32 
CpG-A stimulated PBMCs with feline cell lines of epithelial and fibroblastic origin 33 
induced expression of the antiviral myxovirus resistance (Mx) gene in these target cells, 34 
with a peak of up to 2000-fold increase in transcription after 6 hours and protein levels 35 
reaching a maximum within 24 hours and remaining stable for several days thereafter. 36 
Most importantly, the supernatant-treated cells showed significantly enhanced resistance 37 
to feline viruses from 5 distinct families, namely Coronaviridae, Herpesviridae, 38 
Caliciviridae, Parvoviridae, and Retroviridae. The rate of protection of the cells strongly 39 
correlated with the induction of type I IFN in the PBMCs and was concordant with the 40 
level of Mx expression in the target cells. Altogether, our data highlight the promising 41 
potential of CpG-A to induce a preventive antiviral state in outbred species and to protect 42 
populations against a broad range of virus infections.  43 
 44 
45 
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Author Summary 45 
New preventive strategies are required in order to limit the propagation of emergent viral 46 
diseases, such as severe acute respiratory syndrome (SARS) and avian influenza, which 47 
can endanger human and animal populations. In contrast to vaccination, protection 48 
conferred by modulation of the innate immune system holds the advantages of inducing 49 
immediate responses and overcoming barriers set by the inability to predict the exact 50 
nature of new pathogens. Synthetic oligonuleotides containing unmethylated cytosine-51 
phosphate-guanosine motifs (CpG ODN) are readily recognized by mammalian innate 52 
immune cells and offer a powerful means to stimulate early defense mechanisms. For our 53 
studies related to innate immunity, we selected to work with the domestic cat, which 54 
belongs to an outbred species naturally affected by many viruses with human 55 
counterparts. Herein, we illustrate the broad immunomodulatory and antiviral properties 56 
of a class A CpG ODN (CpG-A) in feline cells. Stimulation of immune cells with this 57 
molecule increased their proliferation, promoted intercellular interactions, and induced 58 
production of soluble molecules that could impair replication of viruses from five 59 
families in feline target cells of various tissue origins. Our results underline for the first 60 
time the promising potential of CpG-A in generating general resistance to viral infection 61 
in an outbred species.  62 
 63 
Introduction 64 
Viruses represent a considerable threat to humans and animals worldwide. Although 65 
vaccination successfully confers protection to certain infectious agents, the currently 66 
most dangerous pathogens tend to be emerging and re-emerging viruses such as the 67 
severe acute respiratory syndrome (SARS)-associated Coronavirus, influenzaviruses, the 68 
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human immunodeficiency virus (HIV) and West Nile and Ebolaviruses, as they are often 69 
of unknown origin, insufficiently characterized or rapidly changing, and threaten to 70 
disseminate before a vaccine or appropriate treatment can be made available to the 71 
population. Thus, in order to diminish risks of pandemics, the development of additional 72 
prophylactic strategies is currently needed.  73 
 74 
A promising addition to vaccination is the manipulation of innate immunity. Innate 75 
pathogen recognition relies on a set of sensory molecules, the Toll-like receptors (TLRs), 76 
which enable the immediate reaction of specific immune cells to pathogen “danger 77 
signals”, the so-called pathogen-associated molecular patterns (PAMPs) [1]. Due to their 78 
abundance in all bacterial as well as some viral genomes, oligodeoxynucleotides (ODN) 79 
containing unmethylated cytosine–phosphate–guanosine (CpG) motifs are effectively 80 
recognized as PAMPs by the vertebrate innate immune system [2]. Response to CpG 81 
ODN stimulation is conferred through TLR9, expressed mainly in the intracellular 82 
compartments of human B cells and plasmacytoid dendritic cells (pDCs) [3,4]. Alarmed 83 
TLR9 is the initial instigator of gene expression profiles that strongly support antiviral 84 
mechanisms: upregulation of costimulatory molecules major histocompatibility complex 85 
(MHC) II, B7.1 and B7.2 on the surface of stimulated cells provides them with a stronger 86 
antigen presenting potential [5,6] and production of cytokines such as type I interferon 87 
(IFN), interleukin (IL)-12, IFNγ, IL-6 and tumor necrosis factor (TNF)α, contribute to 88 
providing an optimal immune environment for the development of innate and adaptive 89 
responses against intracellular pathogens [7,8]. Probably the most important antiviral 90 
property of CpG ODN resides in their potential to stimulate the production of high 91 
amounts of type I IFN by pDCs [9]. This family of cytokines, which includes IFNα, 92 
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IFNω and IFNβ, has been shown to considerably enhance natural killer (NK) cell 93 
cytotoxicity [10], promote differentiation, maturation and immunostimulatory functions 94 
of monocytes and DCs [11], induce B cell production of  immunoglobulin [12] and T-95 
helper (Th)1 differentiation of T cells [13,14]. Moreover, upon binding to their 96 
ubiquitously distributed receptor, type I IFNs effectively induce the synthesis of various 97 
intracellular proteins which interfere with the replication of a broad range of viruses [15]. 98 
The myxovirus-resistance protein (Mx) GTPase is a well-studied example of these 99 
intracellular antiviral effectors. This enzyme is known to be directly regulated by the type 100 
I IFN, and its detection is readily used as marker for upregulation and biological activity 101 
of this cytokine family [16]. 102 
 103 
Distinct classes of ODN have been shown to induce differential responses by human cells 104 
[17]. Class A CpG ODN (CpG-A) consist of CpG motifs in a phosphodiester core, 105 
flanked on both ends by phosphorothioate poly (G) sequences. CpG ODN of this class 106 
are characterized by their potential to both induce massive type I IFN secretion by pDCs 107 
[9] and increase NK cytotoxicity [18], rendering them ideal candidates as prophylactic 108 
enhancers of innate immunity to viral infections. Conversely, class B CpG ODN (CpG-109 
B), which encode multiple CpG motifs on a phosphorothioate backbone, promote 110 
monocyte maturation and B cell activation, thus substantially supporting the development 111 
of humoral immune responses [19,20,21]. Both CpG-A and CpG-B have indicated 112 
immunostimulatory properties in immune cells of mice, primates and many domestic 113 
species in vitro [22,23,24,25,26,27,28,29], while in vivo studies in outbred animals have 114 
mainly been carried out with CpG-B [21,30,31]. In an effort to combine the 115 
advantageous effects of both CpG-A and CpG-B, class C [32,33] and class P ODN [34] 116 
were developed in more recent years. Although in vivo use of these newer classes of CpG 117 
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ODN seems promising [35,36,37,38], CpG-A remain the strongest inducers of type I IFN 118 
described to date. 119 
 120 
In light of their broad immunomodulatory properties, CpG ODN have made their way to 121 
human clinical trials as vaccine adjuvants [39] and as combinatorial or monotherapies for 122 
cancer [40], allergies [41] and chronic infectious diseases [42]. Meanwhile, their 123 
potential as prophylactic stand-alone inducers of innate defense mechanisms has been the 124 
subject of fewer studies. Most works in this field initially described protection of mice 125 
against bacterial [43,44,45,46,47] and parasitic [48,49,50] infections. More recently, 126 
induction of resistance to viral infections was shown also in mouse models for Herpes 127 
Simplex Virus [51], Vaccinia virus [52], neurotropic arenavirus [53] and foot and mouth 128 
disease virus [54]. With exception of the latter, all these studies were carried out with 129 
CpG-B. In an outbred species, partial antiviral protection has only been described in two 130 
studies so far, in which reduced shedding of herpes and parainfluenza viruses was 131 
observed in lambs after administration also of a CpG-B [55,56]. To our knowledge, 132 
prophylactic antiviral potential of CpG-A has not yet been described in outbred animals. 133 
 134 
The feline model holds several advantages in studies related to innate immunity and viral 135 
diseases. First, in contrast to laboratory mice, cats belong to an outbred species, enabling 136 
more realistic consideration of individual variability in immunologic responses. Studies 137 
with felids also enable to circumvent issues related to the notable differences between the 138 
innate immune systems of mice and humans, including altered expression and repartition 139 
of TLRs [57,58], different NK cell activating ligands [57], distinctive stimulatory CpG 140 
ODN sequences [22] and absence of important antiviral mechanisms in inbred strains 141 
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[16]. Furthermore, while felids are naturally affected by viruses with biological 142 
properties very similar to those affecting humans [59], the necessity in murine models to 143 
either modify the infectious agent or to create transgenic animals considerably limit the 144 
possibilities to extrapolate data from mice to humans [57]. Finally, while feline viruses 145 
have acquired challenging propagation strategies throughout evolution, cats have 146 
retaliated with the development of a stark innate antiviral immune system. Altogether, 147 
almost 30 subtypes of feline type I IFN have been identified [60,61,62,63] and their 148 
biological properties characterized [63,64,65]. 149 
 150 
With the objective to characterize both the immunomodulatory and antiviral properties of 151 
CpG-A, we carried out a series of in vitro experiments and observed the induction of 152 
broad immunoprotective effects in the feline model. In addition to strengthening the 153 
antiviral qualities of feline immune cells, we found that the prototype of CpG-A, ODN 154 
2216 [9], can stimulate the production by these cells of soluble molecules possessing 155 
inhibitory properties on the replication of five different families of viruses: 156 
Coronaviridae, Herpesviridae, Caliciviridae, Parvoviridae, and Retroviridae. 157 
 158 
Results 159 
Prototype CpG-A, ODN 2216, induce proliferation of primary feline immune cells and 160 
enhance their expression of costimulatory surface molecules 161 
Proliferation of peripheral blood mononuclear cells (PBMCs) in response to treatment 162 
with CpG ODN gives strong indications about the biological activity of the stimulatory 163 
molecule and has been used to screen ODN in many species [22]. In relation to this, the 164 
potential of CpG-A to induce proliferation of feline PBMCs was assessed by 165 
Manuscript 2 
 
Celine Robert-Tissot • July 2011 77 
measurement of 3H-thymidine incorporation after stimulation. Purified PBMCs from 166 
eight adult cats proliferated significantly in presence of ODN 2216 when compared to 167 
cells treated with either ODN 2243 (p= 0.0039) or phosphate buffered saline (PBS) 168 
(p=0.0078) as inactive controls (Fig 1A).  The cells of four cats (c06, c08, c09, c12) 169 
could be stimulated to particularly high proliferative rates by ODN 2216 (values above 170 
the mean of eight cats illustrated in Fig1A) in the following order: c08>c12>c09>c06. 171 
Another characteristic feature of stimulatory ODN is their ability to enhance interactions 172 
between various immune cell populations by upregulation of cell surface costimulatory 173 
molecules. With the objective to test whether ODN 2216 could exert such properties in 174 
feline immune cells, the expression of B7.1 and MHCII was measured by flow cytometry 175 
in stimulated PBMCs of the same eight cats as above. Difficulties linked to both limited 176 
availability of labeled antibodies for the feline species and few possibilities for co-177 
staining of several markers and cell populations had to be circumvented in these 178 
experiments by evaluating the expression of both co-stimulatory molecules in gates 179 
defined to contain a PBMC population, a lymphocyte population and a non-lymphocyte 180 
population of cells. The observed effects varied considerably between the cells of 181 
individual cats, ranging from no alterations to an increase of 400% stained cells in some 182 
cellular subpopulations after ODN 2216 stimulation. Also, in some animals, stimulation 183 
with the control ODN 2243 indicated similar staining patterns as PBS, whereas in other 184 
cats the induction of effects comparable to those of ODN 2216 could be observed. The 185 
response of cells originating from a particular cat to stimulation with ODN 2243 did not 186 
however correlate with the influence of ODN 2216 on the expression of either surface 187 
molecule on these same cells. Altogether, a significantly larger percentage of cells within 188 
each gated population expressed higher B7.1 levels upon a 24-hour stimulation with 189 
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ODN 2216, when compared to stimulation with ODN 2243 or PBS (Fig 1B). Feline 190 
MHCII expression was assessed by differences in the mean fluorescence intensities in 191 
gated populations of differentially stimulated cells. Such measurements were selected 192 
because, in contrast to mice, MHCII is constitutively expressed in most cellular 193 
subpopulations of feline PBMCs. Overall, an increased expression of MHCII was 194 
measured in gated PBMCs as well as in cells gated as lymphocytes after stimulation with 195 
ODN 2216 for 24 hours. In contrast, the expression of this surface molecule in cells gated 196 
as non-lymphocytes did not alter significantly (Fig 1C). The cells of the three cats (c08, 197 
c09 and c12) that exhibited the highest proliferation rates in response to ODN 2216 (Fig 198 
1A) also indicated the strongest increase in expression of both cell surface molecules in 199 
all cellular subpopulations tested.  200 
 201 
ODN 2216 influence type I IFN and proinflammatory gene expression in primary 202 
feline immune cells 203 
Through interaction with the TLR9, CpG-A typically induce expression of both type I 204 
IFN and proinflammatory cytokines in stimulated cells [9]. In order to understand 205 
whether ODN 2216 exert similar effects in the cat, treated cultures of feline PBMCs, 206 
FEA, CrFK and fcwf-4 cells were systematically screened for increased mRNA 207 
expression of IFNα and IL-6 following stimulation. All tested immortalized feline cell 208 
lines failed to respond to stimulation with ODN 2216 (Fig 2A and data not shown). 209 
However, this molecule exhibited potent immunomodulatory properties in feline 210 
PBMCs: when measured 24 hours post stimulation, a concentration of only 1µg/ml ODN 211 
2216 was sufficient to enhance transcription of IFNα by 40-fold, and a maximum 212 
induction of this gene was observed when 4µg/ml ODN were used (Fig 2B). Although 213 
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affected in a similar pattern, the mRNA expression of the proinflammatory cytokine IL-6 214 
remained comparatively low at all concentrations tested (Fig 2B). In experiments 215 
foreseen to determine gene expression kinetics in feline cells after stimulation with the 216 
ODN 2216 molecule, an influence on IFNα transcription could be measured as early as 3 217 
hours after treatment of PBMCs, whereas increased levels of IL-6 mRNA were observed 218 
only as of 6 hours post stimulation. Notably, the highest induction of both genes was 219 
measured 24 hours after addition of ODN 2216 to the cultures, with transcription 220 
increasing by 9000-fold and 39-fold at this time point for IFNα and IL-6 respectively 221 
(Fig 2C). The observed effects were specifically conferred by the CpG motifs comprised 222 
in the 2216 ODN, since specific control ODN 2243 only induced slight elevations in the 223 
expression of the genes tested (Fig 2B and 2C). Importantly, trypan blue exclusion 224 
experiments indicated no evidence of cellular toxicity after treatment neither with ODN 225 
2216 nor with ODN 2243 at all concentrations tested (data not shown).  226 
 227 
ODN 2216 broadly influence the gene expression profile in primary feline immune 228 
cells of adult cats 229 
In an effort to assess both the breadth of the effects conferred by treatment with a CpG-A 230 
and possible variability in the responses obtained in individual cats, the mRNA 231 
expression of 10 genes relevant to early immune responses was measured in ODN 2216 232 
stimulated PBMCs of fourteen cats divided in four different age groups (group 1: 10 233 
weeks (n=4), group 2: 1.5 years (n=4), group 3: 7 years (n=4), group 4: 14 years (n=2)). 234 
Only slight individual variability in gene induction was observed after 24 hours 235 
stimulation of immune cells from adult cats ranging between 1.5 and 14 years of age (Fig 236 
3A, groups 2-4). Overall, the mRNA expression profile measured in stimulated PBMCs 237 
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of these cats corroborated their induction of strong antiviral immune responses. The 238 
induction of type I IFN mRNA, including IFNα, IFNβ and IFNω was substantially 239 
higher in the immune cells from every adult cat, with minimal inductions of 490, 60 and 240 
1600-fold respectively observed in the older animals of group 4. Moreover, all individual 241 
IFNα subtypes tested were induced at similar levels in the cells of four adult cats from 242 
group 2 (Fig 3B). Increased levels of proinflammatory cytokine mRNA were also 243 
measured in most individuals of groups 2-4, with IL-6 more systematically increased 244 
than TNFα. The cells from these cats indicated a typical Th1 orientation after 245 
stimulation, with enhanced transcription of IL-12 in 9/10 and IFNγ in 6/10 animals, 246 
together with absent or only low induction of IL-4. Stimulation of PBMCs with ODN 247 
2216 also created an optimal environment for NK cell activity, as indicated by the 248 
increases in mRNA expression of NK cell stimulator IL-15 by up to 20-fold and NK cell 249 
effector Granzyme B by up to 7-fold. The cells of those cats (c06, c08, c09, c12) that had 250 
most effectively proliferated (Fig 1A) and/or exhibited the strongest expression of co-251 
stimulatory molecules (Fig 1B and 1C) following ODN 2216 stimulation also 252 
consistently expressed the highest mRNA levels of IFNα, IFNω, IL-6, Il-12, IL-15 and 253 
Granzyme B. PBMCs of cat c08 (group 2) were thereby by far most responsive to 254 
stimulation with ODN 2216. When cells from kittens of group 1 were stimulated, higher 255 
individual variability was observed. The PBMCs of only 2 out of 4 cats from this group 256 
could be stimulated with ODN 2216 to increase mRNA expression of the tested genes. In 257 
both individuals, not only the mRNA expression of type I IFN genes was enhanced at 258 
much lower levels than observed in adult cats but the overall immune response favored a 259 
Th2 direction, characterized by upregulated IL-4 and downregulated IL-12 mRNA levels 260 
(Fig 3A, group 1).  261 
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In order to determine whether a discrepancy in expression of TLR9 between the PBMCs 262 
of adult animals and kittens could play a role in these observations, mRNA levels of this 263 
gene were measured in immune cells of each cat. Although basal TLR9 expression was 264 
similar in the PBMCs of the cats of all age groups (Fig 3C, top panel), ODN 2216 265 
stimulation increased TLR9 transcription in the cells of kittens, but decreased 266 
transcription of this gene in the cells of adult cats so that differences in the mRNA levels 267 
of this receptor were significantly higher in young cats (group 1) than in adult cats of 268 
groups 2 and 3 (p=0.0286) (Fig 3C, bottom panel).  269 
 270 
ODN 2216 induce the production of soluble molecules that activate intracellular 271 
antiviral mechanisms in feline target cells 272 
Protective properties of type I IFN against viruses originate from their ability to trigger 273 
the production of potent antiviral proteins in nearby cells. The expression of one of these 274 
antiviral proteins, the Mx GTPase, is known to be directly stimulated by type I IFN and 275 
can be used as marker for the induction of intracellular antiviral mechanisms by these 276 
cytokines in cats as well as in other species [16,66]. Thus, as detection of feline type I 277 
IFN on a protein level is rendered difficult by the lack of antibodies on the market 278 
specifically recognizing these proteins, mRNA levels of Mx were measured in feline 279 
PBMCs after stimulation with ODN 2216 as indication for production of type I IFN. 280 
Transcription of Mx was significantly enhanced and remained proportional to mRNA 281 
expression of type I IFN in stimulated PBMCs of individual cats (Fig 4A). Moreover, 282 
peak levels of Mx mRNA were measured 24 hours after stimulation of the cells, 283 
indicating the presence of optimal effects of the type I IFN present in the cell culture 284 
medium at this time point (Fig 4B). In order to further determine the potential of the type 285 
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I IFN liberated by PBMCs after ODN 2216 stimulation to induce intracellular antiviral 286 
mechanisms in non-immune target cells, cell-free supernatants of PBMCs derived from 287 
the blood of individual adult cats and stimulated in vitro for 24 hours with ODN 2216, 288 
ODN 2243 or endotoxin-free PBS (Sup 2216, Sup 2243 and Sup Neg respectively), were 289 
incubated with CrFK and fcwf-4 cells. Mx gene transcription was significantly enhanced 290 
in cells treated with Sup 2216 compared to Sup 2243 (p=0.0078) and Sup Neg 291 
(p=0.0078), at levels comparable to those achieved by stimulation of the cells with 100U 292 
recombinant feline IFNα (rfeIFNα) (Fig 4C and data not shown). The Sup 2216 derived 293 
from cells of individual animals (c06, c08, c09, c12), that had shown particularly strong 294 
responses to ODN 2216 in previous experiments, also induced the highest Mx mRNA 295 
expression in both cell lines tested. Although treatment with Sup 2243 systematically 296 
increased Mx transcription in target cells, protein levels remained low (Fig 4C and data 297 
not shown). Furthermore, peak induction of Mx transcription was observed in both cell 298 
lines already within 6 hours of incubation with Sup 2216, while protein levels achieved 299 
maximum levels within 24 hours post stimulation and remained stable thereafter at least 300 
for another 24-48 hours (Fig 4D and data not shown).  301 
 302 
ODN 2216 inhibit replication of common feline viruses in vitro  303 
Felids are frequently affected by four viruses of different families: the feline herpes virus 304 
(FHV), calicivirus (FCV), parvovirus (FPV) and coronavirus (FCoV). Although these 305 
viruses cannot productively infect purified PBMCs in vitro, they share the ability to 306 
induce cytopathic effects (CPE) in CrFK and fcwf-4 cells. These feline cell lines, 307 
however, do not alter their mRNA levels of genes selected as markers for innate 308 
immunity upon direct treatment with ODN 2216 (Fig 2A and data not shown), preventing 309 
Manuscript 2 
 
Celine Robert-Tissot • July 2011 83 
from assessing the potential of this molecule to inhibit viral replication directly in these 310 
cells. Thus, CrFK and fcwf-4 cells were incubated, prior to their inoculation, with the 311 
cell-free supernatants of PBMCs mentioned above: Sup 2216, Sup 2243 and Sup Neg. To 312 
this aim, supernatants derived from PBMCs treated for 24 hours were selected, as Sup 313 
2216 produced by the cells of several adult cats were estimated to contain optimal type I 314 
IFN amounts at this time point, according to the induction of Mx transcription measured 315 
directly in these immune cells (Fig. 4A and 4B). CrFK and fcwf-4 target cells were then 316 
incubated with the supernatants for 24 hours before inoculation, as this time span had 317 
indicated highest induction of antiviral mechanisms (Fig 4D). The antiviral effects of the 318 
supernatants were initially tested on vesicular stomatitis virus (VSV) as control, as this 319 
virus is widely recognized for both its potential to induce CPE in cell lines of multiple 320 
species and for its particularly high sensitivity to the effects of type I IFN [67]. When the 321 
Sup 2216 derived from the PBMCs of eight adult cats that had broadly responded to in 322 
vitro ODN 2216 stimulation (Fig 3A, groups 2 and 3) were incubated with fcwf-4 cells 323 
prior to their inoculation, significant inhibition of VSV replication was observed 324 
(p=0.0039) (Fig 5A). The replication of this virus was also to some degree repressed by 325 
Sup 2243 (p=0.0078), an observation reminiscent of the slight induction of Mx in target 326 
cells incubated with these supernatants (Fig 4C). In turn, the propagation of FCV, FCoV, 327 
FHV and FPV on fcwf-4 cells was also significantly suppressed by the Sup 2216 when 328 
compared to Sup 2243 (p=0.0039, p=0.0039, p=0.0078 and p=0.0039 respectively) and 329 
Sup Neg (p=0.0039), however with expected lower sensitivity than VSV (Fig 5A and 330 
Table 1). Both Sup 2243 and Sup Neg failed to inhibit replication of this heterogeneous 331 
group of feline viruses, underlining the essential role of the 2216 molecule in conferring 332 
the observed effects. Importantly, cells stimulated with ODN 2216 directly did not 333 
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indicate any resistance to viral replication, in concordance to their impaired response to 334 
this molecule already measured on a genetic level (Fig2A and data not shown). With 335 
respect to the younger cats, the Sup 2216 of those 2 kittens whose cells responded to 336 
ODN 2216 stimulation (Fig 3A, group 1) could also inhibit both VSV and FCV on fcwf-337 
4 cells, while the supernatants derived from the PBMCs of the other 2 kittens indicated 338 
no inhibition potential on these viruses (Fig 5C). Altogether, the suppression of viral 339 
replication by the Sup 2216 of the cats could be compared to that conferred by treatment 340 
of the cells with 10 to 100U rfeIFNα (data not shown), and induction of Mx target cells 341 
by the supernatants highly correlated with the inhibition of all viruses (Fig 5B). Finally, 342 
Sup 2216 derived from PBMCs of cats c06 and c08, whose cells had indicated strong 343 
responsiveness to stimulation with ODN 2216 in previous experiments, most efficiently 344 
inhibited the replication of all viruses.   345 
Similar results were notably obtained when the supernatants of PBMCs derived from all 346 
cats were incubated with CrFK cells prior to their inoculation with all the above-347 
mentioned viruses (data not shown). This cell line has previously indicated less 348 
sensitivity to the antiviral effects of type I IFN [68] and concordantly, average fold viral 349 
inhibition in CrFK cells in our experiments was approximately half that observed in 350 
fcwf-4 cells.   351 
 352 
ODN 2216 inhibits replication of a retrovirus in vitro  353 
The life cycle of retroviruses is characterized by the reverse transcription of their 354 
genomic RNA into DNA and subsequent integration of this viral DNA as provirus into 355 
the genome of the host, causing permanent infection most often accompanied by 356 
persistent virus production by infected cells. The feline leukemia virus (FeLV), a 357 
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gammaretrovirus that can be propagated on FEA cells in vitro, affects domestic cats 358 
worldwide. As viral replication in chronically infected cats can be lowered by treatment 359 
with IFNα [69], the potential of Sup 2216 produced by the PBMCs of five adult cats (c06 360 
and c08 from group 2; c09, c10, c12 from group 3) to inhibit productive infection of FEA 361 
cells was analyzed. In initial experiments, this cell line exhibited similar responses as 362 
fcwf-4 and CrFK cells to both direct treatment with ODN 2216 and incubation with the 363 
different supernatants (Fig 2A, 4C and data not shown). Compared to incubation with 364 
medium alone, treatment of FEA cells with Sup 2216 for 24 hours prior to inoculation 365 
with FeLV followed by repetitive treatments of the cells with this supernatant every 2 366 
days thereafter significantly reduced viral RNA (p<0.05) and DNA (p<0.05) measured in 367 
the cell culture supernatants and cells respectively as of 4 days post inoculation (Fig 6A). 368 
The antiviral potential of the supernatants from the individual cats was very similar; 369 
however the best results were conferred by the Sup 2216 derived from cells of c08 370 
(depicted in Fig 6A). The kinetic curve of viral RNA loads in cultures of cells treated 371 
with Sup 2216 of this cat was similar to those obtained in cells treated with 50U rfeIFNα 372 
(data not shown). Also, treatment of the cells with ODN 2216 directly affected neither 373 
viral RNA nor viral DNA loads measured in the supernatants and the cells respectively 374 
(data not shown). Mx mRNA expression was 80-fold higher in the Sup 2216 treated cells 375 
than in all controls 8 days post inoculation, indicating the ability of these supernatants to 376 
sustain antiviral mechanisms when applied to the cells repeatedly (Fig 6B). Furthermore 377 
at this time point, the Sup 2216 treated cells exhibited significantly lower viral DNA 378 
loads (p=0.0313) and produced significantly less virus (p=0.0313) than cells treated with 379 
Sup 2243, Sup Neg or medium alone (Fig 6B). The extent of Mx transcription conferred 380 
by the Sup 2216 of the cats strongly correlated with lower provirus (p=0.0053) and virus 381 
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(p=0.0012) loads measured in the FEA cells and supernatants respectively on day 8 post 382 
inoculation (p=0.0053). Also, the highest Mx mRNA levels in target cells were conferred 383 
by Sup 2216 of cat c08 and reflected by the lowest viral and proviral loads measured at 384 
this time point in our experiments.  385 
 386 
Discussion 387 
In the present study, we show that the broad immunomodulatory effects of CpG-A in 388 
feline cells could prophylactically inhibit the replication of five feline viruses from 389 
different families, namely FCV, FPV, FHV, FCoV and FeLV. ODN 2216, the first 390 
described CpG-A [9], could stimulate feline PBMCs to produce soluble molecules that 391 
significantly increased resistance of various feline target cell lines to viral propagation. 392 
The observed repression of viral replication highly correlated with the mRNA expression 393 
of type I IFN genes in stimulated PBMCs as well as the induction, prior to inoculation, of 394 
antiviral mechanisms in the target cells. To our knowledge, this is the first study 395 
reporting efficient inhibition of viral replication by a CpG-A in an outbred species. 396 
Furthermore, our results demonstrate the potent prophylactic potential of a synthetic 397 
molecule as stand-alone agent against a large range of viral pathogens simultaneously.  398 
 399 
Cells of the feline immune system were strongly influenced when cultured in the 400 
presence of ODN 2216. The CpG motifs comprised in the molecule were essential 401 
contributors to the immunomodulatory and antiviral effects of this molecule, while the 402 
sequence of flanking nucleotides, the single-stranded structure as well as the synthetic 403 
nature of the backbone thereby played a minor role, as indicated by the only slight 404 
stimulatory potential of the GpC control ODN 2243 in most experiments. As shown in 405 
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this study in experiments conducted with PBMCs of eight to fourteen SPF cats, ODN 406 
2216 significantly altered the behavior and phenotype of feline immune cells.   407 
First, feline PBMCs significantly proliferated in presence of ODN 2216 (Fig 1A), 408 
indicating a direct and /or indirect stimulation of one or more immune cell 409 
subpopulations by this molecule. Although in contrast to other classes of ODN, CpG-A 410 
does not generally induce lymphocyte proliferation in mice [9], similar effects have 411 
previously been observed in an outbred species, where higher concentrations of CpG-A 412 
could induce minimal levels of proliferation in ovine cells [70].  413 
Additionally, ODN 2216 increased the expression of cell surface co-stimulatory 414 
molecules in PBMCs (Fig 1B and 1C), reinforcing possible interactions between various 415 
immune cell populations. While B7.1 molecules were upregulated on both lymphocytic 416 
and non-lymphocytic cells after ODN 2216 stimulation, MHCII expression could only be 417 
increased on lymphocytic cells. This observation may be linked to the necessity of 418 
transport to the cell surface of MHCII molecules coupled with antigen for presentation to 419 
other immune cells. Also, not only the presence of CpG motifs but also the chemical 420 
structure of the ODN seemed to play an important role in the upregulation of MHCII and 421 
B7.1 co-stimulatory molecules in feline PBMCs, as control ODN 2243 also significantly 422 
increased expression of both B7.1 and MHCII in stimulated lymphocytic cells. The 423 
potential of synthetic backbones to enhance cell surface molecule expression in immune 424 
cells has indeed already been reported [71]. It should also be noted that results in these 425 
experiments indicated relatively high variability among the cats, reflecting the 426 
heterogeneity of PBMC subpopulations in individuals of the same species. Differential 427 
gating adapted to the PBMC phenotypes of each animal or differentiation of various 428 
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immune cell subpopulations by co-staining for appropriate markers could confer further 429 
information concerning intraspecies stimulatory variability.  430 
Finally, the transcription of a series of markers of innate immune responses was 431 
considerably influenced in feline PBMCs by stimulation with ODN 2216. The most 432 
astonishing effects of this molecule remain the potent induction of IFNα and IFNω, with 433 
mRNA expression of these genes increased by up to 12’000 and 35’000-fold respectively 434 
in PBMCs of certain animals (Fig 3A). In line with observations published recently, the 435 
induction of IFNγ by this CpG ODN remained moderate [72]; nevertheless, the 436 
measurements carried out 24 hours after stimulation of purified feline cells support 437 
induction of Th1-oriented immune responses and enhanced NK cell activity, both highly 438 
desired in the contexts of viral infection.  439 
Altogether, although the immune cells collected from cats of 14 years of age seem to 440 
respond slightly less well to ODN 2216 than those of younger adult animals (Fig 3A), 441 
consistency in stimulatory potential of this molecule among adult animals was reflected 442 
through the highly similar patterns in gene expression profiles induced in immune cells 443 
after stimulation as well as the moderate deviations in those experiments aiming the 444 
characterization of immunomodulatory properties of ODN 2216 (Fig 1A, 1B, 1C and Fig 445 
3A, groups 2-4). The cells of several animals however, in particular cat c08, but also c06, 446 
c09 and c12, indicated particularly strong responsiveness to stimulation throughout the 447 
study. Such observations are most likely linked to the genetic variability of individuals of 448 
an outbred species, as inherited factors are known to play an important role in the 449 
magnitude of innate immune responses [73]. With respect to this observation, it should 450 
be noted that the SPF origin and maintenance in a barrier facility of the animals included 451 
in this study may slightly lower the variability in strength and breadth of innate immune 452 
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responses, and studies with cells obtained from field cats would give further information 453 
on divergence in response to stimulation of the innate immune cells of individual 454 
animals.  455 
Notably, the immune cells of kittens indicated much more reticence to stimulation, with 456 
either limited or absent upregulation of both type I IFN and other genes measured after 457 
incubation with ODN 2216. Stimulated PBMCs from this group of young animals 458 
moreover indicated a tendency to develop an immunologic environment with a Th2 459 
orientation, including higher production of IL-4 and impaired induction of IL-12 460 
compared to cells from adult cats. Although the kittens included in this study were 461 
already of 10 weeks of age, these observations strongly corroborate the immature IFN 462 
system of neonatal mice [74], the impaired immune cell activation via TLR9 in human 463 
neonatal mononuclear cells [75,76] and the bias towards Th2 rather than Th1 responses 464 
in human fetuses and neonates [77,78].  465 
Furthermore, concordantly to findings in human neonatal blood [79,80], basal TLR9 466 
transcription in kittens indicated levels similar to those of adults. However, ODN 2216 467 
stimulation increased mRNA expression of this gene only in the young animals (Fig. 3C). 468 
The lack of specific antibodies to feline TLR9 unfortunately renders further 469 
investigations on the mechanism behind these results and their implications in CpG ODN 470 
stimulation in kittens rather challenging. This observation may however be linked to the 471 
accumulation of TLR9 proteins in the endoplasmic reticulum of adult immune cells as a 472 
pool awaiting transport to the endosomes upon ligand-induced stimulation. Such a 473 
reserve of TLR9 proteins could substantially decrease the necessity of upregulation on 474 
the mRNA level [81]. Young individuals hypothetically have yet to establish this TLR9 475 
pool in the endoplasmatic reticulum, leading to increased transcription of this gene 476 
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following stimulation with CpG ODN. Altogether, the results obtained from this 477 
extensive study regarding the effects of CpG-A on feline immune cells further support 478 
the suitability of the feline model for studies concerning early immune mechanisms and 479 
open new perspectives on possible explanations for the qualitative discrepancy between 480 
innate immune responses in newborns and adults.  481 
 482 
Preventive treatment of cells with CpG ODN strengthens considerably the antiviral 483 
defense mechanisms of these and surrounding cells, restricting viral infections, and thus 484 
tilting the immunological balance in favor of the host. Concordantly, in infections with 485 
rapidly dividing pathogens, optimal protection of mouse models can be observed when 486 
CpG ODN are administered prior to infection [82]. Our data demonstrate that five viral 487 
species belonging to the Calicivirus, Herpes virus, Parvovirus, Coronavirus and 488 
Retrovirus families were sensitive to the immunologic effects of ODN 2216 in cats. 489 
Interestingly, although a recombinant feline type I IFN marketed in both Japan 490 
(Intercat®) and Europe (Virbagen Omega®) has made its way into therapeutic protocols 491 
for FCV, FHV, FeLV and canine parvovirus infections [69,83,84,85,86,87,88] and has 492 
demonstrated preventive capacities in a cattery developing an outbreak of FPV [89], CpG 493 
ODN have not yet been tested in any clinical settings in this species. In view of the 494 
potent induction of IFNα by CpG-A, it seemed reasonable to anticipate viral inhibition 495 
potential by this class of ODN. Surprisingly, CpG-A have shown prophylactic potential 496 
only in a mouse model of orthopoxvirus infection [52], and no studies have been 497 
conducted to date with this class of ODN in outbred species, even though strong 498 
immunomodulatory properties of this molecule have already been reported in cows, 499 
sheep, pigs and primates in vitro [26,28,29]. Moreover, when compared to direct 500 
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initiation of antiviral mechanisms by a recombinant IFNα protein, administration of CpG 501 
ODN holds the advantage of inducing the production of all type I IFN and their subtypes 502 
(Fig 3B), which have been shown to possess differential antiviral properties [90]. Also, 503 
CpG ODN specifically target dendritic cells (DCs), a non-lymphocytic cell population 504 
widely recognized to link innate and adaptive immune mechanisms. Modifications in the 505 
gene expression profile of non-lymphocytic cells by ODN 2216 enhances the expression 506 
of costimulatory molecules on their surface (Fig 1B) as well as the secretion of a broad 507 
range of cytokines (Fig 3A), both mechanisms enabling further transfer of the stimulatory 508 
signals to cells of the innate and specific immune systems.   509 
 510 
In view of future in vivo experiments, a 3-step in vitro system was conceptualized and 511 
utilized in this study: purified PBMCs were first stimulated with ODN 2216 to secrete 512 
soluble molecules, including type I IFN, into the culture medium; cell-free supernatants 513 
of the stimulated PBMCs were then incubated with a target cell line reminiscent of 514 
epithelial (CrFK) or fibroblastic (fcwf-4, FEA) tissue; target cells were finally inoculated 515 
with a feline virus and viral replication was monitored. This method seemed much more 516 
suitable than direct stimulation of CrFK, fcwf-4 and FEA cells, as it enabled to 517 
circumvent the irresponsiveness of these immortalized cell lines to stimulation with ODN 518 
2216 (Fig 2A), which is most probably linked to their insufficient differentiation for 519 
expression of the measured cytokines. Additionally, this system closely mimics an in 520 
vivo situation, as PBMCs comprise pDCs, the main players involved in recognition and 521 
response to CpG-A, enable interplay between heterogeneous populations of immune cells 522 
and circulate systemically, affecting many different tissues with the soluble molecules 523 
they produce. This method had already been utilized successfully in a study screening 524 
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CpG ODN for prevention of SARS [91]. Furthermore, the variety of soluble molecules 525 
present in the supernatants of CpG-treated cells were found to be responsible for the in 526 
vivo effects observed in a trout model [92], supporting the feasibility of this method as 527 
primary model prior to in vivo studies.   528 
 529 
The supernatants of PBMCs stimulated with CpG-A contain a mixture of molecules that 530 
could play a role in the total antiviral effects observed. However, the viral inhibition was 531 
both similar to that obtained after treatment of the cells with rfeIFNα and highly 532 
correlated with the induction of Mx transcription in the cell lines incubated with the 533 
supernatants (Fig 5B), underlining the central role of type I IFN in protection of target 534 
cells against viral invasion. Inhibition of viral replication in the present study moreover 535 
corroborates the sensitivity of the individual viruses to various subtypes of recombinant 536 
feline interferon reported in past studies [65,68]. Importantly, Mx mRNA and protein 537 
could not be directly linked to inhibition of the viruses tested, but rather used as markers 538 
for induction of an antiviral state in tissue cells. Although the expression of other 539 
antiviral molecules such as 2’5’oligoadenylate synthetase (OAS) and the RNA-dependent 540 
protein kinase (PKR) was not measured, their induction has been reported following CpG 541 
ODN stimulation of PBMCs in other species [93,94] and differential interplay between 542 
several effector mechanisms most likely leads to the inhibition of individual viruses. 543 
After a single 24-hour treatment with supernatants of ODN 2216 treated feline PBMCs, 544 
an increased amount of Mx protein could be detected for at least 72 hours in all target 545 
cell lines tested (Fig 4D), corroborating the kinetics of this protein following IFNα 546 
stimulation reported in various cell types previously [95,96,97]. Also, when fcwf-4 cells 547 
were incubated with the supernatants for 72 instead of 24 hours, similar inhibition of 548 
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VSV and FCV was observed (data not shown), further supporting possible protection 549 
against viral infection by ODN 2216 for at least several days, a phenomenon described 550 
already in mouse models [82].  551 
 552 
The characteristic structure of a CpG-A molecule includes poly (G) sequences on a 553 
phosphorothioate backbone at both ends and CG dinucleotides embedded in a central 554 
palindromic sequence with phosphodiester linkages [9]. The necessity for poly (G) 555 
motifs renders CpG-A more difficult to produce than other classes of CpG ODN [29]. 556 
However, when considering the in vivo use of stimulatory molecules, CpG-A hold 557 
several considerable advantages. First, they remain the most potent inducers of type I 558 
IFN, themselves the most biologically active antiviral molecules known to date [16]. 559 
Also, as a result of their poly (G) stretches, they can form G-tetrads, highly ordered 560 
structures with enhanced stability [9]. Their only partial phosphorothioate structure could 561 
moreover help reduce possible long-term side effects related to synthetic backbones 562 
[98,99]. Finally, the flu-like symptoms generally linked with administration of 563 
immunostimulatory molecules in vivo may remain minor in cats treated with ODN 2216, 564 
since we observed only marginal increase in mRNA expression of the proinflammatory 565 
cytokines IL-6 and TNFα in stimulated immune cells when compared to type I IFN 566 
genes (Fig 2B and 2C). Altogether, our data reflect strong potential for this molecule in 567 
the prevention of a large variety of viral diseases, underlining the importance of 568 
developing newly structured molecules or of modifying administration strategies in order 569 
to both profit from the stimulatory sequence of ODN 2216 and circumvent safety, 570 
stability and manufacturing issues. Future in vivo studies with such newly designed ODN 571 
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could substantially support the development of powerful and convenient immune 572 
response modifiers for the prevention of viral infections in humans and animals. 573 
 574 
Materials and Methods 575 
Ethics Statement 576 
This study was carried out in strict accordance with regulations of the Swiss law for 577 
animal protection (SR 445.1). The Veterinary Office of the Swiss Canton of Zurich 578 
officially revised the protocol and approved the study (Permit no. TVB 99/2007 and TVB 579 
100/2007). The animals were housed in groups in an animal-friendly barrier facility 580 
under optimal ethological conditions [100]. For blood collections, the cats were sedated 581 
with a combination of ketamin and midazolam, and all possible efforts were made to 582 
minimize stress and suffering.  583 
 584 
Animals  585 
Fourteen male castrated SPF cats divided in four different age groups were used in this 586 
study: group 1 (c01-c04, 10 weeks), group 2 (c05-c08, 1.5 years), group 3 (c09-c12, 7 587 
years) and group 4 (c13 and c14, 14 years). Cats c13 and c14 from group 4 originated 588 
from the same litter; all other individuals were not related to each other. The animals 589 
were purchased from Liberty Research Inc. (Waverly, NY, USA) and their SPF status 590 
was verified as previously described [101]. Blood samples were collected from the 591 
jugular vein under sterile conditions with K3-EDTA VACUETTE tubes (Greiner Bio-592 
One, St.Gallen, Switzerland) and a BD Vacutainer Luer Adapter (Becton Dickinson, 593 
Allschwil, Switzerland). PBMCs or PBMC supernatants utilized in the separate 594 
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experiments were obtained from those animals mentioned in figure captions or annotated 595 
in the figures. 596 
 597 
Feline PBMC isolation, cell lines, cell culture and cell viability assay 598 
Feline PBMCs were isolated from EDTA-anticoagulated whole blood by Ficoll-Hypaque 599 
density gradient centrifugation using a standard protocol [102]. Purified cells were 600 
counted as described previously [103], using the Sysmex XT 2000iV (Sysmex, 601 
Norderstedt, Germany), prior to their utilization in the different experiments, and 602 
cultured in RPMI 1640 with Glutamax I (Gibco, Invitrogen, Basel, Switzerland).  603 
Adherent Crandell-Rees feline kidney (CRFK) cells (ATCC no. CCL-94) and Feline 604 
Embryonic Fibroblasts (FEA) were maintained in RPMI 1640 with Glutamax I, while 605 
adherent Felis catus whole fetus-4 (fcwf-4) cells (ATCC no. CRL-2787) were cultured in 606 
EMEM (ATCC 30-2003). All media were supplemented with 10% heat-inactivated fetal 607 
calf serum (Bioconcept, Allschwil, Switzerland), 100 U/ml penicillin and 100mg/ml 608 
streptomycin (Gibco, Invitrogen).  609 
The CpG-A prototype, ODN 2216, the control ODN 2243 (Alexis biochemicals, Enzo 610 
Life Sciences AG, Switzerland) and recombinant feline IFNα (rfeIFNα) (PBL Biomedical, 611 
Piscataway, New Jersey, USA) were solubilized in endotoxin-free PBS. ODN 2243 612 
consists of the same sequence as ODN 2216, with CpG motifs inversed to GpC. In all 613 
experiments, both ODNs and rfeIFNα were diluted in RPMI 1640 with Glutamax I 614 
supplemented as described above. 615 
Viability of stimulated cells was compared using the trypan blue exclusion test. Briefly, 616 
cells were stimulated for 24 hours with increasing concentrations ranging from 1µg/ml to 617 
16µg/ml ODN 2216, ODN 2243 or equivalent volumes of PBS as control. Cells were 618 
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then detached with 0.05% trypsin-EDTA (Gibco, Invitrogen) and stained with a 0.4% 619 
trypan blue solution (Dr. Bender and Dr. Hobein AG, Zurich, Switzerland). Both viable 620 
unstained and non-viable stained cells were microscopically counted and percentages of 621 
viable cells were compared.     622 
 623 
Proliferation assay 624 
PBMCs were seeded immediately after isolation at a concentration of 3x106 cells/ml in 96-625 
well U-bottom plates. Triplicate cultures for each cat were treated with either 4µg/ml 626 
ODN 2216 or 2243 or an equal volume of endotoxin-free PBS. After an initial incubation 627 
of 18 hours, the cells were pulsed for 24 hours with 3H-thymidine (Perkin Elmer, 628 
Schwerzenbach, Switzerland). Standard liquid scintillation protocols were used for 629 
harvesting of the cells and uptake of 3H was assessed with the Packard Tri-Carb 1600TR 630 
liquid scintillation analyzer (Perkin Elmer). Proliferation rates were calculated as the 631 
mean counts per minute (c.p.m) of triplicate cultures.  632 
 633 
Flow cytometry 634 
PBMCs were treated at a density of 3x106 cells/ml with 4µg/ml ODN 2216 or ODN 2243 635 
or an equivalent volume of endotoxin-free PBS and cultured for 24 hours in a 12-well 636 
format. During collection of the cells, the adherent cell fraction was removed with 0.05% 637 
trypsin-EDTA (Gibco, Invitrogen). Harvested cells were divided into 3 fractions 638 
labeled separately with either anti feline B7.1 mouse monoclonal IgG (kindly provided 639 
by Prof Mary Tompkins of the flow cytometry and cell sorting laboratory, NC State 640 
College of Veterinary Medicine, USA), anti feline MHCII mouse monoclonal IgG1 641 
(Department of Pathology, Microbiology and Immunology, University of California, 642 
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Davis, USA) or fluoresceinisothiocyanate (FITC)-conjugated mouse IgG1 as isotype 643 
control (BD Bioscience, Allschwil, Swizerland). The fractions were subsequently stained 644 
with R-Phycoerythrin (RPE)-conjugated goat anti-mouse IgG1 (BioConcept, Allschwil, 645 
Swizerland). Fluorescence data was obtained using the FACSCalibur® instrument 646 
(Becton Dickinson) and the CellQuestPro software. Gates representing lymphocyte and 647 
non-lymphocyte populations were set on the basis of forward versus side scatter, and a 648 
total of 50’000 events were acquired in the non-lymphocyte gate. Data was analyzed with 649 
the FlowJo software (Tree Star, Olten, Switzerland), whereby an additional gate was set 650 
comprising both lymphocyte and non-lymphocyte populations (PBMC gate). MHCII 651 
expression was determined as geometric mean of fluorescence intensity for each gated 652 
cell population. In order to asses expression of B7.1 molecules, a cut-off for positive 653 
events was determined for each subpopulation of gated cells, where less than 2% of the 654 
negative events were included in the high analysis region. Identical gates were set for all 655 
cats in such a way that they comprise the desired cell populations of each individual. 656 
 657 
Relative gene expression analysis  658 
All experiments were carried out in a 96-well format.  PBMCs were stimulated with 659 
ODN 2216, ODN 2243 or endotoxin-free PBS at a density of 3x106 cells/ml directly after 660 
isolation, while CrFK, FEA or fcwf-4 cells were cultured to confluency prior to 661 
stimulation. For stimulation of adherent with supernatants (production see below), total 662 
cell culture medium was discarded from the wells and the monolayers were further 663 
cultured in 100µl undiluted supernatants for the rest of the experiment. At time points 664 
relevant to each experiment, the supernatants were removed and cells were lyzed with 665 
mRNA lyzis buffer (mRNA isolation kit I, Roche Diagnostics, Rotkreuz, Switzerland). 666 
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mRNA extractions were performed with the mRNA Isolation Kit I and MagNA Pure LC 667 
Instrument (Roche Diagnostics) and first strand cDNA was synthesized with the High 668 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Rotkreuz, Switzerland). 669 
Real-time quantitative PCR (qPCR) reactions consisted of 5µl cDNA in a total volume of 670 
25µl per reaction using the TaqMan® Fast Universal PCR Master Mix (Applied 671 
Biosystems). Thermocycling conditions included an initial denaturation of 20s at 95°C 672 
followed by 45 cycles of amplification by melting at 95°C for 3s and annealing at 60°C 673 
for 45s. Primers and probes for feline genes have been previously described [104]. 674 
mRNA expression factors of selected genes, which correspond to ratios of mRNA levels 675 
measured in ODN 2216 and ODN 2243 stimulated versus PBS stimulated cells, were 676 
calculated and normalized with GeNorm version 3.5 [105], using either both feline β-677 
glucuronidase (GUSB) and tryptophan 5-monooxygenase activation protein zeta 678 
polypeptide (YWHAZ) (usually) or Glyceraldehyde 3-phosphate dehydrogenase 679 
(GAPDH) alone (when specified) as reference genes, under conditions validated for the 680 
feline species [106]. Generally depicted in the graphs are mean expression factors 681 
calculated from duplicate experiments carried out simultaneously. Where results of one 682 
cat are shown, experiments were conducted with cells of at least 3 individual animals and 683 
representative data is shown.   684 
 685 
Production of supernatants 686 
For each cat, PBMCs were resuspended in supplemented RPMI 1640 with Glutamax I 687 
(Gibco, Invitrogen) at a concentration of 106 cells/ml in 6 well plates and stimulated 688 
immediately after isolation with 4µg/ml ODN 2216, 4µg/ml ODN 2243 or an equivalent 689 
volume of endotoxin-free PBS. After 24 hours incubation, supernatants were harvested by 690 
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centrifugation of the cultures twice at 2000xg for 10 minutes, aliquoted and stored at -691 
20°C. Large supernatant quantities were produced with PBMCs purified after one blood 692 
collection, enabling the utilization of the same supernatants for virus inhibition 693 
experiments concerning VSV, FCV, FCoV, FHV and FPV. New supernatants batches 694 
were produced for use in FeLV inhibition assays. Supernatants derived from PBMCs 695 
stimulated with ODN 2216, ODN 2243 and endotoxin-free PBS are referred to as 696 
Sup2216, Sup 2243 and Sup Neg in the text and in the figures.  697 
 698 
Western Blot 699 
CrFK and fcwf-4 grown to confluency in 12-well plates were stimulated with 600µl of 700 
PBMC supernatants produced as explained above. At the time points indicated, cells 701 
were harvested and counted. 106 cells of either cell line were resuspended in 30µl sample 702 
buffer (0.5M Tris(hydroxymethyl)aminomethane, 5% SDS, 10% β-mercaptoethanol, 703 
40% glycerol, and 0.05% bromphenol blue) and boiled at 95°C for 5 minutes. SDS-704 
PAGE separation and submersed immunoblotting procedures were carried out as 705 
previously described [97].  The Spectra Multicolor Broad Range Protein Ladder 706 
(Fermentas GmbH, St. Leon-Rot, Germany) served as molecular weight standard marker 707 
for each blot. For protein visualization, membranes were first cut immediately below the 708 
80kB marker band. The top and bottom membrane fractions were incubated with murine 709 
anti-human Mx MAb M143 (generously provided by Dr. J. Pavlovic, Institute for 710 
Virology, University of Zürich, Switzerland) and murine anti β-actin monoclonal 711 
antibody as a loading control (Sigma Aldrich GMbH, Buchs, Switzerland) respectively. 712 
Both fractions were subsequently incubated with a peroxidase-labelled goat anti-mouse 713 
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IgG (Jackson Immunoresearch, Newmarket, Suffolk, UK). Bands were digitalized using 714 
the Chemigenius 2 BioImaging System (Syngene, Cambridge, UK). 715 
 716 
Viruses and viral inhibition assays 717 
VSV Indiana strain (Institute of Virology, Vetsuisse Faculty, University of Zurich, 718 
Switzerland), FCoV Wellcome strain (a generous gift from Prof. A. Kipar, University of 719 
Liverpool, Great Britain), FPV (kindly provided by Prof. U. Truyen, University of 720 
Leipzig, Germany), FHV ZH5-04 strain and FCV F9 strain (kindly provided by 721 
Veterinaria AG, Zurich, Switzerland) were titrated on both CrFK and fcwf-4 cells. Viral 722 
stock dilutions inducing 95% cytopathic effect (CPE) after 24 hours (72 hours for FCoV 723 
and FPV) were selected for inhibition experiments in order to ensure proper 724 
measurement of inhibitory effects. Monolayers of CrFK and fcwf-4 cells in 96-well 725 
plates were incubated for 24 hours with the 100µl of the supernatants produced with 726 
PBMCs from cats of groups 1, 2 and 3. With the exception of assays carried out with 727 
FPV, viral inhibition experiments were conducted simultaneously and with supernatants 728 
thawed an equal number of times. The treated cells were then inoculated with virus 729 
(VSV, FCV, FHV, FCoV) or trypsinized with 0.05% trypsin-EDTA (Gibco, 730 
Invitrogen) and allowed to settle in viral suspension (FPV), and plaque assays were 731 
carried out after 24 hours (72 hours for FCoV and FPV) according to the procedure 732 
described previously [107]. Briefly, supernatants were discarded and cell debris was 733 
removed from the wells by 3 cycles of washing with Hank’s balanced salt solution 734 
(HBSS) (Gibco, Invitrogen) and shaking on an orbital shaker for 15 seconds. Remaining 735 
cells were fixed with 5% formalin and stained with a crystal violet solution. For 736 
spectrophotometric measurements, 100% methanol was added to the dried out wells and 737 
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absorbance was read at 595nm on a SpectraMax Plus 384 microtiter plate reader 738 
(Molecular Devices, Bucher Biotec AG, Basel, Switzerland). Viral inhibition rates were 739 
calculated with the following formula:  740 
Mean optical density (OD) values of duplicate wells treated with Supernatant / Mean OD 741 
values of quadruplicate wells treated with medium alone  742 
FeLV-A Glasgow-1 strain (a generous gift from Proff. M. Hosie and O. Jarret, University 743 
of Glasgow, Great Britain) was titrated on FEA cells, and the lowest stock dilution 744 
leading to productive infection of the cells after 48 hours was used for inhibition 745 
experiments. Experiments were carried out in 96-well plates and cells were treated with 746 
100µl of supernatants or relevant controls immediately prior to inoculation. Every second 747 
day thereafter, 50µl culture medium was replaced by the same volume fresh supernatant. 748 
At appropriate time points, cells and supernatants were harvested and total nucleic acid 749 
was extracted from both the cells and supernatants using the MagNA Pure LC DNA 750 
Isolation Kit I and MagNA Pure LC Instrument (Roche Diagnostics). Viral replication in 751 
supernatants and proviral loads in cells were measured by real-time RT-PCR and real-752 
time PCR respectively, with assays previously described [108]. The time course 753 
experiments were conducted with supernatants derived from PBMCs of three cats and the 754 
measurements on day 8 post inoculation were carried out with material derived from two 755 
additional cats. In order to facilitate interpretation of the figures illustrating 756 
measurements of viral RNA loads, 45 cycles -cycle threshold (Ct) values were calculated 757 
and means of duplicate wells are depicted.   758 
 759 
760 
Manuscript 2 
Celine Robert-Tissot • July 2011 102 
Statistical analysis  760 
All statistical analyzes were performed using GraphPad Prism for Windows, version 3.0 761 
(GraphPad Software, San Diego California USA). Due to the limited number of cats 762 
integrated in the study, we refrained from using a parametric approach in the statistical 763 
tests. As such tests require a larger sample size than n=4, it was not possible to calculate 764 
p-values for the induction in expression of each gene shown in figure 3.  Differences 765 
between treatment groups in proliferation of PBMCs and expression of co-stimulatory 766 
molecules on the surface of these cells were analyzed with a Wilcoxon signed rank test, 767 
where values for each cat were paired. Relative Mx mRNA expression, OD values from 768 
plaque assays, ratios for FeLV provirus and Ct values for FeLV viral RNA loads were 769 
analyzed with a Wilcoxon signed rank test with pairing of values for each cat when 770 
treatment with different supernatants were compared, or a Mann-Whitney test when 771 
incubation with supernatant was opposed to treatment with medium alone or rfeIFNα. 772 
Normalized and relative TLR9 mRNA expression ratios between different animal age 773 
groups were also compared with a Mann-Whitney test. Longitudinal effects on FeLV 774 
viral and proviral loads were compared with each other using a Mann-Whitney test 775 
carried out with Area Under the Curve (AUC) values. Correlations were assessed using 776 
the Spearman test.  P-values <0.05 were considered statistically significant.  777 
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 1114 
Figure Captions 1115 
Figure 1. ODN 2216 induce proliferation of primary feline immune cells and 1116 
enhance their expression of costimulatory surface molecules. (A) H3 thymidine 1117 
incorporation was assessed in the feline PBMCs of eight adult cats belonging to groups 2 1118 
and 3 after stimulation with ODN 2216, ODN 2243 or endotoxin-free PBS. Dots indicate 1119 
the mean counts per minute (cpm) of triplicate reactions for one cat. **p<0.01 (B) 1120 
Expression of B7.1 surface molecules was assessed 24 hours post stimulation with the 1121 
indicated treatments. The histogram depicts the fluorescence of gated PBMCs of one cat 1122 
selected as an example. Isotype control samples are indicated as unstained (left panel). 1123 
Percentages of positive events in gated PBMCs, lymphocytic (lc) and non lymphocytic 1124 
(non-lc) subpopulations of cells stimulated with ODN 2216 and ODN 2243 were 1125 
normalized to percentage of events within the same gates after PBS stimulation (set to 1126 
100%). Results for eight cats belonging to groups 2 and 3 are shown (right panel). 1127 
Stimulation with ODN 2216, ODN 2243 and PBS was compared using Wilcoxon signed 1128 
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rank tests performed on logarithmic values corresponding to percentages of positive 1129 
events from the indicated cell populations of eight cats. p values are depicted in the table. 1130 
(C) Expression of MHCII surface molecules was assessed 24 hours post stimulation with 1131 
the indicated treatments. The histogram depicts the fluorescence of gated PBMCs of one 1132 
cat selected as an example (left panel). Mean fluorescence intensity (MFI) of gated 1133 
PBMCs, lc and non-lc subpopulations of cells stimulated with ODN 2216 and ODN 2243 1134 
were normalized to MFI of cells within the same gates after PBS stimulation (set to 1135 
100%). Results for eight cats are shown (right panel).  Stimulation with ODN 2216, ODN 1136 
2243 and PBS was compared using Wilcoxon signed rank tests performed on logarithmic 1137 
values corresponding to MFI of the indicated cell populations of eight cats. p values are 1138 
depicted in the table.  1139 
 1140 
Figure 2. ODN 2216 influence IFNα and IL-6 expression in primary feline immune 1141 
cells. mRNA expression factors of IFNα and IL-6 were measured in (A) fcwf-4 cells 1142 
stimulated with ODN 2216 and (B, C) feline PBMCs from one cat belonging to group 2 1143 
stimulated with either ODN 2216 or control ODN 2243. The transcription of both genes 1144 
was assessed either 24 hours after treatment of the cells with increasing concentrations of 1145 
ODN (A left panel and B), or over time after a single stimulation with 4µg/ml ODN (A 1146 
right panel and C).  1147 
 1148 
Figure 3. ODN 2216 induces an antiviral gene expression profile in PBMCs of adult 1149 
cats. (A) mRNA expression factors of the indicated genes were measured in PBMCs 1150 
isolated from fourteen cats belonging to all four age groups and stimulated with ODN 1151 
2216 for 24 hours. (B) mRNA expression factors of the indicated IFNα subtype genes 1152 
Manuscript 2 
 
Celine Robert-Tissot • July 2011 119 
were measured in PBMCs isolated from four adult cats (group 2) and stimulated with 1153 
ODN 2216 for 24 hours. (C) mRNA levels of TLR9 were measured by real-time qPCR in 1154 
unstimulated PBMCs of all four groups of cats and normalized to the expression of a 1155 
feline housekeeping gene (GAPDH) (top panel). Relative TLR9 mRNA expression 1156 
factors were measured in ODN 2216 stimulated PBMCs from cats of all four groups 1157 
(bottom panel). p<0.05, Perf=perforin, GranB=granzyme B  1158 
 1159 
Figure 4. ODN 2216 induces an antiviral state both in stimulated PBMCs directly 1160 
and in target cells incubated with supernatants from stimulated PBMCs. (A) mRNA 1161 
expression factors of the indicated genes were measured in PBMCs of the individual cats 1162 
(c01-c14) from four different age groups after stimulation with ODN 2216 for 24 hours. 1163 
(B) Mx mRNA expression factors were assessed at the indicated time points in PBMCs 1164 
of one cat after a single stimulation with either ODN 2216 or ODN 2243. (C) Mx mRNA 1165 
expression factors were measured in fcwf-4 cells incubated for 24 hours with 1166 
supernatants (Sup 2216, Sup 2243, Sup Neg) derived from PBMCs of eight adult cats 1167 
(groups 2 and 3) or 100U recombinant feline IFNα (rfeIFNα) (left panel). Mx protein 1168 
was detected by Western blot in fcwf-4 cells incubated with the indicated supernatants 1169 
derived from PBMCs of one cat belonging to group 2 or with 100U recombinant feline 1170 
IFNα (rfeIFNα) for 24 hours (right panel). (D) Mx mRNA expression factors were 1171 
measured in fcwf-4 cells at the indicated time points after a single stimulation with Sup 1172 
2216, Sup 2243 and Sup Neg respectively (left panel). Mx protein was detected by 1173 
Western Blot in fcwf-4 cells at indicated time points after stimulation with Sup 2216 1174 
derived from PBMCs of the same cat (right panel). **p<0.01  1175 
rfeIFNα = recombinant feline IFNα 1176 
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 1177 
Figure 5. Supernatants derived from ODN 2216 stimulated PBMCs inhibit viral 1178 
replication in target cells. (A) fcwf-4 cells were incubated for 24 hours with the 1179 
indicated supernatants derived from PBMCs of eight adult cats (groups 2 and 3) or 1180 
medium only as control before inoculation with the indicated viruses. Each dot represents 1181 
mean optical density (OD) values from spectrophotometric readings of plaque assays 1182 
conducted on duplicate wells treated with supernatants from an individual cat. (B) 1183 
Correlation of individual inhibition ratios of each virus with Mx mRNA expression 1184 
induced in fcwf-4 cells incubated with supernatants of ODN 2216 stimulated PBMCs 1185 
from the eight cats of groups 2 and 3. Note the different scale on the x-axis for each 1186 
graph indicating the differences in the inhibitory effects of these supernatants on the 1187 
different viruses. (C) fcwf-4 cells were incubated for 24 hours with the indicated 1188 
supernatants derived from PBMCs of 4 kittens (group 1) or medium only as control 1189 
before inoculation with VSV (left panel) or FCV (right panel). Each dot represents mean 1190 
OD values from spectrophotometric readings of plaque assays conducted on duplicate 1191 
wells treated with supernatants from one cat. **p<0.01  1192 
VSV = vesicular stomatitis virus, FCV = feline calicivirus, FPV = feline parvovirus, 1193 
FCoV = feline coronavirus, FHV = feline herpes virus  1194 
 1195 
Figure 6. Supernatants derived from ODN 2216-stimulated PBMCs decrease 1196 
retroviral DNA and RNA loads in target cells.  (A) FEA cells were incubated for 24 1197 
hours with the respective supernatants or medium alone, before inoculation with the 1198 
feline leukaemia virus (FeLV), as well as every 2 days thereafter. Viral RNA loads were 1199 
measured at the indicated time points by real time RT-PCR (top panel). FeLV DNA loads 1200 
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in the cells were measured at the indicated time points and Ct values were normalized to 1201 
detection of a housekeeping gene (GAPDH) (bottom panel). Mean values from duplicate 1202 
experiments carried out simultaneously with the supernatants derived from PBMCs of a 1203 
selected cat (belonging to group 2) and with medium alone are shown as an example. 1204 
Results are indicative of those obtained with supernatants from PBMCs of two additional 1205 
adult cats (from group 3). Stars represent statistical differences in area under the curve 1206 
(AUC) measurements between the curves of all three cats obtained in cells incubated 1207 
with Sup 2216 and each of the other treatments. (B) Mx mRNA expression factors (top 1208 
panel), viral loads (bottom left panel) and proviral loads (bottom right panel) were 1209 
measured in the FEA cells of five cats (two from group 2 and three from group 3) on day 1210 
8 post inoculation. Each dot represents the mean of duplicate measurements for an 1211 
individual cat. *p<0.05, **p<0.01 1212 
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4. Addendum 
Additional data that was accumulated during the course of this project but either not 
incorporated or not illustrated (“data not shown”) in the manuscripts of chapter 3, will be 
presented in this chapter. While chapter 4.1 briefly describes materials and methods used 
for the experiments illustrated herafter, each section of chapter 4.2 comprises a short 
explanation regarding the aim of the experiments accompanied by figures and captions. 
When indicated, information concerning the localization of corresponding explanations 
or data in the manuscripts of chapter 3 will be provided. The figures and table included in 
this section are numbered 4.1 to 4.10. The results of this chapter will be discussed 
separately in section 4.4.   
 
4.1 Material and methods 
Unless specified otherwise, all materials and methods utilized to generate the data 
presented in this chapter, including the animals comprised in the study, the experimental 
set-ups, cell culture conditions, IRM concentrations utilized for stimulation, relative gene 
expression analyses, amounts of cells loaded in Western Blot samples, production of 
supernatants as well as viral concentrations and carrying out of viral inhibition assays are 
described precisely in the corresponding “material and methods” sections of both 
manuscripts of section 3. Importantly, the method utilized for the calculations of relative 
mRNA expression factors illustrated in many graphs of this section can be founding the 
“material and methods” section of manuscript 2, under “relative gene expression 
analysis”. The appropriate manuscript section that confers additional information to the 
figures in this section will be referred to in each part of chapter 4.2. 
 
4.2 Innate immune properties of feline cell lines 
4.2.1 Expression of TLRs by feline cell lines 
The IRMs utilized were selected for their known affinity to specific TLRs. Indeed, the 
binding of Poly IC to TLR3, R-848 to TLRs 7 and 8, and dSLIM and ODN 2216 to 
TLR9 is known to initiate cascades of events that eventually lead to the transcription of 
genes belonging to the proinflammatory and type I IFN families. In determining whether 
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the chosen IRMs may successfully stimulate feline cells, the first step was to establish 
whether feline cells expressed these TLRs. CrFK, FEA and fcwf-4 cells, as well as 
purified PBMCs were thus tested for their basal expression of TLRs 3, 7, 8 and 9 when 
left unstimulated in culture. Experiments were carried out as described in the materials 
and methods section of manuscript 2, under “relative gene expression analysis”. 
Furthermore TLR9 expression in PBMCs of fourteen cats belonging to four different age 
groups can be seen in Fig 3C of manuscript 2. 
 
 
Fig 4.1. Toll-like receptor expression in feline cells.  
(A) mRNA expression of the indicated tlr genes  was measured by real-time qPCR in 105 unstimulated 
cells of the indicated cell lines. 45 cycles-cycle threshold (Ct) values were calculated and means of 
triplicate wells are depicted. (B) mRNA levels of TLR9 were measured by real-time qPCR in unstimulated 
PBMCs of one cat and normalized to the expression of a feline housekeeping gene (GAPDH). Values 
represent means of triplicate wells. Results are representative of at least two experiments. 
 
4.2.2 IRM stimulation of feline cell lines 
Although stimulation of purified feline PBMCs with various IRMs effectively altered the 
gene profile measurable in these cells (Fig. 1A-C of manuscript 1 and Fig. 2B-C of 
manuscript 2), immortalized feline cell lines remained largely insensitive to treatment 
with the same IRMs. A series of experiments were initially carried out on cell lines of 
both epithelial (CrFK) and fibroblastic (FEA and fcwf-4) origins to determine whether 
incubation with IRMs would influence the expression of genes related to innate 
immunity in these cells. The effects linked to both concentration and duration of 
incubation with each IRM were tested, and the expressions of IFNα and IL-6 genes were 
selected as readouts for influence on innate immune parameters.  
All three cell lines reacted similarly to incubation with the different IRMs: the selected 
genes remained largely unaffected regardless of the amount of IRM the cells were 
subdued to and the duration of incubation. Altogether, considering all IRMs tested and all 
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cell lines utzilized, the relative expression of both IFNα and IL-6 genes maximally 
decreased upon stimulation by 1.8 fold and maximally increased by 1.6-fold.     
As ODN 2216 clearly indicated the strongest induction of innate immune parameters in 
feline PBMCs when compared to Poly IC, R-848 and dSLIM  (consider Fig. 1A-C of 
manuscript 1 and Fig. 2B-C of manuscript 2), only the effects of this IRM on various 
feline cell lines will be shown here. The observations illustrated below for CrFK and 
FEA cells confirm the results for fcwf-4 cells that can be consulted in Fig. 2A of 
manuscript 2.  Precise information on methods utilized for the in vitro stimulation of the 
cells and the determination of relative expression of IFNα and IL-6 are given in the 
“material and methods” section of manuscript 2, under “relative gene expression 
analyis”. The IRM concentrations and incubation times tested were identical for all 
IRMs, and are indicated in the figure below (Fig. 4.2).  
 
 
Fig 4.2. Feline cell lines remain uninfluenced by the direct stimulation with IRMs  
mRNA expression factors of ifnα and il-6 genes were measured in CrFK (A) and FEA (B) cells stimulated 
with ODN 2216. The transcription of both genes was assessed either 24 hours after treatment of the cells 
with increasing concentrations of ODN (left panels), or over time after a single stimulation with 4µg/ml 
ODN (right panels). Depicted are mean expression factors calculated from duplicate experiments carried 
out simultaneously. 
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4.3 Immunomodulation by ODN 2216 
The experiments described in this section aimed at completing the evaluation of the 
immunomodulatory and antiviral properties of ODN 2216 thoroughly described in 
manuscript 2. Experiments aiming to analyze the induction of both Mx expression (as 
described in section 4.3.1) and viral inhibition (described in section 4.3.2) in target cells 
by other IRMs were also partially conducted, however with insignificant success. These 
experiments will thus not be illustrated here. The methods linked to this section are 
further fully described in the corresponding section of manuscript 2, under “production of 
supernatants”, relative gene expression analysis, “Western blot” and “viral inhibition 
assay”.   
 
4.3.1 Induction of Mx expression in feline target cells 
Stimulation of feline PBMCs with ODN 2216 enhanced the expression of a wide array of 
genes, among which many subtypes of type I IFN (Fig 3A-B, manuscript 2). This led to 
assume that supernatants of stimulated PBMCs most probably contained a broad variety 
of type I IFN subtypes, which should be capable of initiating the production of 
intracellular antiviral proteins in target cells, providing these cells express an IFN 
receptor. In order to determine whether and to which extent the immortalized feline cell 
lines used in this study have conserved the capability to respond to type I IFN 
stimulation, the induction of expression of the Mx gene was measured in these cells after 
stimulation with the rfeIFNα protein. CrFK, FEA and fcwf-4 cells all responded to 
rfeIFNα stimulation, however with different sensitivities: while 10U rfeIFNα sufficed to 
induce a 60 respectively 200-fold increase in Mx mRNA in FEA and fcwf-4 cells, 100U 
were required to attain comparable transcription levels in CrFK cells (Fig. 4.3)  
Thus, as the IRMs did not confer feline cell lines measurable alterations upon direct 
stimulation (see section 4.2.2), the antiviral potential of ODN 2216 on these cells was 
measured indirectly: supernatants derived from feline PBMCs stimulated with ODN 
2216 (or ODN 2243 or endotoxin-free PBS as controls), were incubated with a target cell 
line in which the induction of the Mx gene was then analyzed.  This method was also 
useful for later viral inhibition experiments, as these cell lines are susceptible to different 
feline viruses, while purified PBMCs are not. Large quantities of supernatants were 
produed from the PBMCs purified from the blood of several SPF cats, so that their use in 
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parallel experiments conducted on different cell lines would confer comparable results. 
Also, since the antiviral properties conferred by the supernatants on different cell lines 
could only be effectively compared if the target cells were susceptible to the same 
viruses, two sets of experiments were conducted.  
 
In a first series of experiments, supernatants were produced with isolated PBMCs from 
eight adult cats (four of 1.5 and four of 7 years of age) and four kittens (10 weeks of age). 
With the aim to determine not only the the capability of these supernatants to induce 
antiviral mechanisms (see experiments shown in this section and manuscript 2, Fig. 4C-
D) but also to inhibit viral replication in target cells (see section 4.3.2 and Fig. 5 of 
manuscript 2), they were then utilized to stimulate separate cultures of both CrFK and 
fcwf-4 cells, as FCV, FHV, FCoV and FPV can replicate in both these cell lines and 
induce observable cytopathic effects (CPE). Although the results obtained for fcwf-4 
cells are thoroughly presented in manuscript 2, somewhat modified graphs are shown in 
this section to facilitate comparisons with CrFK cells. 
 
 
Fig. 4.3. Sensitivity of 
feline cell lines to 
recombinant feline IFNα 
mRNA expression factors 
of the mx gene were 
measured in CrFK (A), 
fcwf-4 (B) and FEA (C) 
cells stimulated for 24 
hours with the indicated 
amounts of rfeIFNα. 
Depicted are mean 
expression factors 
calculated from triplicate 
experiments carried out 
simultaneously. 
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The expression of type I IFN genes in the ODN 2216-stimulated PBMCs of individual 
cats highly correlated with the induction of Mx in target cells by the supernatants 
(manuscript 2, Fig. 4A). Thus, as the PBMCs of all adult cats increased their type I IFN 
mRNA expression upon stimulation with ODN 2216 by up to 12’000 fold (manuscript 2, 
Fig. 3A), the supernatants derived from these immune cells significantly induced Mx 
expression in target CrFK and fcwf-4 cells (Fig. 4.4). In the same sense, the Mx mRNA 
levels remained unaltered when both cell lines were treated with supernatants derived 
from the PBMCs of two kittens that failed to respond to ODN 2216 stimulation (Fig 4.5). 
Supernatants of PBMCs treated with the control ODN 2243 could only induce Mx 
mRNA expression accompanied by slightly detectable Mx protein expression in fcwf-4 
cells, the most sensitive cell line to rfeIFN. Direct stimulation of the cells with ODN 
2216 had notably no effect on the expression of Mx in these cells. 
In accordance with the weaker sensitivity of CrFK to rfeIFNα, the induction of Mx in 
these cells appeared weaker than in fcwf-4 cells, not only on the mRNA level but also 
when considering proteins, as can be interpreted by the mRNA expression factors and the 
proportional differences in the Mx and β-actin bands depicted in Fig. 4.4. Actually, the 
mean fold induction in Mx mRNA by the supernatants of eight adult cats in both cell 
lines enable to estimate the amount of supernatant applied in the cell culture experiments: 
supernatants derived from PBMCs stimulated with ODN 2216 appear to contain close to 
100U of type I IFN; consequently, when 100U rfeIFN were applied to the cultures of 
both cell lines, the mean increase of Mx mRNA measured in four wells was highly 
similar to that induced by the ODN-2216 derived supernatants of the eight adult cats (Fig 
4.4). 
Further experiments with these supernatants enabled to observe the kinetics of Mx 
expression in both cell lines. When the target cells were harvested at regular time points 
after treatment with the supernatant of one adult cat, it became evident that Mx protein 
appears with some delay when compared to its mRNA. While the highest mRNA 
expression for the Mx gene was in both cell lines around 6 hours post stimulation, Mx 
protein peaked after 24 hours in fcwf-4 cells, and seemed to remain stable between 6 and 
72 hours in CrFK cells (Fig. 4.6). The proportional protein expressions of Mx compared 
to β-actin as estimated by the density of the bands in each experiment again support 
much stronger Mx expression by fcwf-4 cells. 
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Fig 4.4. Induction of Mx expression in fcwf-4 and CrFK cells by supernatants derived from ODN 
2216-derived PBMCs of adult cats 
Mx mRNA (left panels) and protein (right panels) levels were measured by real-time qPCR and by Western 
blot respectively in fcwf-4 (A) and CrFK (B) cells. mRNA expression factors and were measured in the 
cells after incubation for 24 hours either with supernatants derived from PBMCs stimulated with ODN 
2216 (S 2216), ODN 2243 (S 2243) and endotoxin-free PBS (S Neg), or with 100U recombinant feline 
IFNα (rfeIFNα), or with ODN 22126 (2216) directly. Supernatants from 8 adult cats were used. Each 
symbol represents mean values for duplicate measurements carried out simultaneously with the 
supernatants from the PBMCs of one cat. Mx protein was detected by Western blot in the cells after 
incubation with either the indicated supernatants derived from PBMCs of one cat, or with 100U rfeIFNα, 
or with ODN 2216 directly. **p<0.01 
 
 
 
Fig 4.5. Induction of Mx expression by supernatants derived from ODN 2216-stimulated PBMCs of 
four kittens 
mRNA expression factors and were measured in fcwf-4 (A) and CrFK (B) cells after incubation for 24 
hours either with supernatants derived from the PBMCs stimulated with ODN 2216 (S 2216), ODN 2243 
(S 2243) and endotoxin-free PBS (S Neg), or with 100U recombinant feline IFNα (rfeIFNα), or with ODN 
22126 (2216) directly. Supernatants from 4 kittens were used. Each symbol represents mean values for 
duplicate measurements carried out simultaneously with the supernatants from the PBMCs of an individual 
cat.* p<0.05 
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Fig 4.6. Kinetics of Mx expression after stimulation of target cells with supernatants derived from 
ODN 2216-stimulated PBMC 
Mx mRNA (left panels) and protein (right panels) levels were measured by real-time qPCR and by Western 
blot respectively in fcwf-4 (A) and CrFK (B) cells. mRNA expression factors were measured in the cells at 
the indicated time points after a single stimulation with supernatants derived from PBMCs stimulated with 
ODN 2216 (S 2216), ODN 2243 (S 2243) or endotoxin-free PBS (S Neg). Supernatants from one cat were 
used. Depicted are mean expression factors calculated from duplicate experiments carried out 
simultaneously. 
Mx protein was detected by Western Blot in the cells at the indicated time points after stimulation with S 
2216 derived from PBMCs of the same cat than above. 
 
In a second series of experiments, new supernatants were produced by stimulation of 
purified PBMCs from five adult cats with ODN 2216 and controls ODN 2243 and 
endotoxin-free PBS. The cells of these five animals had already been used in the first 
experiment described above, however, the experiments cannot be directly compared, 
since the blood was collected from the cats at a different time point. These new 
supernatants were incubated with FEA cells, and were predestined to be used in 
experimental inhibition of FeLV, as this virus effectively replicates in this cell line. 
While direct stimulation of these cells with ODN 2216 did not induce any alterations in 
the expression of Mx, the supernatants derived from ODN 2216-stimulated PBMCs 
induced high levels of Mx mRNA in FEA cells, in concordance with the above-
mentioned sensitivity to rfeIFNα of this cell line (Fig 4.7). Direct stimulation with ODN 
2216 did not lead affect Mx mRNA expression. However, in contrast to observations in 
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CrFK and fcwf-4 cells, the supernatants produced by ODN 2243-stimulated PBMCs did 
not significantly induce Mx expression.  
 
 
Fig 4.7. Induction of Mx expression in FEA cells by supernatants derived from ODN 2216-derived 
PBMCs of adult cats 
Mx mRNA levels were measured by real-time qPCR in FEA cells. After incubation for 24 hours either 
with supernatants derived from PBMCs stimulated with ODN 2216 (S 2216), ODN 2243 (S 2243) and 
endotoxin-free PBS (S Neg), or with 100U recombinant feline IFNα (rfeIFNα), or with ODN 22126 (2216) 
directly. Supernatants from the PBMCs of 8 adult cats were used. Each symbol represents mean values for 
duplicate measurements carried out simultaneously with the supernatants from the PBMCs of one cat. ** 
p<0.01, * p<0.05  
 
4.3.2 Viral Inhibition in CrFK cells 
The inhibition of viral propagation in cultures of fcwf-4 cells by supernatants derived 
from ODN 2216-stimulated PBMCs was fully reported in manuscript 2. When the cells 
were incubated, prior to their inoculation, with the supernatants derived from PBMCs of 
adult cats, not only VSV, the common IFN-sensitive control in such experiments, but 
also FCV, FHV, FCoV and FPV were repressed (manuscript 2, Fig. 5A). Also, only the 
supernatants of ODN 2216-stimulated PBMCs of two kittens could also inhibit viral 
replication in fcwf-4, and with lower efficiency (manuscript 2, Fig 5C). Although not all 
viruses indicated the same sensitivity to the supernatants, the extent of inhibition of each 
virus strongly correlated with the induction of Mx in fcwf-4 cells by the individual 
supernatants (manuscript 2, Fig. 5B). These results corroborate those obtained by the 
viral inoculation of CrFK cells previously treated with the same supernatants (Fig. 4.8, 
4.9). The lower sensitivity of CrFK cells to rfeIFNα is also reflected in these viral 
inhibition experiments (Tables 4.1 and 4.2) Notably, if the cells were stimulated directly 
with ODN 2216 in place of supernatants of ODN 2216 treated supernatants, no inhibition 
of virus could be observed (Fig. 4.8, 4.9). Although not shown in manuscript 2 for fcwf-4 
cells, these controls were also carried out and rendered similar results.  
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Fig 4.8. Viral inhibition on CrFK cells by supernatants derived from ODN 2216-stimulated PBMCs 
of adult cats 
(A) CrFK cells were incubated for 24 hours with supernatants derived from PBMCs stimulated with ODN 
2216 (S 2216), ODN 2243 (S 2243) and endotoxin-free PBS (S Neg), or with medium only, or with ODN 
2216 directly (2216) or with 100U recombinant feline IFNα (rfeIFNα), prior to inoculation with the 
indicated viruses. Supernatants from the PBMCs of 8 adult cats were used. Each dot represents mean 
optical density (OD) values from spectrophotometric readings of plaque assays conducted on duplicate 
wells treated with supernatants from an individual cat. (B) Correlation of individual inhibition ratios of 
each virus with Mx mRNA expression factor (Mx Factor) induced in CrFK cells incubated with 
supernatants of ODN 2216-stimulated PBMCs from eight adult cats. Note the different scale on the x-axis 
for each graph indicating the differences in the inhibitory effects of these supernatants on the different 
viruses. ** p<0.01  
VSV = Vesicular Stomatitis Virus, FCV = Feline Calicivirus, FPV = Feline Parvovirus, FCoV = Feline 
Coronavirus, FHV = Feline Herpes Virus 
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Table 4.1. Means of viral inhibition rates measured in CrFK cells after treatment with supernatants 
derived from stimulated PBMCs of 8 adult cats 
 
 VSV FCV FCoV FHV FPV 
S 2216 12.68 8.02 3.78 3.01 2.89 
S 2243 3.65 1.55 1.50 1.43 1.55 
S Neg 3.69 1.44 1.34 1.26 1.44 
Depicted are mean viral inhibition rates for 8 cats. Viral inhinition rates for each cat were calculated with 
the following formula:  
Mean optical density (OD) values of duplicate wells treated with Supernatant / Mean OD values of 
quadruplicate wells treated with medium alone (see materials and methods manuscript 2, “viruses and viral 
inhibition assays”) 
S=supernatant derived from PBMCs stimulated for 24 hours with either ODN 2216 (S 2216), ODN 2243 
(S 2243) or endotoxin-free PBS (S Neg) 
VSV= Vesicular Stomatitis Virus, FCV= Feline Calicivirus, FCoV=Feline Coronavirus, FHV=Feline 
Herpes Virus, FPV=Feline Parvovirus 
 
 
 
Fig 4.9. Viral inhibition on CrFK cells by supernatants derived from ODN 2216-stimulated PBMCs 
of kittens 
CrFK cells were incubated for 24 hours with supernatants derived from PBMCs stimulated with ODN 2216 
(S 2216) or endotoxin-free PBS (S Neg), or with medium only, or with ODN 2216 directly (2216) or with 
100U recombinant feline IFNα (rfeIFNα), prior to inoculation with VSV (A) or FCV (B). Supernatants 
from the PBMCs of 4 kittens were used. Each dot represents mean optical density (OD) values from 
spectrophotometric readings of plaque assays conducted on duplicate wells treated with supernatants from 
an individual cat. VSV = vesicular stomatitis virus, FCV = feline calicivirus 
 
4.3.3 Viral Inhibition kinetics 
The expression of Mx protein in target cells incubated with supernatants derived from 
ODN 2216-stimulated PBMCs remains elevated for at least 72 hours (Fig. 4.4). Also, 
within 24 hours of incubation with these supernatants, the cells acquired significant 
resistance to the inoculation with many viruses (Fig 4.8). The experiments presented in 
this section indicate that even after 72 hours incubation with the supernatants, target cells 
maintain some resistance potential. Due to the insufficient amounts of the supernatants 
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produced for the analyses above (see sections 4.3.1 and 4.3.2), these experiments were 
only conducted on fcwf-4 cells and with VSV and FCV (Fig. 4.10).  
 
Table 4.2. Means of viral inhibition rates measured in fcwf-4 and CrFK cells after treatment with 
supernatants derived from stimulated PBMCs of 4 kittens 
 
 fcwf-4  CrFK 
 VSV FCV  VSV FCV 
S 2216 2.69 2.20  1.47 1.43 
S Neg 1.13 1.32  1.37 1.30 
Depicted are mean viral inhibition rates for 4 cats. Viral inhinition rates for each cat were calculated with 
the following formula:  
Mean optical density (OD) values of duplicate wells treated with Supernatant / Mean OD values of 
quadruplicate wells treated with medium alone (see materials and methods manuscript 2, “viruses and viral 
inhibition assays) 
S=supernatant derived from PBMCs stimulated for 24 hours with either ODN 2216 (S 2216) or endotoxin-
free PBS (S Neg)  
VSV=Vesicular Stomatitis Virus, FCV=Feline Calicivirus, FCoV=Feline Coronavirus, FHV=Feline 
Herpes Virus, FPV=Feline Parvovirus 
 
4.4 Statistics 
The statistical tests utilized to determine significance in the experiments of this section 
are precisely described in the manuscripts of section 3. For clearer understanding of the 
graphics depicting many different conditions, significance is shown with a star (*) only 
for those groups considered relevant or not obvious. Additional information is gien in the 
legends of the figures when required. 
 
4.5 Discussion of additional data 
Altogether, the data presented in this section confirm and complete results shown or 
mentioned in the manuscripts of section 3 of this document. Although CrFK, fcwf-4 and 
FEA cell lines express the receptors required for the recognition of the selected IRMs, no 
response to in vitro stimulation with these synthetic molecules could be detected with the 
available tools. Concordantly, no viral inhibition could be observed in these cell lines 
when they were stimulated with the IRMs directly.  
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PBMCs stimulated with IRMs in vitro, however, liberate soluble molecules that hold the 
potential to support the enhancement of defence mechanisms in the mentioned feline cell 
lines. Out of the four IRMS tested in our experiments, only ODN 2216 could induce 
potent enough production of antiviral molecules by PBMCs. Indeed, when supernatants 
of ODN 2216-treated PBMCs were incubated with fcwf-4 and CrFK cells, they increased 
resistance of these cells to FCV, FHV, FCoV and FPV. In both cell lines, the induction of 
Mx highly correlated with viral inhibition, supporting the hypothesis that the various 
sybtypes of type I IFN present in the supernatants are most probably responsible for the 
observed repression in replication of these viruses. The distinct sensitivities to rfeIFNα 
indicated by both cell lines were reflected in their differential induction of Mx and viral 
inhibition in response to treatment with the supernatants. Notably however, although fold 
inhibition of the individual viruses was much lower in CrFK cells, the ranking of the 
viruses from most to least inhibited was the same in both cell lines. Only the correlations 
of viral inhibition rates with expression of Mx in the target cells did not quite overlap for 
both cell lines, an observation that could be due to a disproportional sensitivity of the 
cells to the individual viruses. In turn, supernatants of ODN 2216 treated PBMCs could 
Fig 4.10. Viral inhibition 72 hours post 
treatment of fcwf-4 cells with 
supernatants derived from ODN 2216-
stimulated PBMCs 
fcwf-4 cells were incubated for 72 hours 
with supernatants derived from PBMCs 
stimulated with ODN 2216 (S 2216), 
ODN 2243 (S 2243) or endotoxin-free 
PBS (S Neg), or with medium only, or 
with ODN 2216 directly (2216) or with 
100U recombinant feline IFNα
(rfeIFNα), prior to inoculation with VSV 
(A) or FCV (B). Supernatants from the 
PBMCs of 8 adult cats were used. Each 
dot represents mean optical density (OD) 
values from spectrophotometric readings 
of plaque assays conducted on duplicate 
wells treated with supernatants from an 
individual cat. ** p<0.01 
Dissertation 
Celine Robert-Tissot • July 2011 141 
induce antiviral mechanisms and repress FeLV replication in FEA cells, extending the 
observataions to an additional cell line and an additional virus.   
 
Importantly, the enhanced resistance to infection of at least one virus (FCV) lasted a 
minimum of 3 days following treatment with the supernatants from ODN 2216-treated 
supernatants. Even though this experiment was conducted with the feline virus that was 
most sensitive to the supernatants, these observations further support the feasibility to 
induce short-term resistance to viruses in vivo. 
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5. Discussion 
The initial aims of this study included developing tools to measure hallmarks of innate 
immunity in the domestic cat and further utilizing these tools to characterize early 
immune responses to viral infection both in vitro and in vivo. It was additionally foreseen 
to assess the possibility to manipulate innate immunity with synthetic molecules called 
IRMs, so as to increase resistance of the host to viral infections. The feasibility of 
“teflonization”, or unspecific protection against infection by various genetically different 
viruses simultaneously, was furthermore to be tested in the feline model. The study of 
innate immune responses confers crucial information regarding the first encounter 
between a pathogen and host immune cells. We anticipated that experiments with newly 
developed PCR assays enabling to measure the expression of a series of genes related to 
the organism’s first line of defence would provide valuable information regarding both 
host and viral factors playing an important role in the early defence mechanisms against 
individual feline viruses. We expected that IRMs that have already shown 
immunomodulatory properties in mice could also affect the behaviour of feline immune 
cells and set out to characterize eventual differences between these species. Furthermore, 
we hypothesized that potent IRMs could increase natural antiviral defence networks to a 
threshold that would confer at least partial protection to several viruses simultaneously. 
The main results obtained in this study are presented in the manuscripts of section 3 and 
thoroughly discussed in the corresponding discussion sections. In this chapter, the 
general findings and challenges of this project will be first summarized. With the 
perspectives of current knowledge in the field of innate immunity to viruses in humans, 
mice and cats, the overall achievements of this study and relevance to researchers in the 
field will then be discussed. Finally, prospects for the future experiments will be 
presented.  
     
5.1 General findings and challenges 
In order to facilitate the evaluation of innate immune responses in the domestic cat, PCR 
assays enabling the measurement of the expression of 12 genes were first developed. 
Species-specific sequences for the dometic cat were retrieved from Ensembl 
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(www.ensembl.org) and GeneBank (www.ncbi.nlm.nih.gov) for the genes encoding 
relevant TLRs, various cytokines, including all subtypes of feline type I IFN, 
proinflammatory and natural killer cell (NK) related cytokines, and the intracellular 
antiviral Mx protein. All these genes are known to play important roles in the network of 
immune cascades responsible for initial responses to viral invasion. Together with 
additional assays previously developed in our laboratory enabling to discern various T 
helper (Th) responses, these tools then enabled to cover essential aspects of early 
immune responses to various feline viruses. Importantly, the amplification efficiency of 
all systems utilized in this study approximated 1 (Table 2, manuscript 1), a crucial 
requirement when analyzing the relative expression of a gene under varying cellular 
circumstances with the comparative Ct method [75].  
 
In the new possession of tools to measure alteration in the gene profiles related to early 
immune mechanisms in the cat, the responses to viral inoculation in vitro of several 
feline cell lines as well as of PBMCs isolated from the blood of domestic cats could be 
evaluated. The initial results presented in manuscript 1 clearly indicate the promotion of 
different immune mechanisms by different viruses. Strength, breadth and kinetics of 
early immune responses elicited by feline cells could be evaluated, and hints on the 
potential evolution of strategies to circumvent host antiviral defences by certain viruses 
were revealed. However, the obtained data obviously represent only a first step in the 
characterisation of innate defence mechanisms to these viruses, as further experiments 
are necessary to determine the significance of individual properties of cells and tissues as 
well as virus-related factors such as source and infectious dose. Also, although the 
induction of systemic type I IFN responses upon FIV infection in vivo could be 
successfully measured in the blood of a group of experimentally infected kittens, the 
modulation of other factors of innate immune mechanisms could however not be 
detected, indicating some challenges in the use of the developed systems for 
measurements in vivo. As innate immune responses occur rapidly and often at specific 
peripheral sites following viral encounter, both the time point and the localization of the 
cells or tissues collected for measurement are of primordial importance. Thus, 
particularly in the case of viral diseases occurring essentially at specific sites such as 
feline herpes virus infections, systemic innate immune responses may be inexistent or too 
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weak to detect due to insufficient sensitivity of the developed PCR assays. Measurements 
should then ideally be carried out in local lymphoid tissues, a necessity that could lead to 
difficulties when the kinetics of a response need to be determined and samples have to be 
collected at various time points over a short period of time. Additional experiments will 
reveal the true potential of the newly designed PCR systems in research linked to feline 
virology and immunology.    
 
A series of in vitro experiments further enabled to assess various IRMs for their 
immunomodulatory potential in the domestic cat. Stimulators for each TLR efficiently 
recognizing natural viral invasion were chosen according to popularity for other species 
in the literature: Poly IC, a synthetic double-stranded polyriboinosinic–polyribocytidylic 
acid, most popular synthetic analogue to dsRNA and stimulator of TLR3 [76], 
resiquimod (R-848) an imidazoquinoline that binds to TLR7/8 [77], and synthetic CpG 
molecules, which trigger TLR9 [78]. As representatives for the latter group, dSLIM 
was selected for its innovative structure with many demonstrated advantages in vivo [79, 
80] and ODN 2216, the prototype of class A CpG molecules, for its particularly potent 
induction of type I IFN previously reported in murine studies [81] (for more information 
concerning different CpG classes, see manuscript 2). In contrast to direct initiation of 
antiviral mechanisms by a recombinant IFNα protein, it was foreseen that stimulation 
with an IRM could confer biological advantages through the induction of a wide range of 
type I IFN subtypes, which have been shown to possess differential antiviral properties 
[82]. Although the effects of all these IRMs have been tested in the context of disease, 
their prophylactic potential against viral infections as stand-alone agents, not to mention 
the concept of “teflonization” (see section 2.1.3), remains under-explored. In this study, 
the application of all IRMs induced immunomodulation in feline immune cells, however 
not always with the expected potency. It became rapidly clear that the toxicity of Poly IC 
for feline cells would highly restrict the utilization of this IRM in the feline host, and that 
the antiviral responses elicited by both R-848 and dSLIM were not strong enough to 
inhibit viral replication. ODN 2216, on the other hand, enhanced expression of the highly 
antiviral type I IFN genes of up to 12’000 fold in feline PBMCs within 24 hours (Fig. 3, 
manuscript 2), indicating powerful antiviral properties. A broad analysis of the 
immunomodulatory effects of ODN 2216 was consequently initiated, including 
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assessment of the responses elicited by various cell types, determination of optimal 
concentrations and analysis of the kinetics of the induced immune responses. Also, the 
collection of available PCR assays enabled to characterize the gene profile alterations 
upon treatment of PBMCs from fourteen individual cats belonging to age groups varying 
between 10 weeks and 14 years of age. Additional experiments then enabled to further 
characterise the network of interactions induced by ODN 2216 within players of innate 
immunity: significant proliferation of lymphocytes was observed in a tritium thymidine 
incorporation assay and upregulation of co-stimulatory molecules on the surface of both 
lymphocytic and non-lymphocytic immune cell populations was detected by flow 
cytometry. The expression of genes encoding for NK cell stimulator IL-15 and effectors 
IFNγ and Granzyme B were increased after the treatment of PBMCs with ODN 2216 
(Fig. 3, manuscript 1) seemed to predict enhanced cytotoxic potential of stimulated NK 
cells. This was accordingly tested with a conventional NK cell cytotoxicity assay, in 
which human erythroleukemia K562 target cells were pulsed with 51Cr prior to their 
incubation with ODN 2216-stimulated PBMCs as effectors. Although this assay is 
normally carried out with purified NK cells, successful results when utilizing PBMCs as 
effector cells have been reported [83]. Unfortunately, despite several attempts in 
optimizing the various influential factors within the assay, the isolated feline PBMCs 
could not be stimulated to kill the target cell line, even when IL-2, the commonly 
employed NK-stimulatory cytokine, was used.  
Another crucial aspect in the natural combat against viruses is the induction, in yet 
uninfected cells, of intracellular antiviral proteins that interfere with viral replication and 
thus prevent productive infection of the cell and viral spread in the host. Many such 
proteins have been described and their roles in the inhibition of different viruses have 
been reported. Unfortunately, none of these genes have been sequenced in the feline 
species to date. One study however described the successful design of primers for 
conventional PCR based on the human Mx1 sequence [67]. This sequence was 
consequently also used to develop the real time PCR assay utilized in this study, as its 
degree of homology with the feline nucleotide sequences seemed relatively high. This 
assumption was confirmed by the high amplification efficiency obtained during 
experiments aiming at determining optimal primer and probe concentrations to be used 
for this system (E=1.00, Table 2, manuscript 1). The new availability of this PCR assay 
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proved to be extremely useful in this study, as the expression of Mx can readily be used 
as a hallmark for the upregulation and biological activity of type I IFN [60], which could 
not be detected on a protein level due to the lack of specific antibodies available on the 
market. It turned out that ODN 2216 not only induced high levels of type I IFN in feline 
PBMCs, but also positively affected the transcription of Mx in these cells, supporting the 
biological activity of the produced type I IFN.   
Altogether, the main steps of an innate immune response following stimulation with 
ODN 2216 are covered in the manuscript 2, including effects of this synthetic molecule 
on the expression of its natural receptor as well as the modulation of both genetic profiles 
and phenotypic characteristics that directly and indirectly affect the roles of various cell 
types. 
 
As the ultimate aim of this study was to determine whether prophylactic IRM treatments 
could inhibit feline viral replication, the next step consisted in linking the innate immune 
mechanisms induced by ODN 2216 with the resistance of target cells to infection with 
various viruses. For this, an in vitro method was utilized, in which the supernatants of 
ODN 2216-stimulated PBMCs were incubated with various feline cell lines prior to their 
inoculation with a particular virus. The supernatants conferred both CrFK and fcwf-4 
cells significant resistance to infection with FCV, FHV, FPV and FCoV, and the spread 
of FeLV in FEA cells could also be considerably inhibited. These results could moreover 
be repeated with supernatants obtained from the stimulated PBMCs of up to 8 individual 
cats, supporting their validity. Admittedly, the utilized supernatants contained a mixture 
of soluble molecules that could all participate in the total antiviral effects observed. Type 
I IFN however, seemed to play a crucial role in the enhanced resistance to viruses in 
these experiments, as the viral inhibition was both comparable to that obtained after 
direct treatment of the cells with rfeIFNα and highly correlated with the induction of Mx 
transcription in the cells to be inoculated (manuscript 2 and section 4, Fig. 4.8). 
Additionally, experiments aiming at the evaluation of the amount of refIFNα required for 
the prophylactic inhibition of different viruses on the individual cell lines in vitro readily 
indicated that supernatants attaining this threshold could inhibit viral replication, whereas 
those not containing comparable levels of type I IFN partially or completely failed to 
decrease viral propagation in the cells (section 4, Fig. 4.8 and 4.9). Although PCR 
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systems are available in our laboratory to measure virus replication [84-89], this method 
failed to indicate significant inhibition of FCV, FHV and FCoV in initial supernatant 
experiments. This was most likely linked to high amounts of residual viral nucleic acids 
present in the culture medium both originating from the stock virus utilized for in vitro 
inoculation and liberated by cells dying as a result of infection. Actually, despite 
technical efforts to minimize their presence, the detection by real-time PCR of FeLV 
RNA and DNA residues in the after removal of the virus from treated cultures can still be 
visualized in the graphs presented in the manuscript 2 (Fig. 6A). The possibility to detect 
viral inhibition of this virus by real time PCR most probably resides in its incapacity to 
induce cytopathic effects (CPE) in the FEA cells used as target, or in unknown viral or 
cellular factors that were affected in the course of the experiments. As the other feline 
viruses utilized in this study readily induce CPE in CrFK and fcwf-4 cells, both viral 
replication and the inhibition thereof were assessed by a plaque assay, which remains 
unaffected by non-infectious viral nucleic acids. Although in each case viral replication 
was inhibited and not eliminated, it is important to keep in mind that regardless of the 
infectious dose utilized, in vitro inoculation should be much more aggressive and thus 
not comparable to the small concentration of virus transmitted in the field. Agents 
conferring partial protection to viruses in vitro may therefore turn out to be much more 
potent in vivo, providing they are able to induce systemic reactions.  
All in all, the successful prophylactic induction of resistance to representatives of five 
different feline virus families simultaneously supports the potential of ODN 2216 to 
confer the host significant advantages in overcoming viral affections in an early phase. 
This synthetic molecule thus represents an ideal candidate for in vivo “teflonization” 
experiments of the cat.  Although molecules of the same CpG-containing IRM subfamily 
have shown antiviral effects against viruses in mice [90-93], the prophylactic potential of 
this particular molecule remains to be discovered in mice, cats and other species. 
 
5.2 Relevance of the study 
Admittedly, the mechanisms reported in this study linked to innate immunity, immune 
modulation by IRMs and viral inhibition have all been described before in the murine 
model as well as in human cells and thus do not constitute a novelty in the field. Also, it 
was not news to us that certain feline viruses were sensitive to type I IFN, as various 
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studies have revealed this already in the past [94-101]. Nevertheless, our findings 
contribute in many ways to providing new perspectives to research groups focusing on 
innate immunity and open original paths for future projects in this field.  
 
First, this project greatly supports the development of the cat as an alternative model for 
studies related to innate immunity to viral infections. As elaborated in section 2.3.2 the 
feline model holds several advantages in studies concerning innate immunology when 
compared to laboratory mice: not only does the cat happen to be very susceptible to a 
wide range of viruses that are biologically similar to those affecting humans, the feline 
model also enables to carry out both in vitro and in vivo studies in an outbred species 
under natural conditions. Along these lines, the data obtained in the present study raises 
fundamental questions concerning age, individuality, species specificity and feasibility of 
extrapolation in studies focusing on the use of IRMs in medicine. Also, the sequencing of 
the entire genome of an Abyssinian cat named Cinnamon in 2006 [102] further supports 
the consideration of cats as good comparative models in human medicine and, together 
with the prospects of modern genomics technologies, will bring valuable information 
concerning the pathogenesis of many diseases. Our group has been significantly 
contributing to feline research for over 25 years. The tools necessary for the monitoring 
of both the replication of a large array of feline pathogens and the corresponding immune 
responses have been established and successfully applied in our laboratory. We strongly 
believe that raising awareness regarding this animal model and strengthening our 
knowledge in feline immune responses would represent a great advancement in both 
human and veterinary medical research.  
 
Second, the domestic cat populations worldwide will greatly profit from this advance in 
feline immunology. The developed real time PCR assays will certainly support the better 
understanding of host virus interactions in the feline species. For example, a more 
detailed investigation of the nature of early immune responses to viruses in animals with 
different outcomes of infection will confer valuable information regarding effective 
defence mechanisms and prognosis in individual cats. The promising results obtained in 
vitro in this project should also encourage further studies for the development of more 
efficient prophylactic and therapeutic strategies against fatal feline viral infections. 
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Third, this study is to our knowledge the first to present the possibility to inhibit 
replication of viruses from many different families simultaneously. Indeed, 5 feline 
viruses belonging to the Coronaviridae, Herpesviridae, Caliciviridae, Parvoviridae, and 
Retroviridae families, in addition to the vesicular stomatitis virus (VSV) used as control 
in the in vitro experiments, could all be significantly inhibited after incubation of various 
cell lines with supernatants of feline PBMCs stimulated with ODN 2216. Moreover, in 
additional experiments carried out with VSV and FCV, these effects were shown to last 
at least 72 hours (section 4, Fig. 4.10). In other words, a single treatment of cells with 
this synthetic molecule as stand-alone agent suffices to induce resistance to viruses with 
completely different genetic properties for several days in vitro. These accomplishments 
support the feasibility of this experimental setup as model for emerging viral diseases, 
and uncover a promising future for the “teflonization” of the cat in vivo (see section 2.1.3 
for definition of “telflonization”). 
 
Finally, our data greatly contributes to the validation of an in vitro screening method for 
IRMs that had only been seldom used to date. Many physiological and immunological 
parameters that greatly influence the success of an immunomodulatory agent cannot be 
taken into consideration when tested in vitro, and answers to such questions are 
oftentimes searched for directly with in vivo experiments. The 3-step system comprising 
1) the stimulation of purified PBMCs with an IRM, followed by 2) the transfer of cell-
free supernatants onto various cell lines and 3) the inoculation of these target cells with 
feline virus and measurement of viral replication mimics to a great extent an in vivo 
situation (explained in the discussion of the manuscript 2), and thus supports growing 
ethical expectations in research with animals [103]. Providing the necessary target cell 
types are available, this method could be used in preliminary tests when predicting the 
use of an IRM as vaccine adjuvant, or in preventive or therapeutic settings for various 
diseases. Both in vitro experiments with cells from other species and in vivo experiments 
in the cat will further validate this strategy.  
 
5.3 Limitations and frustrations 
The major limiting factor in the present study was the restricted availability of 
commercial tools for the feline species. Particularly antibodies recognizing feline 
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proteins could have supported the study of biological properties of viral particles and 
various mechanisms involved in immune responses of the host. In this way, specific 
antibodies against feline type I IFN could have facilitated the determination of both the 
amount of these cytokines present in the supernatants and their role in viral inhibition, 
while the availability of labelled antibodies of various subtypes recognising different cell 
surface molecules would have enabled co-staining for different factors on distinct 
immune cell populations by flow cytometry. Similarly, the investigation of intracellular 
mechanisms following stimulation with an IRM equally requires the availability of 
antibodies specific to the proteins involved in the pathways. Another gap to be filled in 
feline research is the lack of nucleotide sequences for many parameters of immunological 
reactions. The tedious development of 12 real time PCR assays in this study, enabling to 
measure the modulation in relative expression of a selection of genes, could hardly 
confer the information that would be achieved with a microarray. For similar reasons, the 
overexpression or knockdown of specific proteins cannot be undertaken, because the 
necessary constructs are not available. Although such restrictions may pressure the 
development of more innovative concepts in order to demonstrate certain biological 
aspects, the generation of valuable data is much less efficient, which constitutes a great 
handicap in a world where the half-life of a scientific idea is shrinking considerably.     
 
5.4 Future perspectives 
Considerations for future projects are many. An interesting objective would consist in 
defining the individual roles of the numerous feline type I IFN subtypes and the different 
intracellular proteins, particularly Mx, involved in the defence against individual viruses. 
Furthermore, a series of in vivo experiments would enable to determine the clinical 
relevance of ODN 2216 in the “teflonization” of the cat. Dosage of the molecule as well 
as route and time point(s) of administration enabling the successful induction and optimal 
kinetics of a systemic immune response would have to be determined. The induction of 
immunity at peripheral sites may additionally be required, especially in the context of 
infections that remain local, such as those induced by the feline herpes virus. Potential 
safety issues obviously need to be studied. Also, as the structure of ODN 2216 may 
render the molecule sensitive to nucleases in vivo, stabilizing strategies such as 
biodegradable microparticles [104] and lipid-based delivery systems [105] may also need 
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to be taken into consideration. Protection against infection by several viruses should also 
be demonstrated experimentally, ideally in the context of viral transmission by shedding 
to naïve cats. Finally, similar experiments conducted with cells and viruses specific to 
other species could give further indications regarding the feline model and possibilities to 
extrapolate findings to other animal populations and to humans.   
 
5.5 Conclusions 
In an era of permanent emergence of new health-threatening viral diseases such as the 
severe acute respiratory syndrome (SARS) and avian influenza, research groups 
worldwide are concentrating on elaborating the recent idea of inducing innate immune 
responses as prophylactic or therapeutic measures in the setting of infectious diseases. As 
many human and animal diseases share a pathogenic basis, and although veterinary 
species need advances in biomedical research for their own interests, the availability of 
an appropriate comparative small animal model for such research purposes is therefore 
currently highly desirable. It is today widely accepted that the future of many areas of 
human and veterinary biomedical research is very much interdependent. 
 
The present work is thus in line with the scientific trend of this decade. The domestic cat 
represents a powerful model in the analysis of immune responses to viruses, and the 
development of specific tools enabling to characterize innate immune mechanisms in this 
species readily supports further use of this outbred model for studies regarding innate 
host-virus interactions. Our study further suggests that non-specific prophylactic 
manipulation of the cat’s early immune mechanisms holds the potential to induce 
resistance to infection by viruses with a wide range of genotypic and phenotypic 
properties. As evolutionary considerations render the elaboration of preventive measures 
to feline viral infections particularly challenging, these results create an exciting new 
opening for the development of novel short-term antiviral preventive measures in both 
human and veterinary medicine. 
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